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Abstract 
Clinical trials have established the efficacy and safety of the 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) in 
lowering cardiovascular morbidity and mortality in patients with and 
without coronary artery diseases. Traditionally, the beneficial effects of 
statins have been ascribed entirely to their ability to lower serum 
cholesterol. However, evidence indicates that statins may exert 
cholesterol-independent or pleiotropic effects.  As well as reducing plasma 
cholesterol levels, statins induce acute vasorelaxation which may 
contribute to the overall benefits of statins in the treatment of 
cardiovascular disease. The mechanism underlying this relaxation is 
unknown. Statins have been shown to alter mitochondrial function. 
Therefore, the aim of this study was to determine the role of the 
mitochondria in the relaxation to statins. Changes in rhodamine 123 
fluorescence showed that simvastatin, but not pravastatin, depolarized the 
membrane potential of mitochondria in both isolated smooth muscle cells 
and intact blood vessels. As simvastatin, but not pravastatin, causes 
relaxation of the porcine coronary artery, this could be due to this effect on 
mitochondria. Mitochondria are known as the energy generating centre of 
the cells. However, there is growing consensus that mitochondria actively 
participate in intracellular signalling, such as production of reactive oxygen 
species (ROS) and regulation of the intracellular Ca2+ concentration. 
Moreover, ROS could play an important supportive role in a variety of 
vascular cell signalling processes, including activation of nitric oxide 
synthase (NOS), modulation of intracellular Ca2+, and AMP kinase 
activation. Therefore, this study investigated whether the relaxation to the 
lipophilic statin simvastatin is due to an effect on the mitochondria. 
Relaxation of porcine coronary artery segments by statins was measured 
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using isolated tissue baths. Simvastatin, but not pravastatin, produced a 
slow relaxation of the coronary artery, which was independent of K+ 
channel activation, nitric oxide, cyclo-oxygenase, or the endothelium. The 
relaxation was attenuated by the mitochondrial complex I inhibitor 
rotenone and the complex III inhibitor myxothiazol, or a combination of the 
two. Simvastatin inhibited calcium-induced contractile responses, and this 
inhibition was partially reversed by incubation with the complex I inhibitor 
rotenone suggesting that mitochondrial function is required for the effect of 
simvastatin on calcium influx. The effect of mitochondrial complex III 
inhibitor, antimycin A, was examined as a comparison with simvastatin. 
Antimycin A induced porcine coronary relaxation and inhibited Ca2+ influx in 
isolated porcine coronary smooth muscle cells.  
Evidence from a number of clinical trials highlights a potential association 
between treatment with lipophilic statins and increased risk of development 
of diabetes. The close connection between energy metabolism and insulin 
secretion in pancreatic ǃ-cells suggests that the glycaemic effects of 
simvastatin may also result from a direct mitochondrial action with 
reduction in insulin secretion and, hence, result in a reduced control of 
plasma glucose levels. Although simvastatin depolarized mitochondria in 
pancreatic ǃ-cells, it also directly inhibited KATP channels. Pravastatin, on 
the other hand, had no effect on either measurement, suggesting that 
these phenomena relate to the lipophilicity of the compounds. The 
inhibition of KATP channels by simvastatin is likely to underlie the increase 
in insulin secretion observed within days of simvastatin treatment. On the 
other hand, the effects on mitochondrial membrane potential may be 
detrimental, particularly with chronic treatment, although further studies 
are required in order to determine whether this plays a role in the 
increased risk of diabetes observed with lipophilic statins. 
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Overall, our results demonstrated that simvastatin alters mitochondrial 
membrane potential in vascular smooth muscle cells DQGSDQFUHDWLFǃ-cells. 
The relaxation to simvastatin in the porcine coronary artery is dependent, 
in part, upon mitochondrial activity. Alteration of mitochondrial membrane 
potential by simvastatin may lead to inhibition of calcium influx, hence 
stimulation of relaxation. On the other hand, the effects on mitochondrial 
PHPEUDQH SRWHQWLDO LQ SDQFUHDWLF ǃ-cell may be detrimental, particularly 
with chronic treatment due to the increased risk of diabetes observed with 
lipophilic statins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Conference presentations 
1. HM Almukhtar, PA Smith, RE Roberts (2012). Effects of 
mitochondrial complex inhibitors on porcine coronary tone: role of 
reactive oxygen species. BPS Winter Meeting, London, Queen 
Elizabeth II Conference Centre. Poster presentation.  
http://www.pa2online.org/abstracts/vol10issue4abst077p.pdf 
2. HM Almukhtar, PA Smith, RE Roberts (2012). Role of 
mitochondria in the effect of simvastatin in isolated porcine coronary 
artery. 62nd Meeting of the British Microcirculation Society, Keble 
College, Oxford. Poster presentation. 
http://onlinelibrary.wiley.com/doi/10.1111/micc.12018/epdf 
 
3. HM Almukhtar, RE Roberts, PA Smith (2013). Effect of statins on 
mitochondrial membrane potential and KATP activity in mouse 
SULPDU\ ǃ-cells. BPS Winter Meeting, London, Queen Elizabeth II 
Conference Centre. Poster presentation.  
http://www.pa2online.org/abstracts/vol11issue3abst138p.pdf  
 
4. HM Almukhtar, PA Smith, RE Roberts (2013). Role of 
mitochondria in the relaxation to simvastatin in porcine isolated 
coronary artery. BPS Winter Meeting, London, Queen Elizabeth II 
Conference Centre. Poster presentation. 
http://www.pa2online.org/abstracts/vol11issue3abst126p.pdf 
 
5. HM Almukhtar, PA Smith, RE Roberts (2014). Simvastatin 
Induced Porcine Coronary Artery Relaxation: Role of Ca2+ Influx and 
Mitochondrial Function. BPS Winter Meeting, London, Queen 
Elizabeth II Conference Centre. Poster presentation. 
http://www.pa2online.org/abstracts/vol12issue3abst271p.pdf 
 
6. HM Almukhtar, PA Smith, RE Roberts (2014). Mechanism of 
Relaxation to Antimycin A, Mitochondrial Complex III inhibitor, in 
the Porcine Coronary Artery. BPS Winter Meeting, London, Queen 
Elizabeth II Conference Centre. Poster presentation.  
http://www.pa2online.org/abstracts/vol12issue3abst178p.pdf 
 
 
 
 
 
 
 
 
 
6 
 
Acknowledgements  
 
³20\/RUGincreasHPHLQNQRZOHGJH´4XUDQ 
First and above all, I praise ALLAH the Most Gracious, the Most Merciful for 
providing me with the opportunity and the capability to proceed with my 
research. 
  
I would like to express my sincere gratitude to my supervisors Dr. Richard 
Roberts and Dr. Paul Smith for the continuous support throughout my Ph.D 
study, for their patience, motivation, enthusiasm, and immense knowledge. 
Their guidance helped me all the time of research and during the writing of 
the thesis. I could not have imagined having better supervisors for my 
Ph.D study. My deepest gratitude is also to Dr. Michael Garle, Liaque Latif, 
Emeka and Jagdish Heer, for being very helpful and for their great advice.  
 
I would like to thank my fellow lab mates in E34 laboratory: I would thank 
the opportunity that allows me to meet such friends: Thank you to all 
friends I have made in Nottingham. 
  
I would like to acknowledge all staff and members in the University of 
Nottingham, School of Life Sciences. 
  
I would also like to thank Islamic Development Bank IDB for granting me a 
scholarship to pursue my higher education at the University of Nottingham. 
 
I wish to thank my beloved mother, father and brothers for their 
continuous encouragement and help who were all patients during our long 
absence abroad. A big thanks to my wife, my little children. I will never be 
able to pay my debt of gratitude in full.  
Lastly, but most importantly, May Allah's peace and blessing be upon our 
Beloved Prophet Muhammad who said, "Allah makes the way to Jannah 
easy for him who treads the path in search of knowledge." 
 
 
 
 
 
 
 
 
7 
 
Table of contents 
 
CHAPTER I: GENERAL INTRODUCTION ....................................... 14 
1.1. CA
2+
-DEPENDENT CONTRACTION OF SMOOTH MUSCLE ......................................................... 15 
1.2. CA2+ - SENSITIZATION MECHANISM ......................................................................... 17 
1.3. CA
2+
 -TRANSPORT MECHANISMS ACROSS THE PLASMA MEMBRANE ............................................... 18 
1.3.1. Voltage-gated Ca
2+
 channels .................................................................................. 19 
1.3.2. Store-operated Ca
2+
 channels ................................................................................. 20 
1.3.3. Receptor-operated Ca
2+
 channels ........................................................................... 21 
1.4. K
+
 CHANNELS MEDIATED VASODILATATION ............................................................................... 22 
1.4.1. Voltage-activated K
+
 channels ................................................................................ 22 
1.4.2. Calcium-Activated K
+
 Channels ............................................................................... 23 
1.4.3. ATP-sensitive K
+
 channels ....................................................................................... 25 
1.4.3.1. Cellular mechanisms that regulate KATP channels ............................... 26 
1.4.3.2. Structure ............................................................................................. 27 
1.5. THE VASCULAR ENDOTHELIUM ............................................................................................... 28 
1.5.1. Nitric oxide: ............................................................................................................ 29 
1.5.2. Arachidonic acid (AA) metabolites: ........................................................................ 30 
1.5.3. Cyclooxygenase (COX)-derived metabolites of AA: ................................................ 30 
1.5.4. Cytochrome P450-derived metabolites of AA. ........................................................ 30 
1.5.5. Endothelium-derived hyperpolarising factor: ......................................................... 31 
1.6. HMG-COA REDUCTASE INHIBITORS ....................................................................................... 31 
1.6.1. Pharmacokinetics: .................................................................................................. 32 
1.6.2. Adverse effects ....................................................................................................... 33 
1.6.3. Lipophilicity ............................................................................................................ 34 
1.6.4. Mechanism of action as hypolipidaemic agents: ................................................... 34 
1.6.5. The pleiotropic effects of statins. ........................................................................... 35 
1.6.6. Mechanism of action as a pleiotropic agent: ......................................................... 35 
1.6.6.1. Effects of statins on vascular tone. ..................................................... 37 
1.6.6.2. Statin and NO bioavailability: ............................................................. 38 
1.6.6.3. Statin and Prostaglandin bioavailability: ............................................ 39 
1.6.6.4. Statin and Ca
2+ 
distribution: ................................................................ 40 
1.6.6.5. Statin and K
+
 channels ........................................................................ 41 
1.6.6.6. Statin and Reactive Oxygen Species generation ................................. 43 
1.7. MITOCHONDRIA ................................................................................................................. 44 
1.7.1. Mitochondrial oxidative phosphorylation .............................................................. 44 
1.7.2. Mitochondria and ROS generation in the vascular smooth muscle cells ................ 46 
1.7.3. Mitochondria and ROS in the regulation of vascular tone: .................................... 48 
1.7.4. Interplay between mitochondria and cytosolic Ca
2+
 signals ................................... 49 
1.7.5. Mitochondria as a target for statin therapy: ......................................................... 50 
1.8. STARTING HYPOTHESIS: ........................................................................................................ 51 
CHAPTER II: ACUTE EFFECTS OF SIMVASTATIN ON PORCINE 
CORONARY TONE: ROLE OF KATP AND MITOCHONDRIA ............. 52 
8 
 
2.1. INTRODUCTION .............................................................................................................. 53 
2.2. MATERIALS AND METHODS ........................................................................................... 58 
2.2.1. Materials ................................................................................................................ 58 
2.2.2 .Tissue Preparation .................................................................................................. 59 
2.2.3 Isometric tension recording ..................................................................................... 59 
2.2.3.1. The role of endothelial factors in the relaxation response to 
simvastatin ....................................................................................................... 60 
2.2.3.2 The role of K
+
 channels in the relaxation response to simvastatin ..... 61 
2.2.3.3 The role of Na
+
-K
+
 ATPase pump in the relaxation response to 
simvastatin ....................................................................................................... 61 
2.2.3.4. The role of H2S in the relaxation response to simvastatin ................. 61 
2.2.3.5. Role of reactive oxygen species in the relaxation response to 
simvastatin ....................................................................................................... 62 
2.2.3.6. The role of NADPH inhibition in the relaxation response to 
simvastatin: ...................................................................................................... 62 
2.2.3.7. Role of mitochondria in the relaxation response to simvastatin ....... 62 
2.2.4. Assessment of Mitochondrial membrane potential using Rh123: .......................... 63 
2.2.4.1 Effect of statins on mitochondrial function isolation from porcine 
hearts: .............................................................................................................. 63 
2.2.4.2. Effect of statins on mitochondrial function in isolated vascular 
smooth muscle cells. ........................................................................................ 65 
2.2.4.3. Effect of statins on mitochondrial function in intact porcine coronary 
artery ............................................................................................................... 66 
2.3. DATA ANALYSIS .................................................................................................................. 67 
2.4. RESULTS ......................................................................................................................... 67 
2.4.1. Acute effects of lipophilic versus hydrophilic statins on rings precontracted with 
U46619, ET-1 and KCl: ...................................................................................................... 67 
2.4.1.1. Effect of simvastatin and lovastatin: .................................................. 67 
2.4.1.2. Effect of pravastatin and sodium salt of simvastatin: ........................ 72 
2.4.2. Role of endothelium-derived vasodilator factors in the relaxation response to 
simvastatin. ...................................................................................................................... 73 
2.4.3. Role of AMPK in the relaxation response to simvastatin. ....................................... 76 
2.4.4. Role of K
+
 Channels in the relaxation response to simvastatin ............................... 77 
2.4.5. Role of the mitochondria in the relaxation response to simvastatin. ..................... 79 
2.4.5.1 Effect of Mitochondrial Inhibitors on Simvastatin-induced relaxations.
 ......................................................................................................................... 79 
2.4.5.2 Effect of Mitochondrial uncouplers on Simvastatin-induced 
relaxations. ...................................................................................................... 86 
2.4.5.3 Effect of Mitochondrial ATPase inhibitor on Simvastatin-induced 
relaxations. ...................................................................................................... 88 
2.4.5.4 Role of mitochondrial KATP channels: ................................................... 88 
9 
 
2.4.6 Role of Reactive Oxygen Species in the Relaxation Response to Simvastatin: ........ 89 
2.4.6.1 Reactive oxygen species of mitochondrial origin ................................ 89 
2.4.6.2 Effect of NADPH oxidase inhibition on simvastatin mediated coronary 
relaxation: ........................................................................................................ 92 
2.4.6.3 Role of peroxynitrite ............................................................................ 92 
2.4.7. Effect of the antioxidant quercetin on simvastatin relaxation: .............................. 93 
2.4.8 Effect of DTT on simvastatin relaxation: ................................................................. 94 
2.4.9. Role of H2S in simvastatin-induced coronary relaxation: ....................................... 95 
2.4.10. Effect of Na
+
/K
+
 pump inhibition on Simvastatin-induced relaxations. ................ 96 
2.4.11 Acute effects of Simvastatin on Mitochondrial Membrane Potential. .................. 97 
2.4.11.1 Effect of simvastatin on Membrane Potential of the isolated 
mitochondria ................................................................................................... 97 
2.4.11.2. Acute effects of Simvastatin on Mitochondrial Membrane Potential 
in human aortic smooth muscle cells .............................................................. 99 
2.4.11.3. Acute effects of Simvastatin on Mitochondrial Membrane Potential 
in segments of porcine coronary artery ........................................................ 102 
2.5 DISCUSSION .................................................................................................................. 103 
CHAPTER III: EFFECT OF SIMVASTATIN ON Ca
2+
 INFLUX IN 
PORCINE CORONARY ARTERY.................................................. 110 
3.1. INTRODUCTION ................................................................................................................. 111 
3.2 MATERIALS AND METHODS ................................................................................................. 114 
3.2.1 Materials ............................................................................................................... 114 
3.2.2. Preparation and characterization of the smooth muscle cells (SMCs) ................. 114 
3.2.2.1. Preparation of the SMCs ................................................................... 114 
3.2.2.2. Immunohistochemistry: Characterization of the Smooth Muscle Cells
 ....................................................................................................................... 116 
3. 3 DATA ANALYSIS ................................................................................................................ 117 
3.4 EXPERIMENTAL PROTOCOL ................................................................................................... 117 
3. 4.1 organ bath isometric studies ................................................................................ 117 
3.4.2. Effect of simvastatin on calcium influx in freshly isolated smooth muscle cells. .. 118 
3.5. RESULTS ....................................................................................................................... 119 
3.5.1. Simvastatin inhibits KCl-induced contraction in porcine coronary arteries .......... 119 
3.5.2. Role of endothelium-derived vasodilator factors in the relaxation response to 
simvastatin. .................................................................................................................... 120 
3.5.3. Role of Sarcoplasmic reticulum Ca
2+
 -ATPase in acute simvastatin relaxation: ... 120 
3.5.4. Simvastatin relaxation in Ca2+-free Krebs: .......................................................... 121 
3.5.5. Simvastatin suppressed Ca
2+
-induced contraction in coronary arteries: .............. 122 
3.5.6. Role of voltage-gated Ca
2+
 channel in the acute simvastatin relaxation ............. 124 
3.5.7. Effect of complex I mitochondrial inhibitor, rotenone, on simvastatin relaxation in 
porcine coronary segments precontracted submaximally with KCl: .............................. 125 
3.5.8. Simvastatin inhibited Ca
2+
 rise in isolated coronary porcine smooth muscle cells:
 ........................................................................................................................................ 128 
3.5.8.1 SMC in Cultures .................................................................................. 128 
10 
 
3.5.8.1 Freshly isolated smooth muscle cells ................................................ 130 
3.6. DISCUSSION ..................................................................................................................... 132 
CHAPTER IV: Effect of complex III inhibition with antimycin A on 
porcine coronary tone: mechanism of action & comparison with 
other mitochondrial inhibitors ................................................ 140 
4.1 INTRODUCTION .................................................................................................................. 141 
4.2. MATERIALS AND MEHODS ................................................................................................... 144 
4.2.1. Materials .............................................................................................................. 144 
4.2.2. Solutions ............................................................................................................... 144 
4.2.3. Data Analysis ........................................................................................................ 144 
4.2.4. Method ................................................................................................................. 145 
4.2.4.1 Role of reactive oxygen species in antimycin A-induced relaxation . 146 
4.2.4.2. Effect of antimycin A on calcium-induced contractions ................... 146 
4.2.4.3. Effect of antimycin A on calcium influx in freshly isolated smooth 
muscle cells. ................................................................................................... 146 
4.2.4.4. Atomic absorption spectrophotometric determination of 3Na
+
/2K
+
 
ATPase activity ............................................................................................... 147 
4.2.4.5. Measurement of AMP Kinase activation .......................................... 148 
4.3. RESULTS .......................................................................................................................... 151 
4.3.1. Acute effects of antimycin A and myxothiazol on porcine coronary artery tone . 151 
4.3.2. Effects of complex I inhibitor rotenone, and complex II inhibitor on PCA tone .... 153 
4.3.3. Effects of mitochondrial uncoupler FCCP on PCA tone ......................................... 154 
4.3.4. Effects of ATP synthase inhibitor oligomycin on PCA tone ................................... 155 
4.3.5. Role of NO, Prostacyclin in the relaxation response to antimycin A ..................... 156 
4.3.6. Role of AMPK in the relaxation response to antimycin A ..................................... 157 
4.3.7. Role of K
+
 channels in the relaxation response to antimycin A ............................. 158 
4.3.8. Effect of pre-incubation with FCCP, or rotenone, on the relaxation response to 
antimycin A..................................................................................................................... 159 
4.3.9. Role of Na
+
/K
+
 ATPase pump in the relaxation response to antimycin A ............. 161 
4.3.10. Role of reactive oxygen species in the relaxation response to Antimycin A ....... 162 
4.3.11. Effect of antimycin A on Calcium-Induced contractions ..................................... 164 
4.3.12. Effect of antimycin A on calcium influx in freshly isolated smooth muscle cells. 165 
4.3.13. Effect of antimycin A on AMPK activation in porcine coronary artery ............... 166 
4.4. DISCUSSION ..................................................................................................................... 168 
CHAPTER V: Effect of statins on mitochondrial membrane 
potential and KATP ŝŽŶĐŚĂŶŶĞůĂĐƚŝǀŝƚǇŝŶŵŽƵƐĞƉƌŝŵĂƌǇɴ-cells.
 ............................................................................................... 176 
5.1 INTRODUCTION .................................................................................................................. 177 
5.2. MATERIALS AND METHODS ................................................................................................ 181 
5.2.1. Solutions: .............................................................................................................. 181 
5.2.2. Preparation of the ɴ -cell ...................................................................................... 182 
5.3. METHOD ......................................................................................................................... 182 
5.3.1. Patch clamp recording .......................................................................................... 182 
11 
 
5.3.2. The use of rhodamine 123 for detection of mitochondria polarization. ............... 183 
Measurement of mitochondrial membrane potential .................................. 184 
5.3.3. Superoxide measurement using MitoSOX: ........................................................... 186 
5.4. STATISTICAL ANALYSIS: ....................................................................................................... 186 
5.5. RESULTS: ......................................................................................................................... 187 
5.5.1. Patch clamp recordings ........................................................................................ 187 
5.5.1.1. Effect of glucose on KATP channel activity ......................................... 187 
5.5.1.2. Effect of statins on KATP channel activity ........................................... 188 
5.5.1.3. Effect of simvastatin on KATP channel activity in the absence glucose:
 ....................................................................................................................... 189 
5.5.1.4. Effect of the solvent control on KATP channel activity ....................... 192 
5.5.1.5. Effect of the pravastatin on KATP channel activity ............................. 193 
5.5.1.6. Effect of simvastatin on KATP channel activity using inside-out 
configuration: ................................................................................................ 195 
5.5.1.7. Effects of simvastatin on KATP channel kinetics: ................................ 196 
5.5.1.8. Effect of antimycin A and myxothiazol on KATP channel activity: ...... 198 
5.5.2. Effects of simvastatin on mitochondrial potential in B-cell: ................................. 199 
5.5.3. Effects of simvastatin on superoxide generation in MIN6: ................................... 202 
5.6. DISCUSSION ..................................................................................................................... 204 
6. CHAPTER VI: DISCUSSION & CONCLUSION ........................... 211 
6.1. GENERAL DISCUSSION .................................................................................................. 212 
6.1.1. Short term effect of Simvastatin in comparison with Lovastatin and Pravastatin:
 ........................................................................................................................................ 212 
6.1.2. Simvastatin induced relaxation of the coronary vessels precontracted with 
U46619, ET-1 and KCl: .................................................................................................... 213 
6.1.3. Clinical significance of mitochondria and KATP channel inhibition induced by 
simvastatin: .................................................................................................................... 215 
 ? ? ? ? ? ?ĨĨĞĐƚŽĨ^ƚĂƚŝŶƐŽŶWĂŶĐƌĞĂƚŝĐɴ-cells. ................................................................. 218 
6.1.5. Additional Benefits of Statins in Cardiovascular Disease ..................................... 219 
6.1.6. Simvastatin concentrations used in the study ...................................................... 220 
6.2. GENERAL CONCLUSION ...................................................................................................... 223 
REFERENCES: ........................................................................... 224 
Appendix: ............................................................................... 265 
 
 
 
 
12 
 
Abbreviations   
3-NP               3-nitropropionic acid 
AA Arachidonic acid 
ADP  adenosine diphosphate 
AICAR    5-aminoimidizole-4-carboxamide riboside 
AKt Protein kinase B  
AMPK Adenosine monophosphate-activated protein kinase  
ANOVA Analysis of variance  
AOAA amino-oxyacetic acid  
ATP  adenosine triphosphate 
BAECs bovine aortic endothelial cells 
BKCa large conductance Ca
2+-activated K+ channel 
BSA    bovine serum albumin 
Ca2+_CaM Ca2+/calmodulin-dependent protein kinase  
CCCP Carbonyl cyanide m-chlorophenyl hydrazone 
cGMP Cyclic guanosine monophosphate 
CICR  calcium-induced calcium release 
Complex I NADH±ubiquinone oxidoreductase 
Complex II Succinate±ubiquinone oxidoreductase  
Complex III Ubiquinone±cytochrome c oxidase 
Complex IV Cytochrome c oxidase  
COX1 Cyclooxygenase  
CPA cyclopiazonic acid 
Cu/ZnSOD  copper/zinc superoxide dismutase 
DAG diacylglycerol 
DCF    2,7-dichlorofluorescein  
DETCA             diethylthiocarbamate 
DHETs dihydroxyeicosatrienoic acids  
DMEM Dulbecco Modified Eagle Medium  
DMSO Dimethyl sulfoxide 
EDHF Endothelium-derived hyperpolarizing factor 
EDTA Ethylenediaminetetraacetic acid  
EETs epoxyeicosatrienoic acids  
EGTA ethylene glycol tetraacetic acid 
eNOS Endothelial nitric oxide synthase  
ER  endoplasmic reticulum 
ERK Extracellular signal-regulated kinases  
ET-1 endothelin 
ETC Electron transport chain  
FADH  reduced flavin adenine dinucleotide 
FADH2 Flavin adenine dinucleotide  
FCCP               Carbonyl cyanide p-trifluoromethoxyphenylhydrazone 
H2O2  hydrogen peroxide 
HDL High-density lipoprotein  
HETEs monohydroxyeicosatetraenoic acids  
HMG-CoA  3-hydroxy-3-methyl-glutaryl-CoA  
IKCa intermediate conductance calcium activated K
+ channel  
IP3 inositol 1,4,5-trisphosphate 
IP3R  inositol-1,4,5-triphosphate receptor 
KATP ATP-sensitive K
+ channels 
KCl Potassium chloride  
Kir inward rectifier K
+ 
Kv Voltage-gated potassium channel  
LDL Low density lipoprotein  
L-NAME  L-nitroarginine methyl ester 
13 
 
MLC kinase myosin light chain kinase 
MLCP MLC phosphatase 
MnSOD  manganese superoxide dismutase 
MYPT1 myosin phosphatase target subunit 1 
NADH  reduced nicotinamide adenine dinucleotide 
NADPH  reduced nicotinamide adenine dinucleotide phosphate 
NCX sodium Na+/Ca2+ exchanger 
NOS nitric oxide synthase 
Nox                   nicotinamide adenine dinucleotide phosphate-oxidase 
NPo channel activity  
O2
āí  superoxide anion 
ONOO    peroxynitrite 
ox-pho oxidative phosphorylation 
PBS Phosphate buffered saline  
PCA Porcine coronary artery 
PEG-catalase &DWDODVHíSRO\HWK\OHQHJO\FRO 
PGI2 prostacyclin  
PI3K      phosphoinositide 3-kinase  
PKC protein kinase C 
PKG protein kinase G 
PMCA plasma membrane Ca2+-DGHQRVLQH¶WULSKRVSKDWDVH 
PPG propargylglycine  
QH Quinone  
QH2 Quinol  
Rh123  Rhodamine 123 
RNS reactive nitrogen species 
ROCCs receptor-operated Ca2+ channels 
ROS                reactive oxygen species 
sGC soluble guanylyl cyclase 
SKCa small conductance Ca
2+ activated K+ channel 
SOCCs store-operated Ca2+ channels 
SOD    superoxide dismutase  
SR  sarcoplasmic reticulum 
SUR sulphonylurea receptors 
SV simvastatin  
TEA Tetraethylammonium chloride  
TRP transient receptor potential 
TTFA               4,4,4-trifluoro-1-(2-thienyl)-1,3-butanedione 
TXA2 thromboxane A2  
U46619 9,11-Dideoxy-ĮĮ-HSR[\PHWKDQRSURVWDJODQGLQ)Į 
VDAC  voltage dependant anion channel 
VDCCs voltage-dependent Ca2+ channels 
VSMC vascular smooth muscle cell  
Ʃƺm  membrane potential 
 
 
 
 
 
14 
 
CHAPTER I: GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
1.1. Ca2+-dependent contraction of smooth muscle  
 
Vascular tone is regulated by contraction of the smooth muscle cells. 
Smooth muscle cells are the major constituent of the blood vessel wall. 
Vascular smooth muscle contractility is determined by the free intracellular 
Ca2+ and Ca2+ sensitivity of contractile proteins. The entry of Ca2+ from the 
extracellular space, through Ca2+ channels, as well as Ca2+ release from 
intracellular stores results in Ca2+ binding to the acidic protein, calmodulin, 
forming a Ca2+/calmodulin complex. The complex in turn activates myosin 
light chain kinase (MLC kinase) with subsequent phosphorylation of the 
myosin light chains (Gao et al., 2013), which enables cross-bridge 
formation with actin. The latter is a key event in smooth muscle 
contraction (Webb, 2003) (Figure 1.1).        
Agonists such as endothelin-1 act on receptors coupled to Gq proteins 
which activate phospholipase C enzyme (a membrane-bound enzyme). The 
membrane enzyme then catalyses the phosphatidylinositol cascade with 
the formation of two second messengers: inositol 1,4,5-trisphosphate (IP3) 
and diacylglycerol (DAG). IP3 diffuses through the cytoplasm and binds to 
receptors on the sarcoplasmic reticulum (SR), causing release of Ca2+ into 
the cytosol (Berridge and Irvine, 1989, Northcott et al., 2002, Sata and 
Nagai, 2002). Mitochondrial uptake of Ca2+ may regulate the local Ca2+ 
near the IP3 receptor, so maintaining the sensitivity of the IP3 receptor to 
release Ca2+ from the SR (McCarron and Muir, 1999, Taylor et al., 1989). 
Indeed, IP3-induced Ca2+ release is inhibited by mitochondrial 
depolarization (Collins et al., 2000). DAG, along with Ca2+, activates 
protein kinase C (PKC), which has contraction-promoting effects such as 
phosphorylation of L-type Ca2+ channels (Schuhmann and Groschner, 
1994).      
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Smooth muscle relaxation occurs by decreasing the intracellular Ca2+ 
concentration (Morgan and Morgan, 1984) and increasing MLC 
phosphatase activity. Two mechanisms participate in removing Ca2+ from 
the cell to the external environment. Firstly, the membrane Ca2+ ATPase 
pumps Ca2+ from the intracellular into the extracellular space. Secondly, 
the sarcoplasmic reticulum Ca2+ ATPase pumps Ca2+ into the SR. Ca2+ 
uptake into the sarcoplasmic reticulum is dependent on ATP hydrolysis; in 
fact, mitochondria ensure efficient sarcoplasmic reticulum refilling (Poburko 
et al., 2009). The plasma membrane also contains a Na+/Ca2+ exchanger 
which provides an additional mechanism for reducing intracellular Ca2+ 
(Campbell and Paul, 1992, Barron et al., 2000, Marin et al., 1999). In 
addition to the Ca2+-dependent activation of MLCK, the state of MLC 
phosphorylation is further regulated by MLC phosphatase (Koga and Ikebe, 
2008), which removes the high-energy phosphate from the MLC, thus 
promote smooth muscle relaxation (Webb, 2003). There are several 
reports of relaxation of smooth muscle that occur independent of changes 
in myosin light chain phosphorylation, small heat shock proteins (HSP) e.g. 
HSP20, HSP22 and HSP27, often termed as stress proteins, are likely 
candidates (Brophy et al., 1997, Knoepp et al., 2000, Salinthone et al., 
2008). Phosphorylated HSP20 is thought to inhibit smooth muscle 
contraction as part of the mechanism of action of nitrovasodilators and ǃ-
adrenergic agonists (Rembold et al., 2000). On the other hand cellular 
stress which leads to increases in the phosphorylation of HSP27 inhibits 
phosphorylation of HSP20 (Fuchs et al., 2000). Several vasoactive 
hormones enhance expression of HSP27 in vascular smooth muscle, e.g. 
vasopressin, thrombin and sphingosine 1-phosphate, by a MAPK-
dependent mechanism (Salinthone et al., 2008).   
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Figure 1.1. Regulation of smooth muscle contraction. Agonists like 
endothelin bind to a specific receptor and increased phospholipase C 
activity through G protein. Phospholipase C produces two potent second 
messengers: diacylglycerol (DG) and inositol 1,4,5-trisphosphate (IP3). IP3 
binds to specific receptors on the sarcoplasmic reticulum, causing release 
of calcium (Ca2+). DG along with Ca2+ activates PKC, which has 
contraction-promoting effects such as phosphorylation of Ca2+ channels. 
Ca2+ binding to calmodulin leads to activation of myosin light chain kinase 
(MLC kinase). The latter phosphorylates the light chain of myosin, and, in 
conjunction with actin, cross-bridge cycling occurs, initiating shortening of 
the smooth muscle cell, the contractile response is maintained by a Ca2+-
sensitizing mechanism brought about by the inhibition of myosin 
phosphatase activity by Rho kinase.  
 
1.2. Ca2+ - sensitization mechanism  
 
The state of MLC phosphorylation and smooth muscle contraction is 
maintained independently of Ca2+ concentration by a Ca2+ sensitizing 
mechanism; this is brought about by Rho kinase, also known as ROCK. 
MLC phosphatase (MLCP), also known as myosin phosphatase, removes 
the high-energy phosphate from the MLC to promote smooth muscle 
relaxation. MLCP is a heterotrimeric protein consisting of a catalytic subunit 
and a regulatory subunit, MYPT1. Inhibition of MLCP is ascribed to 
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phosphorylation of MYPT1. Rho kinase plays an important role in the 
regulation of MYPT1 phosphorylation. Rho kinase, by inactivating MLC 
phosphatase, increases the level of phosphorylated MLC and thereby 
prolongs smooth muscle contraction (Uehata et al., 1997, Nobe and Paul, 
2001, Sakurada et al., 2003, Pearson et al., 2013). Pharmacological 
inhibitors of Rho kinase, such as fasudil and Y-27632, block its activity and 
induce relaxation of isolated smooth muscle segments (Budzyn et al., 
2006, Suzuki et al., 2012). The degree of myosin light chain 
phosphorylation and, hence, smooth muscle tone is determined by the 
relative activities of these two opposing enzymes, MLCK and MLCP (Webb, 
2003).  
1.3. Ca2+ -transport mechanisms across the plasma membrane  
  
Ca2+ entry from the extracellular medium occurs through plasma 
membrane ion channels in response to a wide variety of stimuli, including 
membrane depolarization (Pesic et al., 2004), stretch, extracellular 
agonists (Ruegg et al., 1989), and the depletion of intracellular stores 
(Berridge et al., 2003, Weirich et al., 2005). Based on the mechanism of 
activation, there are three main routes by which Ca2+ enters cells across 
the plasma membrane: voltage-dependent Ca2+ channels (VDCCs), 
receptor-operated Ca2+ channels (ROCCs), and store-operated Ca2+ 
channels (SOCCs) (Gibson et al., 1998, Bootman et al., 2001, 
Brueggemann et al., 2006). On the other hand the removal of Ca2+ from 
the cytosol into the extracellular space occurs via plasma membrane Ca2+-
DGHQRVLQH ¶ WULSKRVSKDWDVH $73DVH 30&$ DQd sodium Na+/Ca2+ 
exchanger (NCX) or intracellular pumps, which recycle Ca2+ back into 
organelles (Berridge et al., 2003). Interplay between these opposing 
processes is responsible for the maintenance of cytosolic Ca2+ at ~100 nM 
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whereas the extracellular medium is more than 1 mM (Rizzuto and Pozzan, 
2006). 
1.3.1. Voltage-gated Ca2+ channels  
 
Voltage-gated Ca2+ channels (VDCCs) play a central role in the regulation 
of vascular tone and blood pressure regulation (van Meel et al., 1983, 
Moosmang et al., 2003). Activation of Ca2+ channels by membrane 
depolarization, leads to Ca2+ influx, Ca2+ elevation, and vasoconstriction 
(Berridge et al., 2000), whereas membrane potential hyperpolarization 
closes voltage-gated Ca2+ channels and leads to vasodilatation 
(Yanagisawa et al., 1993). Findings revealed that Ca2+ influx could also 
stimulate Ca2+ release from intracellular stores (Fernandez-Tenorio et al., 
2011). L-type Ca2+ channel blockers are widely used to treat hypertension 
because of their ability to reduce arterial smooth muscle cell contractility 
(Saida and van Breemen, 1983, Kalsner, 1997). There are five distinct 
subtypes of voltage-gated calcium channels: L, T, N, P and R. Voltage-
gated calcium channels are protein complex of 5 subunits: the central 
pore-IRUPLQJ VXEXQLW WHUPHG Į is associated with other accessory 
subunits that regulate channel gating and trafficking like the intracellular 
(ǃ) subunit and the disulfide-linked glycoprotein subunits (ĮDQG Ǆ). The 
fifth subunit is the transmembrane (į) subunit (Catterall, 2011). In general 
L-type Ca2+ channels are particularly important in regulating contraction of 
cardiac and vascular smooth muscles. T and N channels mediate Ca2+ 
entry into neurons and involved in neurotransmitter release (Kuga et al., 
1990, Todorovic and Jevtovic-Todorovic, 2011). Results have 
demonstrated the existence of two different types of Ca2+ channels, L-type 
and T-type, in smooth muscle cells from coronary arteries of guinea-pigs 
(Ganitkevich and Isenberg, 1990). However, the contribution of T-channels 
to the peripheral resistance still has not been ruled out (Cribbs, 2001, 
20 
 
Cribbs, 2006). 7KHĮVXEXQLWs of the L-type channels contain binding sites 
for dihydropyridine Ca2+ channel blockers (Campbell et al., 1988). 
Clinically, Ca2+ channel antagonists like nifedipine, verapamil and diltiazem 
are commonly used for their cardiovascular effects e.g. blood pressure 
control (Klein, 1987, Kalsner, 1997). On the other hand, vasodilators like 
nitroprusside, by acting through cGMP and protein kinase G, could regulate 
the open-probability of Ca2+ channels thereby inhibiting Ca2+ influx. By 
contrast, vasoconstrictors act through the protein kinase C pathway, with 
subsequent activation of Ca2+ channels (Ishikawa et al., 1993, Taguchi et 
al., 1997, Chaplin and Amberg, 2012)   
Data have shown that mitochondrial reactive oxygen species generation at 
complex III result in cardiac L-type Ca2+ channel inhibition (Scragg et al., 
2008). Similarly, superoxide anion impairs Ca2+ channel function in arterial 
smooth muscle cells (Fusi et al., 2001). Conversely, hydrogen peroxide 
(H2O2) has been shown to stimulate arterial smooth muscle L-type Ca
2+ 
channels by a mechanism involving oxidative activation of PKC (Tabet et 
al., 2004, Chaplin and Amberg, 2012).  
1.3.2. Store-operated Ca2+ channels 
 
Store-operated Ca2+ channels (SOCCs) are plasma membrane, non-
selective, cation channels. They are activated to allow Ca2+ entry when the 
endoplasmic reticulum (ER) stores are depleted (Parekh, 2003). SOCCs are 
distinct from other membrane calcium channels. Many of them are 
speculated to belong to the family of transient receptor potential (TRP) 
channels (Golovina et al., 2001, Xu and Beech, 2001). It is unclear what 
kind of linkage couples them to the ER. However, two major theories have 
been proposed. First, SR Ca2+ depletion stimulates a second messenger, 
which activates plasma membrane Ca2+ channels (Bootman et al., 2001). 
Second, SOCCs are activated by either a conformational coupling between 
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Ca2+ channels on the SR and those on the plasma membrane; The protein 
STIM1 is the Ca2+ store sensor located in the membrane of the ER (Liou et 
al., 2005),  and the PM protein Orai1 is the SOC channel (Yang et al., 
2012). Cultured proliferative VSMCs display increased SOCE and high 
levels of STIM1 and Orai1 compared with their quiescent contractile freshly 
isolated counterparts (Potier et al., 2009). Store-operated Calcium entry 
does not appear to play a significant role in smooth muscle or cardiac 
contractility. In contrast, skeletal muscle contractility appears to depend on 
SOCE (Trebak, 2012). However, others have suggested that SOCCs play a 
role in Ca2+ entry and the control of vascular contractility (Zhang et al., 
2002, Brueggemann et al., 2006). Like the SR channels, the SOCCs serve 
to amplify the rise in intracellular Ca2+ (Park et al., 2008). So far, only 
experimental compounds are known to block these channels. However, 
efforts are being made to develop specific blocking agents for therapeutic 
use as smooth muscle relaxants (Tosun et al., 1998a, Leung et al., 2008). 
1.3.3. Receptor-operated Ca2+ channels   
 
Receptor-operated Ca2+ channels (ROCCs) refers to Ca2+ permeable 
nonselective cation channels. These channels are opened independently of 
membrane potential or intracellular Ca2+ stores (Leung et al., 2008). 
Furthermore, ROCCs are not inhibited by organic Ca2+ channel antagonists. 
In fact, ROCCs are activated by a wide variety of agonists such as 
acetylcholine, angiotensin II, endothelin-1, noradrenaline, 5-HT and 
vasopressin that stimulate Ca2+ entry into the SMCs (Leung et al., 2008). 
The Ca2+ entry through ROCCs could be blocked by the multivalent cations 
La2+, Cd2+, Mn2+, Ni2+ and Mg2+ (Ruegg et al., 1989). ROCCs are thought 
to be involved in guinea pig aorta contraction induced by noradrenaline, 
since the contraction was only partially blocked by Ca2+ channel blockers 
(Gouw et al., 1990). Similarly, in rat cultured aortic smooth muscle cells, 
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ATP, angiotensin II, and vasopressin caused Ca2+ influx that was 
independent of membrane depolarization and unaffected by Ca2+ channel 
antagonists, while significantly reduced by phospholipase C inhibitors 
(Ruegg et al., 1989). 
1.4. K+ channels mediated vasodilatation  
 
Potassium channels are the dominant ion conductive pathways in 
electrically excitable cells, including those found in vascular muscle cells. 
As such, they contribute to the regulation of the membrane potential and 
vascular tone (Nelson et al., 1990). Opening of K+ channels in the cell 
membrane increases K+ efflux with membrane potential hyperpolarization. 
This effect is followed by the closure of voltage-dependent Ca2+ channels, 
with subsequent reduction in Ca2+ entry and vasodilation (Yanagisawa et 
al., 1993). Closure of K+ channels has the opposite effect i.e. K+ channels 
inhibition contributes to membrane depolarization and vasoconstriction 
(Post et al., 1992, Kirschstein et al., 2009). Thus, the presence of a 
physiological or pharmacological agent that alters membrane potential, for 
example, the KATP channel opener cromakalim, should cause a significant 
change in blood vessel diameter and eventually result in reduction in blood 
pressure (Yanagisawa et al., 1993). In the microcirculation, as in other 
vascular muscles, four distinct types of K+ channel in arterial smooth 
muscle have been identified: voltage-dependent K+ (KV) channels, Ca
2+-
activated K+ (BKCa) channels, ATP-sensitive K
+ (KATP) channels, and inward 
rectifier K+ (Kir) channels (Standen and Quayle, 1998). 
1.4.1. Voltage-activated K+ channels  
 
Voltage-activated K+ channels (Kv) are a class of K
+ channels expressed by 
the vascular smooth muscle cells. These channels are activated by 
membrane depolarization with threshold potentials of ~-30 mV to allow an 
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efflux of K+ resulting in repolarization and return to the resting membrane 
potential (Jackson, 1998). Therefore, they are thought to serve an 
important buffering function against depolarization and vasoconstriction. 4-
aminopyridine is widely used as a pharmacological blocker of Kv channels 
(Heaps and Bowles, 2002). The concentration for half-maximal inhibition of 
Kv channel function has been shown to be ~ 1 mM (Okabe et al., 1987, 
Smirnov and Aaronson, 1992, Gelband and Hume, 1992). Studies from 
hypertensive animal models indicated decreased expression of functional 
Kv channels in vascular muscle cells (Jepps et al., 2011). Kv channel 
activity was also reduced in animal models of diabetes, in vivo, and 
similarly when vessels were incubated in high glucose solutions, in vitro 
(Bubolz et al., 2005, Liu et al., 2001, Li et al., 2004). Furthermore, 4-
aminopyridine incubation causes arterial depolarization and constriction, 
suggesting that Kv channel activity exists in some blood vessels under 
basal conditions in health and disease (Jackson, 1998, Heaps and Bowles, 
2002). Prostacyclin, through Kv activation, may contribute to endothelium-
dependent relaxation in rabbit cerebral arteries (Dong et al., 1998). 
Vasodilators that act via nitric oxide, may also directly activate Kv channels 
(Irvine et al., 2003). Similarly, reactive oxygen species are also considered 
as modulators of Kv activity (Fike et al., 2013). On the other hand, 
vasoconstrictors may inhibit Kv by mechanisms that involve protein kinase 
C activation (Clement-Chomienne et al., 1996).   
1.4.2. Calcium-Activated K+ Channels 
 
Calcium-activated K+ channels (Kca) are particularly abundant in vascular 
smooth muscle cells and appear to play a fundamental role in regulating 
resting membrane potential and vascular tone (O'Rourke, 1996, Ledoux et 
al., 2006, Dalsgaard et al., 2009). Kca channel activity in vascular smooth 
muscle cells (VSMCs) is correlated with the occurrence of spontaneous 
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transient outward K+ currents (STOCs). Localized calcium release events 
from ryanodine receptors, termed calcium sparks, activate nearby calcium-
activated potassium channels, causing a hyperpolarizing current i.e. STOCs 
to oppose vasoconstriction (Zhuge et al., 2004). Therefore arterial tone 
results from the interplay of opposing calcium-dependent processes: 
constriction, which is driven by global increases in calcium induce 
vasoconstriction while localized calcium concentrations induce 
vasorelaxation. The KCa channel family consists of small conductance 
(SKCa), intermediate conductance (IKCa,) and large conductance Ca
2+-
activated K+ channel (BKCa) subtypes. In the microcirculation, physiological 
activation of vascular BKCa channels may be an important negative 
feedback mechanism to counteract vessel depolarization and active 
vasoconstriction in response to some vasoconstrictors, for example, the 
thromboxane A2 (TXA2) mimetic (U46619) (Knot et al., 1998), ET-1 and 
angiotensin II (Scornik and Toro, 1992, Minami et al., 1995). Kca thus 
represent an important pharmacological target. Pharmacological agents 
commonly used to inhibit BKCa channels include tetraethylammonium ion 
(1 mmol/L), charybdotoxin, and iberiotoxin, whereas NS-1619 has been 
shown to activate BKca channels (O'Rourke, 1996, Heaps and Bowles, 
2002). Vasodilators that act through the cGMP and cAMP cascades may 
result in Kca channel activation (Minami et al., 1993b). Results have also 
suggested that both PKG and PKA activate BKca channels (Song and 
Simard, 1995). Reactive oxygen species have been reported as modulators 
of BKca activity in porcine coronary artery smooth muscle cells (Barlow and 
White, 1998, Tang et al., 2004). In fact, the effects range from channel 
activation to inhibition depending on the type of ROS involved and local 
ROS concentration (Barlow and White, 1998, Soto et al., 2002, Gutterman 
et al., 2005).  
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1.4.3. ATP-sensitive K+ channels   
 
ATP-sensitive K+ channels (KATP) were first identified in guinea pig cardiac 
myocytes (Suzuki et al., 2001, Noma, 1983). From then on, similar 
channel currents have been identified in pancreatic ǃ-cells (Tarasov et al., 
2004), smooth and skeletal muscles (Davies, 1990, Yokoshiki et al., 1998), 
central nervous system neurones (Ashcroft, 1988, Bernardi et al., 1988), 
and renal tubular cells (Mauerer et al., 1998, Loutzenhiser and Parker, 
1994). The activity of KATP channels is controlled by intracellular ATP (see 
below); an increase in the ATP/ADP ratio closes the KATP channels (Cook 
and Hales, 1984). Cardiac KATP channels have a physiological role in 
modulating cardiac function under conditions of metabolic stress when ATP 
is reduced. During ischaemia, opening of cardiac KATP channels is thought 
to protect against myocardial damage. Increasing K+ efflux and shortening 
of the action potential duration will decrease Ca2+ influx and the 
subsequent contraction, the latter eventually result in reducing cardiac 
work and conserving ATP (Gross and Peart, 2003, Yang et al., 2007, Yao 
and Gross, 1994). In fact, the reduction in infarct size by preconditioning 
was blocked completely by intracoronary 5-hydroxydecanoate (a 
mitochondria KATP channel blocker) or glibenclamide (a plasma membrane 
KATP channel blocker) (Auchampach et al., 1992, Foster et al., 2012). 
Moreover, ischaemia, hypoxia and metabolic inhibition-induced vasodilation 
in the coronary and cerebral circulation can be prevented by glibenclamide. 
Studies in dogs (Samaha et al., 1992) and humans (Farouque et al., 2002) 
have shown that in vivo application of glibenclamide increases coronary 
tone. Such evidence points to a functional role for KATP channels under 
physiological conditions (Daut et al., 1994). However, in porcine isolated 
coronary arteries KATP channels inhibition caused no change in basal 
contractility (O'Rourke, 1996).   
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In pancreatic ǃ-cells, when the plasma glucose level rises, the 
concentration of ATP increases, the latter results in closure of KATP channels 
(Cook and Hales, 1984, Kakei et al., 1986). Closure of KATP channels in the 
plasma membrane allows the cells to depolarize, subsequently triggering 
calcium entry and insulin release (Miki et al., 1999, Henquin, 2000). KATP 
channels are targets for several clinically important groups of drugs, 
including the sulphonylureas, commonly used to treat type II diabetes 
(Nagashima et al., 2004), and the KATP channel openers, used to treat 
angina and hypertension (Arena and Kass, 1989, Gollasch et al., 1995).  
1.4.3.1. Cellular mechanisms that regulate KATP channels 
 
KATP channels are sensitive to the intracellular ATP/ADP ratio. In pancreatic 
ǃ-cells, KATP channels are rapidly inhibited by ATP (Cook and Hales, 1984) 
and activated by ADP e.g., MgADP (Gribble et al., 1998). By sensing the 
ATP and ADP levels, these KATP channels are able to couple the cellular 
metabolism to membrane excitability (Tarasov et al., 2004). Beech et al. 
suggested that KATP channels in vascular smooth muscle may not respond 
primarily to changes in ATP nucleotide, instead diphosphates may play a 
primary role in the regulation of these channels under physiological 
conditions (Beech et al., 1993). Vasodilators like, isosorbide dinitrate, 
increase cGMP in the vascular smooth muscle cells. The increased levels of 
cellular cGMP result in protein kinase G (PKG) activation. In turn vascular 
KATP channels are opened by vasodilators that activate PKA and PKG. 
Vasodilators coupled to PKA could also activate Kca (Song and Simard, 
1995) and Kv (Aiello et al., 1995) to inhibit VDCC (Orlov et al., 1996). On 
the other hand, KATP are closed by vasoconstrictors that activate PKC 
(Chrissobolis and Sobey, 2002). In fact, vasoconstrictors coupled to PKC 
also inhibit Ca2+-activated K+ channels (Minami et al., 1993a) and voltage-
dependent K+ channels (Clement-Chomienne et al., 1996). 
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Inhibition of cellular metabolism with oxidative phosphorylation inhibitors 
e.g. cyanide or dinitrophenol, or with glycolysis inhibitors e.g. 2-
deoxglucose or iodoacetic acid caused activation of KATP currents in smooth 
muscle cells (Silberberg and van Breemen, 1992, Teramoto and Brading, 
1996). Several vasoconstrictors, for example, noradrenaline, histamine, 5-
HT (Bonev and Nelson, 1996), endothelin-1 (Miyoshi et al., 1992), 
vasopressin (Wakatsuki et al., 1992) and angiotensin II (Miyoshi and 
Nakaya, 1991, Sampson et al., 2007)  have been shown to inhibit vascular 
KATP channels in pig coronary artery. Using patch clamp, results have 
shown that H2O2 activates KATP current in smooth muscle cells isolated from 
mice aortas (Sharifi-Sanjani et al., 2013). Similarly, in guinea-pig 
ventricular myocytes, exposure of the patch membrane to ROS, O2
± and 
H2O2, increased the opening of KATP channels. Such effect of ROS was 
prevented by perfusion with glibenclamide (Tokube et al., 1998). On the 
other hand, H2O2 suppressed pinacidil-induced KATP channel activation in 
cultured aortic VSMCs (Yasui et al., 2012). Moreover, exposure of isolated 
mesenteric rings to H2O2 impaired the KATP channel-mediated vascular 
dilation (Yang et al., 2010).    
1.4.3.2. Structure 
 
The KATP channel is a hetero-octamer composed of two subunits, K
+ 
channel (Kir6.x) pore forming subunits and regulatory SUR subunits 
arranged in stoichiometry of 4:4. Two types are currently known: Kir6.1 
which acts as the pore-forming subunit in vascular smooth muscle and 
Kir6.2 which forms the KATP channel pore in pancreatic ǃ-cells, cardiac and 
skeletal muscles, and neurones. On the other hand, the sulphonylurea 
receptors (SUR): SUR1 and SUR2 (SUR2A, SUR2B) function as regulatory 
subunit, conferring sensitivities of the channel to several KATP channel 
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activators and inhibitors like sulfonylureas, MgADP and some channel 
openers. Different combinations of Kir and SUR subunits generate tissue-
specific KATP channel subtypes, table 1.1 (Miki et al., 1999). 
   
Table 1.1 KATP channel subunits distributions in different tissues 
Tissue type                                        Major Subunit composition 
3DQFUHDWLFǃ-cell type Kir6.2 
 
SUR1 
 
Neuron  Kir6.2 
 
SUR1 
Cardiac and skeletal muscle type Kir6.2 
 
SUR2A 
 
Vascular smooth muscle type 
 
Kir6.1 
 
SUR2B 
 
 
In 1991, Inoue et al. identified the KATP channel in rat liver mitochondrial 
inner membrane (mitoKATP) (Inoue et al., 1991). It has been proposed that 
mitoKATP may also consist of Kir and SUR subunits. Subsequent work 
revealed a possibly unique pharmacology in that mitoKATP was inhibited by 
5-hydroxydecanoate and activated by diazoxide. Work on the mitoKATP 
channel has mainly been focused on ischemic preconditioning (Pain et al., 
2000).    
1.5. The vascular endothelium  
 
The vascular endothelium is the inner lining of blood vessels. In the past, 
the endothelium was considered to be a passive, semipermeable barrier. In 
1980, studies confirmed the necessity of an intact vascular endothelium in 
order to obtain a vasodilatation induced by acetylcholine (Furchgott, 1999, 
Furchgott and Zawadzki, 1980). It is now becoming clear that the 
endothelium actively participates in vascular homeostasis regulation 
through the release of potent vasoactive agents that elicit either 
contraction or relaxation of vascular smooth muscle (Pearson and 
Vanhoutte, 1993). The most important endothelial-derived substances are: 
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nitric oxide (NO) and prostacyclin (PGI2) that act as vasodilators (Ignarro 
et al., 1987, Luckhoff et al., 1988, Mitchell et al., 2008), while 
thromboxane (TXA2) and endothelin (ET-1) act as vasoconstrictors (Hill et 
al., 2000, Wilson et al., 2005, Loomis et al., 2005).  
1.5.1. Nitric oxide:  
 
In vascular endothelial cells, nitric oxide (NO) is formed from the cationic 
amino acid L-arginine during the conversion to L-citrulline. The reaction is 
catalysed by the endothelial isoform of NO synthase (eNOS) (Guterbaum et 
al., 2013) which is constitutively expressed. NOS is activated via changes 
in intracellular calcium and calmodulin in response to changes in shear 
forces or via a receptor-mediated process (White and Martin, 1989). 
Released NO is able to diffuse to adjacent smooth muscle cells where it 
activates soluble guanylyl cyclase (sGC) (Arnold et al., 1977, Rapoport and 
Murad, 1983). The latter converts GTP to cyclic-3,5-guanosine 
monophosphate. Accumulation of cGMP activates protein kinase G (PKG), 
which mediates the effects of NO/cGMP in the smooth muscle (Archer et 
al., 1994, Pfeifer et al., 1998). cGMP inhibits IP3 levels which explains the 
findings that cGMP inhibits cytosolic calcium, through both inhibition of 
calcium influx and reduction of intracellular calcium release (Collins et al., 
1986, Luckhoff et al., 1988). This in turn decreases the phosphorylation of 
myosin light chains, causing smooth muscle vasodilatation. NO could also 
directly activate Kca channels of the vascular smooth muscle (Bolotina et 
al., 1994). Thus, nitric oxide plays a pivotal role in regulating vessel wall 
homeostasis.      
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1.5.2. Arachidonic acid (AA) metabolites: 
  
Arachidonic acid metabolites play a key role in the regulation of diverse 
processes in both physiological and pathological states. Their vasoactive 
properties are evident from the finding that AA itself, when applied to 
blood vessels, produces relaxation (Rosolowsky and Campbell, 1993). 
1.5.3. Cyclooxygenase (COX)-derived metabolites of AA:  
 
Prostacyclin (PGI2) has long been recognised as the chief AA metabolite in 
blood vessels, where it acts to mediate vasodilatation (Pratt et al., 1996). 
Prostacyclin is normally produced by cyclooxygenase, COX, from 
arachidonic acid (Caughey et al., 2001). COX-1 is present constitutively in 
most tissues. COX-2 is also present constitutively in the vascular 
endothelium and kidney (Dogne et al., 2005). PGI2 diffuses to vascular 
muscle where it activates adenylyl cyclase, the latter in turn increases the 
production of adenosine 3,5-cyclic monophosphate (cAMP) which results in 
vascular relaxation. (Kukovetz et al., 1979).   
1.5.4. Cytochrome P450-derived metabolites of AA. 
 
The products of AA metabolism by the cytochrome P450 system are 
epoxyeicosatrienoic acids (EETs), monohydroxyeicosatetraenoic acids 
(HETEs) and dihydroxyeicosatrienoic acids (DHETs) (Zeldin, 2001). Of 
these, EETs are most relevant in blood vessels. They have been shown to 
mediate relaxation of vascular muscle by activating large-conductance, 
Ca2+-activated K+ (BKCa) channels (Dong et al., 1997, Hayabuchi et al., 
1998, Fisslthaler et al., 1999, Campbell et al., 2001, Gauthier et al., 2005, 
Huang et al., 2005). 
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1.5.5. Endothelium-derived hyperpolarising factor:  
 
Considerable evidence shows that several receptor-dependent agonists, 
such as acetylcholine, bradykinin, histamine and substance P, release 
endothelium-derived hyperpolarizing factor (EDHF) that causes vascular 
smooth muscle hyperpolarization (Dong et al., 1997). In general, EDHF 
may be of greater importance in resistance than in large conduit arteries 
(Garland et al., 1995). The contribution of EDHF to endothelium dependent 
relaxation appears to be dependent on tissue and the type of the agonist 
(Waldron et al., 1996, Graier et al., 1996). EDHF diffuses to vascular 
smooth muscle where it activates potassium (K+) channels activity with 
subsequent hyperpolarization and relaxation of the vascular muscle 
(Hayabuchi et al., 1998). In fact, the identity of EDHF remains to be 
established. The classical EDHF involves K+ that effluxes via K+ channels 
on endothelial cells. Spread of hyperpolarizing current from the endothelial 
cells, via myoendothelial gap junctions, to the smooth muscle cells 
hyperpolarizes and relaxes adjacent smooth-muscle cells by activating K+ 
channels and Na+/K+ ATPase (Edwards et al., 1998). It could be a product 
of AA metabolism, EETs. The latter hyperpolarize and relax vascular 
smooth muscle cells (SMCs) by activating calcium-sensitive potassium 
(KCa) channels. Another possible mediator of EDHF- induced smooth-
muscle relaxation is by activating of Na+/K+ ATPase (Edwards et al., 1998). 
H2O2 also considered as an endogenous EDHF and plays an important role 
in coronary autoregulation in co-operation with NO (Yada et al., 2003, 
Matoba et al., 2003, Liu et al., 2011).   
1.6. HMG-CoA reductase inhibitors 
 
Atherosclerosis, a pathologic and progressive process affecting the arterial 
walls, is characterized by the accumulation of lipid particles and immune 
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cells in subendothelial regions, and by the proliferation of vascular smooth 
muscle (VSM) cells, leading to a narrowing of the arterial lumen, following 
plaque rupture and thrombosis. An endothelial dysfunction, which is the 
first step in the disease, can be induced by a variety of risk factors such as 
elevated levels of LDL-cholesterol (Badimon and Vilahur, 2012). 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, known as 
statins, are some of the most effective and best tolerated lipid modifying 
agents for the treatment of hyperlipidemia (Schaefer et al., 2004, Cheung 
et al., 2004, Jorge et al., 2005). Many are presently approved for clinical 
use. Some are fungal ±derived metabolites, like simvastatin, lovastatin and 
pravastatin. Others are totally synthetic like atorvastatin, cerivastatin  
fluvastatin and pitavastatin, but all share the HMG-CoA like moiety on their 
polycyclic backbone (Figure 1.2) (Schachter, 2005a). 
  
Figure 1.2. Chemical structure of simvastatin: simvastatin (left) have 
a lactone ring similar to HMG-CoA biologically active moiety (right). 
Adapted from (Wang and Asgharnejad, 2000). 
 
1.6.1. Pharmacokinetics:  
 
Simvastatin and lovastatin are administered orally as a lactone prodrug 
while pravastatin is administered as the active open ring form. Liver 
enzymes hydrolyse the prodrugs, simvastatin and lovastatin, to the active 
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hydroxyl acid derivatives. Gastrointestinal absorption of statins varies from 
30% to 80%, with almost complete absorption for fluvastatin (Scripture 
and Pieper, 2001). The oral bioavailability of simvastatin and lovastatin is 
low, largely owing to their cytochrome P450 (CYP3A)-mediated first-pass 
metabolism (Neuvonen et al., 1998), whereas the bioavailability of 
fluvastatin and pravastatin is higher than simvastatin. All undergo first 
pass metabolism, either oxidized by CYP3A4 in the liver, or hydrolysed to 
several metabolites. Most of the absorbed dose is excreted in the bile. The 
lipophilic statins, simvastatin and lovastatin, enter the liver passively 
(Komai et al., 1992, Schachter, 2005a), whereas the water soluble agents, 
e.g. pravastatin, are taken up by an active transport (Komai et al., 1992). 
Thus in terms of tissue selectivity, pravastatin exhibits liver selectivity in 
comparison with other lipophilic statins (Koga et al., 1992). Plasma half-life 
of the parent compound ranges from 1 to 3 hours except for atorvastatin 
may reach up to 14 hours and rosuvastatin about 20 hours (Garcia et al., 
2003).  
1.6.2. Adverse effects   
 
Statins are well tolerated. However, mild unwanted effects have been 
reported like myalgia, gastrointestinal disturbance, raised plasma level of 
liver enzymes, insomnia and rashes (Bitzur et al., 2013). Recently, 
increased risk of glucose intolerance has been reported especially with 
lipophilic statins (Byrne and Wild, 2011, Bellia et al., 2012, Wang et al., 
2012, Carter et al., 2013, Dormuth et al., 2014, Turan et al., 2014, 
Macedo et al., 2014). More serious adverse effects are rare, but include 
severe myositis (Simsek Ozek et al., 2014). Myositis, rhabdomyolysis, is a 
class effect of statins, occurs also with other lipid-lowering drugs 
(especially fibrates) and it is dose-related.  
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1.6.3. Lipophilicity  
 
Simvastatin and lovastatin are both examples of lipophilic statins that can 
cross the plasma membrane. On the other hand, the hydrophilic statins 
like pravastatin remain associated with the polar surface of the membrane 
(Koga et al., 1992). The lipophilic statins can enter the cell membrane 
passively with a large volume of distribution among tissues (Ohtawa et al., 
1999), while the water soluble agents are liver specific and an essential 
carrier mechanism is required for their uptake (Lennernas and Fager, 
1997). Under physiological pH conditions the relative lipophilicity of various 
statins was: simvastatin = cerivastatin > lovastatin = fluvastatin = 
atorvastatin >> pravastatin (Joshi et al., 1999).  
1.6.4. Mechanism of action as hypolipidaemic agents:   
 
Statins act by reversible inhibition of 3-hydroxy-3-methylglutaryl-
coenzyme-A reductase (HMG- CoA reductase), the enzyme responsible for 
HMG-CoA conversion to mevalonate (Stancu and Sima, 2001) . The 
structural similarity between the statins side chain and the enzyme 
substrate, HMG-CoA, renders them effective competitive blockers of the 
rate determining step in mevalonate biosynthesis (Schachter, 2005a) 
(Fig.2). Reducing intracellular cholesterol leads to upregulation of low 
density lipoprotein (LDL) receptor expression on the hepatocyte surface, 
resulting in an increase in the catabolism of LDL by increasing LDL 
extraction from the blood. Statins also have been shown to reduce, to a 
lesser extent, the level of triglyceride (Branchi et al., 1999) and increase 
high density lipoprotein (Asztalos et al., 2002). However, simvastatin 
might also exert cholesterol independent effects. Several landmark clinical 
trials have shown that simvastatin reduces mortality and morbidity in 
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patients both with and without hypercholesterolaemia (Fichtlscherer et al., 
2006).  
1.6.5. The pleiotropic effects of statins. 
 
Several clinical and experimental studies have demonstrated that statins 
exert a variety of clinically useful outcomes in patients with a wide range of 
cholesterol levels, which cannot be attributed to their cholesterol lowering 
effects alone. Such outcomes are collectively known as pleiotropic effects 
of statins (Sadowitz et al., 2010a, Sadowitz et al., 2010b). These are 
unrelated, or indirectly related, to their effect on plasma cholesterol and 
are usually unanticipated. Understanding such effects is important to 
optimize statin use in the treatment and prevention of cardiovascular 
disease (Bonetti et al., 2003). The pleiotropic effects have been 
appreciated in cardiovascular disease (CVD). Some of the added benefits in 
CVD include: blood pressure-lowering effect with normalized vasomotion 
(Correa et al., 2014), improved endothelial cell function (Wolfrum et al., 
2003), attenuation of endothelin-1 synthesis, down regulation of 
angiotensin receptor synthesis (Ichiki et al., 2001), improved 
bioavailability of NO (Hernandez-Perera et al., 1998), attenuation of 
vascular inflammation (Wassmann et al., 2002), decreased vascular 
smooth muscle cell (VSMC) proliferation and migration (Corpataux et al., 
2005b), stabilization of atherosclerotic plaque, and inhibition of platelet 
aggregation (Libby, 2001). 
1.6.6. Mechanism of action as a pleiotropic agent:  
 
Statins are potent inhibitors of the rate-limiting step of the mevalonate 
pathway. They have a high affinity for HMG-CoA reductase and are able to 
significantly block the production of mevalonate, a necessary precursor for 
cholesterol synthesis. Furthermore, mevalonate is the building block for a 
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variety of other important isoprenoid intermediates, such as farnesyl 
pyrophosphate and geranylgeranyl pyrophosphate (Corpataux et al., 
2005b, McTaggart, 2006). These lipophilic isoprenyl groups permit small G-
proteins to anchor to cell membranes, thus enabling sub-cellular 
localisation, and intracellular trafficking of membrane-associated proteins 
(Lane and Beese, 2006). Ras translocation is dependent on farnesylation, 
whereas Rho translocation is dependent on geranylgeranylation (Noguchi 
et al., 1998), both of which exert important effects on vascular smooth 
muscle cells (Brown et al., 2006). Statins, by inhibiting isoprenylation, 
effectively lower membrane levels and activity of Ras/Rho proteins as a 
likely mechanism mediating some of the pleiotropic effects of statins and 
thus improve vascular function (Figure 1.3) (Nohria et al., 2009).  
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Figure 1.3. Cholesterol biosynthesis pathway and site of statins 
action, Statins inhibits HMG-CoA reductase. Thus, statins decrease 
isoprenoid intermediates such as farnesylpyrophosphate (F-PP) and 
geranylgeranyl-pryophosphate (geranylgeranyl-PP), with subsequent 
inhibition of isoprenylation of the small GTPases such as Ras, Rho, Rac1.  
 
1.6.6.1. Effects of statins on vascular tone.  
 
The role of HMG-CoA reductase inhibitors has been demonstrated to go 
beyond cholesterol biosynthesis, such as regulation of smooth muscle tone. 
Lipophilic statins such as cerivastatin, simvastatin, atorvastatin and 
lovastatin, but not the hydrophilic pravastatin induced coronary 
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vasodilation in the isolated bovine coronary arteries (Lorkowska and 
Chlopicki, 2005). Simvastatin also produced relaxation of both aorta and 
small mesenteric artery, with and without functional endothelium (Alvarez 
De Sotomayor et al., 2000). The relaxation of rat aorta was observed in 
rings precontracted with noradrenaline, endothelin-1 and KCl (60mM) 
(Mraiche et al., 2005). Similarly, lipophilicity is an important factor behind 
the effects of statins on vascular tone in the cerebral circulation (Beretta et 
al., 2011). On the other hand, pravastatin might induce vascular relaxation 
which appears to be endothelium-dependent. This could be due to 
differential expression in endothelial cells and smooth muscle cells of 
organic anion transporters required for cellular uptake of hydrophilic 
statins (Hasegawa et al., 2002). Clinically, in patients with type II 
diabetes, simvastatin improved the lipoprotein profile and significantly 
improved flow-mediated dilator response (Koh et al., 2005). Furthermore, 
simvastatin lowers blood pressure in patients with hypertension (Juncos et 
al., 2012), particularly in the presence of high levels of cholesterol. Thus, 
statins might work synergistically with antihypertensive drugs to 
significantly improve inadequately controlled hypertension (Mangat et al., 
2007, Juncos et al., 2012, Xing et al., 2007, Correa et al., 2014). Similarly, 
lovastatin reduced vascular reactivity in kidneys of spontaneously 
hypertensive rats and attenuated the development of hypertension (Jiang 
and Roman, 1997). Lastly, statin therapy is associated with improved 
survival in patients suffering from peripheral vascular disease (Schillinger 
et al., 2004). 
1.6.6.2. Statin and NO bioavailability:   
 
A considerable number of studies have demonstrated a key role of 
endothelial nitric oxide synthase (eNOS) in statin-associated cardiovascular 
protection (Chen et al., 2000, Kalinowski et al., 2002, Kuhlmann et al., 
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2004, Brandes, 2005, de Sotomayor et al., 2005, Rikitake and Liao, 2005). 
Results revealed that simvastatin acutely enhances NOS phosphorylation 
via the phosphatidylinositol -3 kinase protein kinase/Akt pathway. (Nakata 
et al., 2007, Ghaffari et al., 2011). Inhibition of Rho isoprenylation is one 
of the best examined pleiotropic effects of statins (Rashid et al., 2009, 
Rattan, 2010). It is well known that Rho/Rho kinase pathway negatively 
regulates eNOS phosphorylation through inhibition of protein kinase B (Akt) 
(Ming et al., 2002). Thus, long-term use of statins results in enhanced NO 
bioavailability in part due to blocking isoprenoid synthesis.  
Caveolin, which acts as an inhibitor of eNOS activation, impairs NO release 
in the endothelial cells. It is interesting to consider that long-term statin 
therapy could improve endothelial function via down-regulation of caveolin, 
with subsequent activation of eNOS. On the other hand, Rossoni et al., 
demonstrated that short-term incubation with simvastatin result in 
phosphorylation of AMP kinase (Rossoni et al., 2011). AMPK plays a role in 
the regulation of energy homoeostasis. However, it is now evident that 
AMPK is engaged in eNOS phosphorylation and NO production (Sun et al., 
2006). Thus, short term simvastatin therapy could directly modulate small 
vessel contractility via a NO-dependent mechanism that is associated with 
AMPK phosphorylation (Rossoni et al., 2011).   
1.6.6.3. Statin and Prostaglandin bioavailability:  
 
Cyclooxygenase (COX) enzymes are involved in the metabolism of 
arachidonic acid. Two major products, thromboxane A2 (TXA2) and 
prostacyclin (PGI2), are produced from arachidonic acid via COX. TXA2 
participates in vascular contraction, whereas PGI2 acts as a vasodilator 
(Dogne et al., 2005). Results reveal the involvement of vasodilatory 
products from COX in the endothelium-dependent relaxation to statins in 
the aorta and small mesenteric artery (Alvarez De Sotomayor et al., 2000). 
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In fact, statins have been reported to stimulate the production of 
prostacyclin (Degraeve et al., 2001, Lorkowska B, 2005, Birnbaum et al., 
2005). Degraeve et al. suggested that geranylgeranylated proteins 
negatively regulate COX-2 expression (Degraeve et al., 2001). Thus, statin 
therapy might enhance PGI2 formation in a COX-2-dependent manner 
through inhibition of Rho (Degraeve et al., 2001). Conversely, data have 
shown that lovastatin inhibited prostacyclin release in cultured vein 
endothelial cells by reducing activity of COX-1 independent of mevalonate 
(Zhou et al., 2009). On the other hand, Alvarez De Sotomayor et al. 
demonstrated that simvastatin had no effect on prostacyclin release. 
Instead it might inhibit thromboxane TXA2 formation from cyclooxygenase 
(de Sotomayor et al., 2005).   
1.6.6.4. Statin and Ca2+ distribution:   
 
Experimental observation revealed that simvastatin incubation suppressed 
the contraction induced by Bay K8644, an activator of voltage- dependent 
Ca2+ channel (VDCC) in rat aortic rings (Kang et al., 2014). Similarly, 
simvastatin suppressed the contraction mediated by high potassium-
induced membrane depolarization, with subsequent opening of VDCC 
(Kang et al., 2014). Both results suggested that voltage-dependent Ca2+ 
entry might be altered in response to simvastatin. Alvarez de Sotomayor et 
al. demonstrated that simvastatin effects in the vascular smooth muscle 
might involve both Ca2+ release from intracellular pools with concurrent 
blockade of extracellular Ca2+ entry (Alvarez de Sotomayor et al., 2001). 
However, the data also show that the relaxant effect induced by 
simvastatin was not counteracted by the addition of CaCl2, thus 
simvastatin might indirectly inhibit Ca2+ influx. Such a mechanism could be 
related to the inhibition of isoprenoid synthesis, the latter affects G-
proteins function which is involved in communication among intracellular 
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Ca2+ pools and capacitative Ca2+ entry (Alvarez de Sotomayor et al., 
2001). Similarly L-type Ca2+ channel blockade with a concomitant 
reduction in intracellular free Ca2+ has been proposed as a mechanism for 
lovastatin-induced relaxation in the cerebral circulation, independently of 
cholesterol and isoprenoid synthesis (Bergdahl et al., 2003). In the same 
study of Bergdahl et al., the hydrophilic pravastatin had no effect on 
contraction; The authors explained that cellular penetration by the 
lipophilic statin, lovastatin, was prerequisite for induction of vascular 
relaxation (Bergdahl et al., 2003). Similarly, LQ UDW SDQFUHDWLF ǃ-cells the 
lipophilic simvastatin, but not by the hydrophilic pravastatin, inhibited Ca2+ 
influx through voltage gated Ca2+ channel (Yada et al., 1999). 
On the other hand, simvastatin induced an increase in cytosolic calcium in 
endothelial cells, by releasing Ca2+ from intracellular stores and by 
increasing Ca2+ entry through mevalonate-dependent pathway (Alvarez de 
Sotomayor and Andriantsitohaina, 2001). In skeletal muscle, acute 
application of simvastatin resulted in alteration of Ca2+ homeostasis with 
increase in cytoplasmic Ca2+. The latter was a downstream result of an 
early alteration of mitochondrial membrane potential (Sirvent et al., 
2005b).   
1.6.6.5. Statin and K+ channels   
 
Another possible explanation for the simvastatin vasorelaxant effects is a 
direct modulation of K+ channel activity. Lopez et al. suggested the Kca 
subfamily as a potential target for rosuvastatin relaxation in rat aortic rings 
(Lopez et al., 2008). Furthermore, Lopez-Canales et al. reported that the 
methyl ester derivative of rosuvastatin mediated relaxation by activation of 
K+ channels as a complementary mechanism for the relaxation induced by 
the NO pathway (Lopez-Canales et al., 2011). Similarly, Kuhlmann et al. 
demonstrated that cerivastatin activates calcium-activated K+ channels in 
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endothelial cells isolated from human umbilical cord veins. The latter 
mechanism was suggested as a class effect of statins since the channel 
activation was completely reversed by the addition of mevalonate 
(Kuhlmann et al., 2004). Cerivastatin and fluvastatin, but not pravastatin, 
relaxed rat aorta and mesenteric arteries via multiple mechanisms that 
involve endothelium-dependent relaxations through nitric oxide and 
endothelium-independent relaxations via K+ channel±mediated 
hyperpolarizations. The latter were abolished by 118 mM KCl and the K+ 
channel inhibitors, 4-AP (Kv channel blocker) and TEA (nonselective 
inhibitor of K+ channels) (Mukai et al., 2003). Another study by Miller et al. 
in insulin-resistant rats showed that statins lower cardiovascular morbidity 
and improve coronary and cerebral relaxation by restoring Kca channel 
function to the normal level (Miller et al., 2004). Inadequate myocardial 
re-perfusion therapy, P\RFDUGLDO µQR-UHIORZ¶, after ischaemia and 
reperfusion of the acute myocardial infarction has been suggested to be 
due to suppression of KATP channel opening. It is possible that simvastatin 
has beneficial effects in reducing myocardial no-reflow via activation of KATP 
channels (Zhao et al., 2006, Yang et al., 2007). In another study, 
glibenclamide (KATP channel blocker) significantly inhibited cerivastatin 
relaxation in rat aortic rings, suggesting involvement of KATP channel 
activation in cerivastatin relaxation (Sonmez Uydes-Dogan et al., 2005). 
Conversely, in porcine vascular coronary myocytes, simvastatin inhibited 
cromakalim- and pinacidil-evoked KATP channel openings (Seto et al., 
2013). The same authors also reported that the lipophilic simvastatin 
causes inhibition of Kca in coronary myocytes while the hydrophilic salt 
form of simvastatin has no effect on channel amplitude (Seto et al., 2007). 
Furthermore, simvastatin and lovastatin, but not pravastatin, inhibited pig 
coronary artery relaxations to KATP channel opener pinacidil, (Uhiara et al., 
2012). Findings of Seto et al., and Uhiara et al., suggested that 
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simvastatin induced porcine coronary relaxation by K+-channel 
independent mechanism. 
1.6.6.6. Statin and Reactive Oxygen Species generation     
 
Alvarez De Sotomayor et al. demonstrated that endothelium-dependent 
relaxation induced by simvastatin was significantly inhibited with 
superoxide dismutase (SOD) incubation in rat aorta. Such an observation 
highlighted the participation of free radicals in simvastatin-induced 
relaxation. On the other hand, acetylcholine-induced aortic relaxation was 
inhibited in simvastatin or atorvastatin-dosed rats (Parker et al., 2003). 
The latter study suggested an increased reactive oxygen species 
generation with the lipophilic simvastatin or atorvastatin, but not the 
hydrophilic pravastatin. Other reports have also demonstrated impaired 
endothelial relaxation to acetylcholine following lovastatin treatment 
(Roullet et al., 1993, Roullet et al., 1995). Furthermore simvastatin 
treatment resulted in AMPK activation through reactive nitrogen species 
(Choi et al., 2008). As simvastatin has been shown to inhibit different 
mitochondrial complexes in the respiratory chain (Nadanaciva et al., 
2007b), it is possible that simvastatin could stimulate mitochondrial 
reactive oxygen species (ROS) generation which in turn might regulate 
vascular tone. Interestingly, endothelium-dependent coronary 
vasodilatation operates through NADPH oxidase-derived ROS to activate 
Akt-eNOS axis (Feng et al., 2010). NADPH oxidase±mediated ROS release 
is associated with increased Rac1 activity (Sohn et al., 2000, Wassmann et 
al., 2002, Maack et al., 2003). The critical process in the activation of 
NADPH oxidase is the isoprenylation of Rac1 via geranylgeranylation, with 
subsequent translocation to the cell membrane (Seshiah et al., 2002). 
Thus, simvastatin treatment may contribute to inhibition of NADPH 
oxidase-mediated superoxide generation via targeting of Rac1 activation 
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(Erdos et al., 2006). Taking these published data into account, it is 
plausible that simvastatin could modulate coronary vascular tone via ROS. 
Such properties of statins might partly account for their early benefits in 
cardiovascular events. 
1.7. Mitochondria 
 
The main function of mitochondria is thought to be the synthesis of ATP 
which is used as an energy source by many cellular processes (Buttgereit 
and Brand, 1995). Mitochondrial oxidative phosphorylation employs the 
energy released by the oxidative transfer of electrons, from chemically-
reduced substrates, to oxygen in order to generate transmembrane 
electrochemical gradient, the mitochondrial proton motive force (ƩP), The 
latter is subsequently used to power the phosphorylation of ADP via ATP 
synthase (Hatefi, 1985). 
1.7.1. Mitochondrial oxidative phosphorylation 
  
Mitochondria are intracellular organelles found in all human cells 
responsible for aerobic metabolism by oxidative phosphorylation. They are 
composed mainly of two lipid bi-layer membranes. The two membranes 
differ considerably in their permeability. The outer membrane is rich with 
cholesterol and permeable to ions, a property attributed to voltage 
dependent anion-selective channels (VADC) (Liu and Colombini, 1992). By 
contrast, the inner membrane is devoid of cholesterol and impermeable to 
ions. The latter is folded to form a shelf-OLNHVWUXFWXUHFDOOHG³FULVWDH´ZKLFK
are filled with enzymes that extract energy from nutrients. Embedded in 
the inner membrane are the proteins that are involved in the process of 
electron transport (Murphy and Smith, 2000). The space between the two 
membranes is called the intermembrane space. The electron carrier 
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proteins are arranged side by side like a chain. Three of these proteins are 
ion pumps. Most of the energy harvested is held in energy carriers such as 
NADH and FADH2 (Figure 1.4). The first step in NADH oxidation by 
complex I, or NADH-ubiquinone oxidoreductase, is the transfer of two 
electrons from NADH to the flavin mononucleotide (FMN) within the 
complex. Subsequently, these two electrons are passed from FMN to 
ubiquinone (Q), these electrons reduce ubiquinone (UQ) to ubiquinol (QH2) 
which diffuses through the membrane to complex III. Energy from the 
electrons are also used to pump H+ ions from the matrix into the 
intermembrane space (Hirst, 2010), The transfer of electrons can be 
blocked by the inhibitor rotenone (Friedrich et al., 1994). Complex II, 
succinate ubiquinone oxidoreductase is a second entry to the electron 
transport chain starting from FADH2, produced through the citric acid 
cycle, UQ is reduced to QH2 through the oxidation of FADH2 to FAD. This 
step can be competitively inhibited by malonate (Thorn, 1953). Electron 
transfer from succinate to ubiquinol does not release sufficient free energy 
for proton translocation, and so, unlike complex I, complex II does not 
pump protons to the intermembrane space. Therefore, complex II does not 
contribute the generation of ƩP. Electrons continue to travel down their 
electrochemical gradient to complex III, ubiquinol cytochrome-c 
oxidoreductase. Cytochrome-bc1 in complex III transfers electrons from 
QH2 to cytochrome-c. QH2 is oxidized back to UQ which is now able to 
return to transport another pair of electrons, with the protons also being  
transferred across the membrane (Fernie et al., 2004). The electron 
transfer at complex III can be inhibited by antimycin A (Gao et al. 2003), 
and this ultimately prevents the oxidation of ubisemiquinone molecules 
bound at the Qo site by complex III. The electrons shift down to the last 
protein of the chain, complex IV or cytochrome-c oxidase complex, with 
more H+ ions being pumped into the intermembrane space (Verkhovsky et 
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al., 1999). Complex IV then transfers electrons from cytochrome-c to 
oxygen, the terminal electron acceptor, and water is formed as the final 
product. The inner mitochondrial membrane is impermeable to H+ ions, 
thus the intermembrane space generates a proton motive force across the 
inner membrane of the mitochondria due to H+
 
gradient. Subsequently, the 
H+ ions diffuse back to the matrix through special channel protein called 
ATP synthase, complex V. The energy derived from the movement of these 
protons is used to synthesize ATP from ADP and phosphate. Formation of 
ATP by this mechanism is referred to as oxidative phosphorylation. 
Mitochondria are characterized by an alkaline and negatively charged 
matrix. Lipophilic cations can easily pass through the lipophilic barrier. As a 
consequence mitochondria can trap lipophilic compounds, like simvastatin, 
efficiently (Horobin et al., 2007).  
1.7.2. Mitochondria and ROS generation in the vascular smooth muscle cells  
 
The main enzymatic sources of superoxide production within the vascular 
wall are mitochondrial electron transport chain (Freed et al., 2014), 
NAD(P)H oxidase (Feng et al., 2010), cytochrome P450 Xanthine oxido-
reductase (Fleming et al., 2001), nitric oxide synthases (Wang et al., 
2000) and cyclooxygenases and lipoxygenases (Gunasekar et al., 1998). 
In addition to the generation of cellular energy, mitochondria also play an 
important role in a wide range of cellular activities like cellular signalling 
(Zhang and Gutterman, 2007). Mitochondria seem to be an important 
redox signalling node because of the ROS generated by the respiratory 
chain within the mitochondria. The site of the O2
± production is mainly 
thought to be complex III (Chandel et al., 2000, Guzy et al., 2005). In the 
matrix, the O2
± is converted to H2O2 by manganese superoxide dismutase 
(Mn-SOD). The latter is present in high concentrations within the matrix 
and it reacts very rapidly with O2
± (figure 1.4). The formed H2O2 can pass 
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easily through mitochondrial membranes and acts as a redox signal from 
the mitochondria to the rest of the cell. Complex III can also release O2
± 
into the intermembrane space (St-Pierre et al., 2002, Muller et al., 2004, 
Han et al., 2001). O2
±, within the intermembrane space, can either be 
converted to H2O2 by an intermembrane space Cu,Zn-SOD or diffuse the 
outer membrane to the cytosol through the voltage-dependent anion 
channel. Although O2
± is shorter lived and less diffusible than H2O2. It can 
act as a redox signal (Zhou et al., 2010).   
 
Figure 1.4.  The mitochondrial electron transport chain complexes I 
and II reduce coenzyme Q via NADH and FADH2 electrons. Coenzyme Q in 
turn shuttles the electrons to complex III, with subsequent transfer to 
cytochrome c. Complex IV reduce molecular oxygen to water via electrons 
from cytochrome c.  The action of complexes I, III, and IV generates a 
proton motive force across the inner membrane of the mitochondria, which 
is used to phosphorylate ADP at ATP synthase. Complexes I and II 
generate superoxide into the mitochondrial matrix through the incomplete 
reduction of oxygen to superoxide, whereas complex III produces 
superoxide into both the matrix and the intermembrane space. The 
PLWRFKRQGULDOPHPEUDQH SRWHQWLDO ƩƺP LV the electrochemical gradient 
that is present across the inner mitochondrial membrane and is generated 
by pumping H+ by complexes I,III,IV of the respiratory chain. This 
potential is used to drive ATP synthesis via complex V.   
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1.7.3. Mitochondria and ROS in the regulation of vascular tone: 
 
ROS generation is traditionally considered as a pathological response since 
free radicals in blood vessels quench NO produced by the endothelium with 
resultant impairment in vasomotor function. However, experimental data 
have shown that NADPH-mediated ROS, within the physiological levels, are 
necessary to activate the phosphatidylinositol 3-kinase±Akt±endothelial NO 
synthase axis. Subsequent endothelial NO synthesis mediates endothelial-
dependent coronary relaxation (Feng et al., 2010). H2O2 also mediates 
coronary vessels relaxation via BKca channel activation (Barlow et al., 
2000, Thengchaisri and Kuo, 2003). Alternatively, H2O2 increased coronary 
blood flow by acting directly on vascular smooth muscle via Kv channel 
(Rogers et al., 2006). H2O2 might also act as EDHF in human mesenteric 
arteries (Matoba et al., 2002).   
In the large vessels, superoxide and hydrogen peroxide-activate calcium 
sparks in the endothelial cells. The Ca2+ spark could raise local Ca2+ 
concentrations sufficiently to participate in eNOS activation, thereby 
inducing endothelium-dependent relaxation (Gutterman, 2005) In fact, 
H2O2 exposure could increase eNOS mRNA expression (Drummond et al., 
2000). On the other hand, in the small coronary arterioles, mitochondrial 
respiratory chain-derived H2O2 was found to be responsible for flow-
mediated vasodilatation that was independent of NO (Cai, 2005). The 
majority of ROS produced by the cells originates from mitochondrial 
metabolism. Thus mitochondria could play a key role in cell signalling (Xi et 
al., 2005, Zhang and Gutterman, 2007). In general, mild mitochondrial 
depolarization or electron transport blockade induced ROS elevation with 
increased calcium spark frequency, the latter stimulating KCa channels with 
resultant cerebral artery vasodilation (Xi et al., 2005). By contrast, marked 
depolarizations of the mitochondria using FCCP or rotenone reduced 
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calcium spark activity, thereby reducing opening of BKCa channels. In 
human coronary arterioles, complex I and III-derived H2O2 was responsible 
for flow-mediated vasodilation (Liu et al., 2003). Moreover, mitochondrial 
depolarization with subsequent activation of eNOS by ROS ±independent 
mechanisms had been suggested as a mechanism for cerebral artery 
vasodilation (Katakam et al., 2013). On the other hand, ROS generation by 
smooth muscle mitochondria could act as the initial stimulus for cold-
induced cutaneous artery vasoconstriction through RhoA activation (Bailey 
et al., 2005). Similarly, experiments under hypoxic conditions revealed 
that increased mitochondrial peroxide generation might attenuate bovine 
coronary arterial relaxation (Gao et al., 2009).      
1.7.4. Interplay between mitochondria and cytosolic Ca2+ signals  
 
Mitochondria are now have an acknowledged importance in the control of 
physiological Ca2+ signals in various cell types, including smooth muscle. 
7KH PLWRFKRQGULDO SURWRQ JUDGLHQW DQG ¨ƺ0 GULYHs Ca2+ uptake into the 
organelle. Therefore, mitochondria may take up and sequester a large 
amount of Ca2+ from the cytoplasm over a wide range of concentrations, 
~200 nM to >10 µM, and modulate the time course and amplitude of Ca2+ 
signals (McCarron et al., 2012). Mitochondria also supply ATP for ion 
pumps within the smooth muscle cell, thereby regulating Ca2+ efflux 
(Drummond and Fay, 1996). The mitochondria appeared to be located 
close to influx and release sites to modulate Ca2+ signals (McCarron et al., 
2012) and the results suggest a new role for mitochondrial Ca2+ influx in 
regulating calcium release activated channel (CRAC) activity in intact cells 
(Glitsch et al., 2002, Malli et al., 2003). Results also suggest mitochondrial 
ROS can modulate voltage-gated Ca2+ channel (Fearon, 2006, Scragg et 
al., 2008).  
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1.7.5. Mitochondria as a target for statin therapy:  
 
Considering the complexity of mitochondria, it is not surprising that they 
could be a target for the statin-induced pleiotropic effects. Results have 
shown that fluvastatin produces mitochondrial membrane depolarization in 
human hepatocellular carcinoma cells (Zhang et al., 2010). Similarly, 
simvastatin, atorvastatin and lovastatin, caused a dose-dependent 
cytotoxicity of rat hepatocytes with subsequent ROS formation and 
mitochondrial depolarization (Abdoli et al., 2013). It is well established 
that the mevalonate pathway is involved not only in the biosynthesis of 
cholesterol but also in the biosynthesis of ubiquinone, coenzyme Q10. The 
latter is an obligatory coenzyme for mitochondrial enzyme complexes in 
oxidative phosphorylation for the production of ATP. As such, HMG-CoA 
reductase inhibitors block the cellular production of both cholesterol and of 
coenzyme Q10 leading to impairment in mitochondrial bioenergetics, e.g. 
simvastatin-induced CoQ10 deficiency has been proposed as a reason for 
hepatotoxicity (Tavintharan et al., 2007). Similarly, simvastatin, but not 
pravastatin, caused worsening of myocardial mitochondrial respiration 
during ischaemia by reducing myocardial coenzyme Q10 levels (Satoh et 
al., 1995). In skeletal muscle, statins induce toxicity which is related to 
alterations in mitochondrial respiration calcium homeostasis (Kwak et al., 
2012, Galtier et al., 2012). In fact, the results have shown that simvastatin 
and lovastatin inhibit complex I, II + III, IV and V in heart and liver 
mitochondria and they may even act as mitochondrial uncoupler 
(Nadanaciva et al., 2007a, Nadanaciva et al., 2007b). By contrast, 
pravastatin has no observable effect on any of the complexes, which could 
be related to the structural difference of the latter i.e. ǃ-hydroxy acid in 
pravastatin in comparison to lactone ring in simvastatin (Nadanaciva et al., 
2007a, Nadanaciva et al., 2007b).   
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Conversely, simvastatin attenuated mitochondrial membrane 
depolarization in the cardiac myocytes after exposure to oxidative stress 
(Jones et al., 2003b). Similarly, in isolated rat liver mitochondria, 
simvastatin and atorvastatin have antioxidative properties by lowering 
intra-mitochondrial ionized calcium (Parihar et al., 2011). Interestingly, 
opposite effects of simvastatin on mitochondria from cardiac and skeletal 
muscles have been suggested i.e improvement of antioxidant capacities in 
heart, while conversely the ROS production by the skeletal muscle induced 
mitochondrial impairments (Bouitbir et al., 2012). Collectively, these data 
confirm mitochondrial modulation by simvastatin; the mechanism needs to 
be carefully considered. 
1.8. Starting hypothesis: 
 
As well as reducing plasma cholesterol levels, statins induce acute 
vasorelaxation which may contribute to the overall benefits of statins in the 
treatment of cardiovascular disease. The mechanism underlying this 
relaxation is unknown. Statins have been shown to alter mitochondrial 
function. Therefore, this study investigated the role of mitochondria in the 
relaxation to simvastatin. 
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CHAPTER II: ACUTE EFFECTS OF SIMVASTATIN ON 
PORCINE CORONARY TONE: ROLE OF KATP AND 
MITOCHONDRIA 
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2.1. INTRODUCTION 
  
HMG-CoA reductase inhibitors, or statins, are the drug of first choice for 
treatment of hypercholesterolemia (Dansette et al., 2000, Pedersen et al., 
2004, Gupta et al., 2010). Treatment with statins reduces cardiovascular 
risk and, more specifically, has a beneficial effect on coronary artery 
disease (Waters et al., 1994). However, these beneficial effects cannot be 
explained fully through reductions in plasma cholesterol levels (Omori et 
al., 2002). A number of studies have demonstrated an effect of statins on 
vascular tone (McGirt et al., 2002, Mukai et al., 2003, Lorkowska and 
Chlopicki, 2005). These direct effects on vascular smooth muscle tone are 
thought to underlie some of the improvements in cardiovascular outcomes 
in patients on statins. Treatment with statins has also been shown to 
improve endothelial function in disease states (Treasure et al., 1995, 
Dupuis et al., 1999, Alvarez De Sotomayor et al., 2000, Tiefenbacher et 
al., 2004). Indeed, statins have been shown to produce both endothelium-
dependent and ±independent relaxations of blood vessels. For example 
simvastatin, atorvastatin, cerivastatin, but not pravastatin, display 
endothelium-dependent vasorelaxation, suggested to be mediated by nitric 
oxide and prostanoids (Alvarez De Sotomayor et al., 2000, Sonmez Uydes-
Dogan et al., 2005, Lorkowska and Chlopicki, 2005). Previous clinical 
investigations demonstrated that the effects of statin on vascular coronary 
tone occur within hours (Iida et al., 2007, Kono et al., 2013). Data from 
the isolated heart preparation showed that simvastatin caused a 
concentration-dependent coronary vasodilatation within minutes 
(Gryglewski et al., 2001). Similarly, simvastatin elicits dilation of the 
isolated porcine retinal arteriole within a few minutes (Nagaoka et al., 
2007).  
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NO with PGI2 are essential for the maintenance of cardiovascular health 
(Mitchell et al., 2008). NO has numerous beneficial effects including the 
regulation of arterial tone and thus blood flow (Sausbier et al., 2000, 
Drouin et al., 2007). Kureishi et al reported that simvastatin and 
pravastatin treatment led to a dose-dependent increase in Akt 
phosphorylation which is implicated in NO regulation within 15 minutes, 
and peaked at about 1 hour (Kureishi et al., 2000). Moreover, lovastatin 
and pravastatin stimulate eNOS phosphorylation in bovine aortic 
endothelial cells as early as 1 min which reach maximal levels at 30 min in 
Akt-dependent manner (Harris et al., 2004). Similar evidence from bovine 
aortic endothelial cell culture using nitric oxide electrode measurement has 
demonstrated that simvastatin activates NO increase within 1 minute 
(Kaesemeyer et al., 1999). In rat mesenteric artery, simvastatin acutely 
phosphorylate eNOS and modulate vascular contractility via AMPK 
dependent phosphorylation (Rossoni et al., 2011). Activation of the soluble 
guanylyl cyclase/cGMP pathway is generally considered to be a major 
vasodilatory mechanism for NO (Sausbier et al., 2000). However, studies 
have demonstrated that NO also elicits vasodilation through cGMP-
independent pathways by activating potassium channels (Bolotina et al., 
1994, Deka and Brading, 2004).  
The results regarding prostacyclin production are inconsistent. For 
example, atorvastatin increased the tissue concentration of COX2 as 
downstream to eNOS phosphorylation (Birnbaum et al., 2005). Others, like 
De Sotomayor et al. have suggested that simvastatin did not affect the 
release of prostacyclin but it inhibited the generation of thromboxane A2 
from the COX-2 isoform (de Sotomayor et al., 2005).  On the other hand, 
lovastatin diminished prostacyclin production (Zhou et al., 2009). 
Atorvastatin also has been shown to reduce the expression of 
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cyclooxygenase-2 in cultured smooth muscles (Hernandez-Presa et al., 
2002).   
Interestingly, in studies in which the hydrophilic pravastatin produces a 
relaxation, the responses are dependent upon the presence of the 
endothelium (Jorge et al., 2005, Ghaffari et al., 2011), whereas 
endothelium-independent effects only seem to be observed by lipophilic 
statins (Tesfamariam et al., 1999, Bergdahl et al., 2003). This could be 
due to differential expression in endothelial cells and smooth muscle cells 
of organic anion transporters required for cellular uptake of hydrophilic 
statins (Hasegawa et al., 2002).  
As well as stimulating vasodilatation, our laboratory has demonstrated that 
simvDVWDWLQ LQKLELWV ǃ-adrenoceptor-mediated relaxation of porcine 
coronary artery (Uhiara et al., 2012). Previously, Seto et al have shown 
that simvastatin inhibits Ca2+-activated K+ channels in coronary artery 
smooth muscle (Seto et al., 2007), which may be responsible for the 
LQKLELWLRQ RI ǃ-adrenoceptor-mediated relaxations. Moreover, Seto et al 
provided evidence for KATP channel inhibition by simvastatin in porcine 
coronary artery myocytes (Seto et al., 2013). On the other hand, Yang et 
al suggested that simvastatin increased coronary blood flow after 
myocardial infarction via activation of the KATP channels (Yang et al., 2007). 
Similarly, cerivastatin-induced rat aortic ring relaxation was significantly 
reduced in the presence of glibenclamide, a KATP channel blocker, and 
ouabain, a Na+-K+ ATPase inhibitor (Sonmez Uydes-Dogan et al., 2005). 
Rosuvastatin has been proposed to improve Ca2+-activated K+ channel 
function (Miller et al., 2004). Indeed, rosuvastatin-induced relaxation of rat 
aorta may be due to opening of Ca2+-activated K+ channels (Lopez et al., 
2008). In the last few years H2S has been suggested to be other mediator 
RI VWDWLQV¶ UHOD[DQW HIIHFW YLD .ATP channel activation (Wojcicka et al., 
2011
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On the other hand, alteration of mitochondrial function could be proposed 
as the main mechanism by which statins regulate vascular smooth muscle 
tone (Liu et al., 2003). Clearly, simvastatin has been proved to cause 
mitochondrial depolarization in skeletal muscle (Sirvent et al., 2005b) and 
hepatocytes (Abdoli et al., 2013). In fact, simvastatin and lovastatin inhibit 
mitochondrial complexes I, II, III, IV and V, and may even act as 
respiratory uncouplers. By contrast, pravastatin has no observable effect 
(Nadanaciva et al., 2007a, Nadanaciva et al., 2007b). Similarly, fluvastatin 
has been shown to produce depolarization of the mitochondrial membrane 
(Zhang et al., 2010). Inhibition of mitochondrial activity could lead to an 
increase in production of reactive oxygen species (ROS). An in vitro study 
using NO and superoxide sensor provided direct evidence that vascular 
endothelial cells released NO with concurrent release of superoxide within 
seconds after statin addition (Dobrucki et al., 2001). Interestingly, Alvarez 
de Sotomayor et al reported that the relaxation to simvastatin was 
sensitive to superoxide dismutase incubation, thus superoxide anion might 
contribute towards the actions of simvastatin on vascular tone (Alvarez De 
Sotomayor et al., 2000). ROS from mitochondria can activate Ca2+-
activated K+ channels through generation of short, calcium sparks, leading 
to vasodilatation (Xi et al., 2005). Acute stimulation of mitochondrial 
superoxide generation in some cases is required for eNOS activation 
(Rowlands et al., 2011). Moreover, Katakam et al provided evidence for 
eNOS activation via pharmacological depolarization of the endothelial 
mitochondria (Katakam et al., 2013). On the other hand, data suggest a 
cross talk between mitochondria and NADPH oxidases (Doughan et al., 
2008). For example, the complex I inhibitor, rotenone, or complex III 
inhibitor, myxothiazol, inhibit mitochondrial ROS production and prevent 
activation of NADPH oxidase (Lee et al., 2006, Rathore et al., 2008). 
Furthermore, inhibition of mitochondrial respiration might depress 
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intracellular ATP levels with subsequent KATP channels activation and 
smooth muscle relaxation (Yang et al., 2007, Tavackoli et al., 2004).  
The aim of this study was to determine the effect of simvastatin on porcine 
coronary tone, and to determine whether the effects induced by 
simvastatin were mediated by NO, PGI2 and/or KATP channels, and to 
examine the role of mitochondria as a possible target for simvastatin-
mediated effects.  
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2.2. MATERIALS AND METHODS 
 
2.2.1. Materials    
 
Simvastatin, pravastatin, lovastatin and the sodium salt of simvastatin 
were obtained from Tocris Cookson, Bristol UK. Rotenone, antimycin A, 3-
nitropropionic acid (3-NP), 4,4,4-trifluoro-1-(2-thienyl)-1,3-butanedione 
(TTFA), FCCP, oligomycin, TEA, 4-aminopyridine, glibenclamide, ebselen, 
PEG-catalase, DETCA, AOAA, PPG, U46619, rhodamine 123, nifedipine and 
indomethacin were obtained from Sigma-Aldrich, Poole, UK. Krebs-
Henseleit buffer (NaCl 118, KCl 4.8, CaCl2.H2O 1.3, NaHCO3 25.0, KH2PO4 
1.2, MgSO4.7H2O, glucose 11.1 in mM). Mitochondrial isolation buffer: 
Mannitol 210 mM, Sucrose 70mM, EDTA 1mM, Trizma 50mM (pH 7.4). 
Mitochondrial respiration buffer (potassium chloride 100 mM, mannitol 75 
mM, sucrose 25mM, Trizma 10 mM, EDTA 0.1 mM, potassium dihydrogen 
phosphate 10 mM, magnesium sulphate 1 mM pH 7.1) at 37oC. Medium 
231 (Invitrogen) is a basal medium for the growth of human vascular 
smooth muscle cells. This medium is HEPES and bicarbonate buffered and 
is designed for use in an incubator with an atmosphere of 5% CO2/95% 
air. Medium 231 is supplemented with smooth muscle growth supplement 
to induce differentiation of normal human vascular smooth muscle cells: 
fetal bovine serum 5% v/v, recombinant human basic fibroblast growth 
factor 2 ng/ml, recombinant human epidermal growth factor 0.5 ng/ml, 
and insulin 2 µg/ml. Hanks buffer containing (in mM): 5.6 KCl, 138 NaCl, 
4.2 NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2, 1.2 MgCl2, 5 glucose and 10 HEPES 
[pH 7.4]. 
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2.2.2 .Tissue Preparation  
 
Porcine coronary arteries were used to characterize the effects of 
simvastatin (Sahni et al., 2008, Suzuki et al., 2011).  Porcine hearts from 
pigs of both sexes were obtained from a local abattoir and transported 
back to the laboratory in an ice box containing Krebs-Henseleit buffer 
gassed with a mixture of 95% O2 and 5% CO2. A crude dissection was 
conducted to isolate the anterior proximal descending branch of the 
coronary artery. The artery was dissected out and cleaned of fat and 
connective tissues as previously described (Uhiara et al., 2012). The 
vessels were stored overnight at 4ºC in Krebs±Henseleit solution pre- 
gassed with 95% O2: 5% CO2. Previous experiments have demonstrated 
that these conditions have negligible effect on contractile and vasodilator 
function in isolated blood vessels (Lot and Wilson, 1994). On the next day, 
a fine dissection was performed to remove any excess connective tissues, 
fibers and fat. The artery segments were cut into rings of approximately 5 
mm in length and these pieces then were ready to use in the experiment. 
Each coronary ring was suspended between two stainless steel metal 
hooks in 5 ml organ baths. The upper hook was connected to a force 
transducer for isometric tension recording while the other was connected 
to a glass support. Each bath was filled with 5 ml of Krebs-Henseleit 
solution and was connected to a thermostat to maintain the temperature at 
37oC and constantly gassed with carbogen (95% O2, 5% CO2). The whole 
setup was linked to Powerlab data acquisition system via an amplifier (AD 
Instruments). The transducers were calibrated with a weight of 10 grams.     
2.2.3 Isometric tension recording  
 
Tissues were initially pre-tensioned to 8 g, determined from preliminary 
studies and then left to relax to baseline for approximately 45-60 minutes. 
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Once a stable baseline was reached, two consecutive KCl responses with 
bath concentration of 60 mM were obtained for standardization. After 
about 10-15 min the tissue was washed out with Kreb-Henseleit, and then 
left for 30 min for the tone to re-stabilize to baseline. To elicit reproducible 
responses, the process was then repeated with a second KCl addition to 
each ring segment. Once again, the tissue was washed out with Kreb-
Henseleit solution, to allow the segment tone to return to baseline. After 
about 30 min minutes, cumulative addition of U46619 (20 nM to 30 nM), a 
thromboxane A2-mimetic, was added to stimulate tissue contraction to 
about 50-70% of the second KCl response before addition of a single 
concentration of simvastatin (300 nM to 10 µM), sodium salt of 
simvastatin, lovastatin or pravastatin (all 10 µM) once an appropriate level 
of U46619 response had been achieved (figure 2.2). Control tissues 
contained vehicle only (0.1% v/v DMSO for simvastatin and lovastatin). 
The tone was measured for a further 2 hours. In separate experiments, the 
effect of simvastatin after pre-contraction with endothelin-1 (10-30 nM) or 
40-60 mM KCl was determined. In all experiments, the concentration of 
contractile agent was adjusted to obtain a similar level of pre-contraction 
between tissues. The general experimental protocol described above was 
repeated for each treatment experiments.  
 
2.2.3.1. The role of endothelial factors in the relaxation response to 
simvastatin 
 
In order to determine the role of endothelial factors on the effects of 
statins, tissues were incubated with the nitric oxide synthase inhibitor, L-
NAME (300 µM), the cyclooxygenase inhibitor indomethacin (10 µM) or a 
combination of the two for 30-60 minutes prior to pre-contraction with 
U46619. The role of the endothelium in the statin-induced relaxation was 
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determined by endothelium denudation, achieved by gently rubbing the 
innermost surface of the artery with a pair of fine forceps on a wet tissue 
paper before attaching it to the setup. Successful removal of endothelium 
was tested at the end of the experiment with substance P (10 nM). 
Endothelium denuded segments which relaxed to less than 10% of the 
U46619-induced contraction were considered acceptable. 
2.2.3.2 The role of K+ channels in the relaxation response to simvastatin 
 
In some experiments, to evaluate the role of K+ channels, the segments 
were incubated with the non-selective K+ channel blocker 
tetraethylammonium (TEA; 10 mM), KATP channel blocker glibenclamide (3 
µM) or the Kv channel blocker 4-aminopyridine (1 mM) for 60 minutes prior 
to addition of U46619. Such concentrations of K+ channel blockers have 
been shown effective in previous studies. Glibenclamide (10 µM) inhibits 
coronary contraction significantly, while Kv blockers 4-AP (10 µM) increases 
basal tone more than 50%.   
2.2.3.3 The role of Na+-K+ ATPase pump in the relaxation response to 
simvastatin 
 
In order to determine the role of the Na+-K+ ATPase pump in the relaxation 
response, rings were pre-incubated with 10 µM ouabain. Such 
concentration has been used in a previous study (Sonmez Uydes-Dogan et 
al., 2005). In another set of experiments, a lower concentration of ouabain 
(100 nM) was shown to be effective in this tissue (see chapter IV). 
2.2.3.4. The role of H2S in the relaxation response to simvastatin 
 
The possible involvement of H2S in the relaxation response to simvastatin 
(Wojcicka et al., 2011) was examined by incubating the tissues with the 
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H2S synthesizing enzyme inhibitors amino-oxyacetic acid, AOAA, (100 µM) 
and propargylglycine, PPG, (10 µM) prior to pre-contraction with U46619.   
2.2.3.5. Role of reactive oxygen species in the relaxation response to 
simvastatin  
 
The role of reactive oxygen species in the relaxation response to statins 
was investigated by pre-incubation with a combination of ebselen (10 µM), 
a scavenger of hydrogen peroxide, PEG-catalase (300 Uml-1), which 
metabolises hydrogen peroxide, and PEG-superoxide dismutase (100 Uml-
1), which metabolises superoxide free radicals. In a separate set of 
experiments, tissues were incubated with diethylthiocarbamate (DETCA), 
which inhibits superoxide dismutase (10 mM).  
2.2.3.6. The role of NADPH inhibition in the relaxation response to 
simvastatin:  
 
To examine a possible link between simvastatin relaxation and NADPH 
oxidase inhibition, tissues were exposed to the NADPH oxidase inhibitor 
DPI (10 µM), prior to pre-contraction with U46619.  
2.2.3.7. Role of mitochondria in the relaxation response to simvastatin  
 
To determine the role of mitochondria in simvastatin-induced relaxation, 
rings were incubated for 30 min prior to addition of U46619 with rotenone 
10 µM, a complex I inhibitor, 3-NP and TTFA, complex II inhibitors (both at 
10 µM), antimycin A 10 µM, an inhibitor of complex III at Qi site, 
myxothiazol 10 µM, an inhibitor of complex III at Qo site. The effect of 
FCCP 1 µM, a respiratory chain uncoupler, and oligomycin 10 µM, a Fo/F1 
ATP synthase inhibitor were also determined.  
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2.2.4. Assessment of Mitochondrial membrane potential using Rh123:   
 
Mitochondria are involved in a large variety of cellular functions. A 
characteristic feature of mitochondria is the generation of a large 
transmembrane potential mediated by the H+ transport through activity of 
the respiratory chain. Modulation of the mitochondrial potential has been 
implicated in many different pathological situations (Lu et al., 2010). 
Therefore, the determination of the mitochondrial potential is important for 
the understanding of cellular functions. Rhodamine 123 (Rh123) is used to 
measure changes in mitochondrial potential with time (Palmeira et al., 
1996). When the concentration of Rh123 is above threshold, quenching of 
the indicator occurs. On mitochondrial depolarization, dye moves out from 
the organelles thus increasing the fluorescence signal (Johnson et al., 
1981). On the other hand, mitochondrial membrane hyperpolarization will 
decrease fluorescence intensity due to further concentration of the dye in 
the mitochondria.  
2.2.4.1 Effect of statins on mitochondrial function isolation from porcine 
hearts: 
  
Initial studies to determine the effect of statins on mitochondrial 
membrane potential were carried out using mitochondria obtained from 
porcine hearts. Heart tissue was washed with isolation buffer (Mannitol 210 
mM, Sucrose 70mM, EDTA 1mM, Trizma 50mM, pH 7.4) to remove excess 
blood and weighed. Then about 1 g of tissue was chopped with scissors 
and homogenised in 10 ml of ice-cold isolation buffer using an ultra-turax 
homogenizer at 150 rpm for 10 min. Mitochondria were isolated from the 
tissue as previously described with minor modification (Frezza et al., 
2007). Homogenate then centrifuged at 1000xg for 5 min to remove nuclei 
and unhomogenised material. The supernatant was then spun at 5000xg 
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for 10 min. The resulting supernatant was discarded and the pellet re-
suspended. This was re-centrifuged at 5000xg for 15 min. The resultant 
pellets were then re-suspended in a minimum volume of isolation buffer 
and kept ice cold (figure 2.1). Mitochondria were added to respiration 
buffer (potassium chloride 100 mM, mannitol 75 mM, sucrose 25mM, 
Trizma 10 mM, EDTA 0.1 mM, potassium dihydrogen phosphate 10 mM, 
magnesium sulphate 1 mM, pH 7.1) at 37oC. Glutamic acid 10 mM, and 
malic acid 2.5 mM were added to provide respiratory substrates for the 
mitochondria. Then Rh123 (200 nM) was added to the mixture. Changes in 
fluorescence of Rh123 were measured at an excitation wavelength of 503 
nm, and emission 527 nm using a fluorometer (Hitachi F-2500). After the 
addition of the Rh123 and establishment of a steady reading, mitochondrial 
addition resulted in rapid drop in the fluorescence reading caused by 
quenching of the dye in the mitochondria. After the fluorescence reached a 
new steady state, the compounds of interest, simvastatin, lovastatin, 
pravastatin (10 µM each) in a minimum volume of solvent were examined. 
Finally, FCCP 1 µM was added at the end to completely uncouple the 
mitochondria and cause the fluorescence to raise as a positive control.  
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Figure 2.1: Isolation of mitochondria from pig heart. 
2.2.4.2. Effect of statins on mitochondrial function in isolated vascular 
smooth muscle cells.  
 
In order to determine whether statins alter mitochondrial membrane 
potential ǻƺP in intact cells, human aortic smooth muscle cells (Lonza; 
passages 7 to 9) were grown on sterilized glass cover slips were loaded 
with ǋJPO±1 Rh 123 at 37°C for 10 min in Hanks buffer containing (in 
mM): 5.6 KCl, 138 NaCl, 4.2 NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2, 1.2 MgCl2, 
10 glucose and 10 HEPES with 5 mmol/L glucose (pH 7.4). Cover slips 
were then washed with HANKS and placed in a superfusion system. Cells 
were continuously illuminated at an excitation wavelength of 485±10 nm 
at the lowest light intensity that gave a fluorescent signal. The emitted 
light was long pass filtered at 515 nm and visualised with a Zeiss 
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PlanNeofluar 40X/1.3 oil objective (Carl Zeiss Ltd, Welwyn Garden City, 
Herts, UK) heated to 32°C with an Bioptechs objective heater (Intracel 
LTD, Royston, Herts, UK). Images were captured at a frequency of 1Hz 
with a Photonics ISIS CCD camera, DT3155 frame grabber (Data 
translation, UK) and Imaging workbench software (IW5.2 INDEC 
BioSystems, Santa Clara, CA, USA). Mitochondrial membrane potential 
during perfusion with simvastatin or pravastatin (both 10 µM) was 
monitored by the distribution of Rh123 across the inner mitochondrial 
membrane. Control cells were perfused with vehicle only (0.1% v/v 
DMSO). Images were analyzed using equation below:    
(A-100)/ (B-100)*100 
Where the basal fluorescence is considered to be 100 i.e. mitochondria is 
fully polarized. A value represents the increase in fluorescence induced by 
simvastatin, and B value represents the maximum fluorescence induced by 
FCCP perifusion. 
2.2.4.3. Effect of statins on mitochondrial function in intact porcine coronary 
artery 
 
In order to determine if statins alter mitochondrial membrane potential in 
intact blood vessels, coronary artery segments were incubated with Rh123 
(10 µg/ml) at 37 °C for 10 min in Krebs-Henseleit buffer. The tissue was 
then washed twice with Krebs-Henseleit buffer and placed in a cuvette in a 
fluorometer (Hitachi F-2500) at 37 °C. Changes in fluorescence of Rh123 
were measured at an excitation wavelength of 503 nm, and emission 527 
nm. Fluorescence signals were allowed to stabilise before addition of 
simvastatin (10 µM), or DMSO (0.1% v/v) and fluorescence measured for 
about 20 min. Experiments were terminated by adding FCCP (1 µM) to 
uncouple mitochondrial respiration and establish the maximum release of 
Rh123.  
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2.3. Data Analysis 
 
The relaxation responses were expressed as a percentage change from the 
agonist-induced pre-contraction over time. Values for all figures refer to 
mean ± SEM. Negative numbers indicate relaxation. Relaxation responses 
over time were compared by using two-way analysis of the variance 
(ANOVA) followed by a Bonferroni post-hoc test. Differences were 
considered to be significant when the P value was < 0.05. Changes in 
Rh123 fluorescence were analyzed by one-way ANOVA, followed by 
Tukey's multiple comparisons test. *** indicates p < 0.001, ** indicates 
p<0.01, * indicates p<0.05 (2- way ANOVA followed by a Bonferroni post-
hoc test) versus values obtained from the solvent control DMSO (0.1% 
v/v). 
2.4. RESULTS  
2.4.1. Acute effects of lipophilic versus hydrophilic statins on rings 
precontracted with U46619, ET-1 and KCl:    
2.4.1.1. Effect of simvastatin and lovastatin: 
 
As shown in figure 2.2 & 2.3, acute application of simvastatin elicited a 
concentration and time-dependent relaxation in pig proximal coronary 
artery pre-contracted submaximally with U46619. A lower concentration of 
simvastatin (300 nM) also produced a slow, time-dependent relaxation, but 
this did not achieve significance until 145 minutes (figure 2.4). A similar 
relaxation to simvastatin was obtained with coronary arteries pre-
contracted submaximally with 10-30 nM endothelin-1 and 30-40 mM KCl 
(fig. 2.5 & 2.6).  
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Figure 2.2. Original organ bath trace for simvastatin induced 
porcine coronary relaxation: KCl (60 mM) bath concentration were 
obtained for standardization, after about 10-15 min the tissue was washed 
out with Kreb-Henseleit, and then left to re-stabilize to baseline. Then 
cumulative addition of U46619 was added to stimulate tissue contraction to 
about 50-70% of KCl response before addition of a single concentration of 
simvastatin (3 µM or 10 µM). Control tissues contained vehicle only (0.1% 
v/v DMSO. 
 
Figure 2.3. Effect of simvastatin (1 µM or 10 µM) in porcine coronary 
artery rings pre-contracted with U46619. Data are expressed as a 
percentage relaxation of the U46619-induced contraction and are mean ± 
SEM from 6-9 different animals.  
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Figure 2.4. Effect of simvastatin (300 nM) in porcine coronary artery rings 
pre-contracted with U46619. Data are expressed as a percentage 
relaxation of the U46619-induced contraction and are mean ± SEM from 5 
different animals.  
 
Figure 2.5. Effect of simvastatin (10 µM) in porcine coronary artery rings 
pre-contracted with 10-30 nM ET-1. Data are expressed as a percentage 
relaxation of the ET-1-induced contraction and are mean ± SEM from 9 
different animals.  
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Figure 2.6. Effect of simvastatin (10 µM) in porcine coronary artery rings 
pre-contracted with 40-60 mM KCl compared to U46619 pre-contraction. 
Data are expressed as a percentage relaxation of the KCl-induced 
contraction and are mean ± SEM from 7 different animals.  
 
The doses of simvastatin used in the study are supra-therapeutic compared 
(3-10 ǋM) to the doses used in hypercholesterolemia patients. However, 
the ranges of doses are very similar to those used in other in vitro studies 
of simvastatin (1±30 ǋM) (Luckhoff et al., 1988, Lorkowska et al., 2004), 
In fact, nonspecific tissue cytotoxicity was not involved with 10 µM 
simvastatin in vascular smooth muscle, as determined by another study 
(Kang et al., 2014). Moreover, coronary segments incubated with ǋ0 
simvastatin (1 h) have a comparable contractile response to DMSO-treated 
control segments (figure 2.7). Similarly, smooth muscle cells incubated 
with simvastatin 10 ǋ0 respond normally to 60 mM KCl depolarization after 
simvastatin washout (chapter III, figure 3.15).  
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Figure 2.7. Contractile response of coronary segment treated with 
simvastatin. Coronary segments incubated with  ǋ0 simvastatin 
(statin) or DMSO as a solvent control for 1 h. Then U46619 (20 nM) was 
added to both segments to stimulate tissue contraction. As shown the 
statin treated segment had comparable response to DMSO treated 
segment.   
 
Lovastatin (10 ǋM), another lipophilic HMG-CoA reductase inhibitor, also 
elicited a slow, time-dependent relaxation in a manner similar to 
simvastatin (figure 2.8). 
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Figure 2.8. Effect of lovastatin (10 µM) in porcine coronary artery rings 
pre-contracted with U46619. Data are expressed as a percentage 
relaxation of the U46619-induced contraction and are mean ± SEM from 8 
different animals.  
 
2.4.1.2. Effect of pravastatin and sodium salt of simvastatin: 
 
On the other hand, neither pravastatin nor the sodium salt of simvastatin 
(figure 2.9 & 2.10) caused any significant relaxation in pig proximal 
coronary artery pre-contracted submaximally with U46619.   
 
 
Figure 2.9. Effect of pravastatin (10 µM) in porcine coronary artery rings 
pre-contracted with U46619. Data are expressed as a percentage 
relaxation of the U46619-induced contraction and are mean ± SEM from 8 
different animals.   
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Figure 2.10. Effect of sodium salt of simvastatin (10 µM) in porcine 
coronary artery rings pre-contracted with U46619. Data are expressed as a 
percentage relaxation of the U46619-induced contraction and are mean ± 
SEM from 8 different animals. 
 
2.4.2. Role of endothelium-derived vasodilator factors in the relaxation 
response to simvastatin. 
 
Pretreatment of the porcine coronary rings with a nitric oxide synthase 
inhibitor, L-NAME 300 µM had no significant effect on the relaxation to 10 
µM & 3 µM simvastatin (figure 2.11A  & 2.12 respectively). L-NAME 300 µM 
incubation increased basal tone of the isolated coronary segments by 10-
20 % of the basal tone (figure 2.11B). Similarly, the cyclooxygenase 
inhibitor, indomethacin 10 µM (figure 2.13), or a combination of the two 
compounds (figure 2.14) had no significant effect on the relaxation to 10 
µM simvastatin. Similar concentrations of L-NAME and indomethacin 
diminished simvastatin relaxation in bovine coronary artery in a previous 
study (Lorkowska and Chlopicki, 2005). Similarly, removal of the 
endothelium had no effect on the relaxation response to simvastatin 
(figure 2.15).  
A-  
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B- 
 
Figure 2.11. (A) Effect of L-NAME (300 µM) on relaxations to simvastatin 
(10 µM) in porcine coronary artery rings pre-contracted with U46619. Data 
are expressed as a percentage relaxation of the U46619-induced 
contraction and are mean ± SEM from 17 different animals. (B) Original 
organ bath trace for simvastatin induced porcine coronary relaxation in the 
presence of L-NAME: Contractions to KCl (60 mM) were used for 
standardization KCl, after about 10-15 min the tissue was washed out with 
Kreb-Henseleit, and then left to re-stabilize to baseline. L-NAME (300 µM) 
was added to one segment and compared with the control segment. As 
shown, L-NAME incubation increased basal tone of the coronary segment. 
Then a cumulative addition of U46619 was added to stimulate tissue 
contraction to about 50-70% of KCl contraction before the addition of a 
single concentration of simvastatin (10 µM). Control segments treated with 
simvastatin vehicle only (0.1% v/v DMSO). 
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Figure 2.12. Effect of L-NAME (300 µM) on relaxations to simvastatin (3 
µM) in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 5 different animals.  
 
 
Figure 2.13. Effect of indomethacin (10 µM) on relaxations to simvastatin 
(10 µM) in porcine coronary artery rings pre-contracted with U46619. Data 
are expressed as a percentage relaxation of the U46619-induced 
contraction and are mean ± SEM from 6 different animals.  
 
 
Figure 2.14. Effect of indomethacin (10 µM) and L-NAME (300 µM) 
combination on relaxations to simvastatin (10 µM) in porcine coronary 
artery rings pre-contracted with U46619. Data are expressed as a 
percentage relaxation of the U46619-induced contraction and are mean ± 
SEM from 6 different animals.  
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Figure 2.15. Effect of endothelium removal on relaxations to simvastatin 
(10 µM) in porcine coronary artery rings pre-contracted with U46619. Data 
are expressed as a percentage relaxation of the U46619-induced 
contraction and are mean ± SEM from 12 different animals. 
  
2.4.3. Role of AMPK in the relaxation response to simvastatin. 
 
A previous study by Rossoni et al demonstrated that AMP kinase plays a 
role in the simvastatin mediated relaxation of isolated rat mesenteric 
resistance arteries (Rossoni et al., 2011). However, in the porcine coronary 
artery, incubation with the AMP kinase inhibitor dorsomorphin (10 µM) had 
no effect on simvastatin (10 µM) relaxation (figure 2.16). 
 
Figure 2.16. Effect of dorsomorphin (10 µM) on relaxations to simvastatin 
(10 µM) in porcine coronary artery rings pre-contracted with U46619. Data 
are expressed as a percentage relaxation of the U46619-induced 
contraction and are mean ± SEM from 9 different animals. 
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2.4.4. Role of K+ Channels in the relaxation response to simvastatin 
 
The incubation of coronary rings with the non-selective K+ channel blocker 
TEA (10 mM), the KATP channel blocker glibenclamide (3 µM), or the Kv 
blocker 4-aminopyridine (1 mM) had no effect on the relaxant responses to 
simvastatin (figure 2.17, 2.18 and 2.19 respectively). Since NO acts by 
activation of cGMP or directly by the activation of potassium channels 
(Bolotina et al., 1994), we have examined the combination of TEA (10 mM) 
and L-NAME (300 µM) on simvastatin relaxation. The combination as 
shown in (figure 2.17) had no effect on simvastatin relaxation in porcine 
coronary vessels. Previous studies have shown that TEA 1-10 mM is 
effective in Kca block (White et al., 2001, Bratz et al., 2008). In this study, 
the maximum effective concentration has been used to examine the effect 
of Kca channel on simvastatin 10 µM mediated relaxations. TEA 10 mM 
incubation increased contraction of the isolated coronary segments by 20-
30 % of the basal tone (Heaps and Bowles, 2002).   
 
 
Figure 2.17. Effect of TEA (10 mM) alone or in combination with L-NAME 
(300 µM) on relaxations to simvastatin (10 µM) in porcine coronary artery 
rings pre-contracted with U46619. Data are expressed as a percentage 
relaxation of the U46619-induced contraction and are mean ± SEM from 
10 different experiments. 
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The effect of glibenclamide 10 µM was examined on simvastatin 10 µM 
relaxation. The concentrations of U46619 required to pre-contract coronary 
segments treated with glibenclamide was much higher than the 
concentration required to contract the control rings i.e. 40-50 nM for the 
treated rings compared to 10 nM for the control rings, thus glibenclamide 3 
µM was chosen to examine the effects of KATP block on simvastatin 
relaxation. Such a concentration has been proved to effectively block KATP 
channels in porcine and human coronary arteries (Gollasch et al., 1995). In 
our experiments, glibenclamide incubation had no effect on basal tone of 
the porcine isolated coronary arteries in organ bath preparation. Similarly 
O'Rourke et al have shown that KATP channel block has no effect on porcine 
coronary tone (O'Rourke, 1996).  
 
  
Figure 2.18. Effect of glibenclamide (3 µM) on relaxations to simvastatin 
(10 µM) in porcine coronary artery rings pre-contracted with U46619. Data 
are expressed as a percentage relaxation of the U46619-induced 
contraction and are mean ± SEM from 7 different animals.   
 
The role of Kv in simvastatin relaxation has been examined by incubation 
with Kv channel blocker, 4-AP, 10 µM. However such concentration of 4-AP 
increased the coronary segments tone up to 70-90 % of the basal tone. 
Previous study has shown that 4-AP increases coronary basal tone even 
more than TEA (Heaps and Bowles, 2002). Thus lower concentration of 4-
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AP 1 mM have been used in our experiment to examine the effects of Kv 
block on simvastatin 10 µM relaxation, such concentration increased the 
basal tone by 10-20% only.  
 
Figure 2.19. Effect of 4-AP (1 mM) on relaxations to simvastatin (10 µM) 
in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 6 different animals.  
 
2.4.5. Role of the mitochondria in the relaxation response to simvastatin. 
2.4.5.1 Effect of Mitochondrial Inhibitors on Simvastatin-induced relaxations. 
 
Rotenone (10 ǋM), a complex I inhibitor, caused ~25% inhibition of the 
simvastatin relaxation in pig coronary rings pre-contracted with U46619 
(figure 2.20 A&B & 2.23). Similarly myxothiazol (10 ǋM), a complex III 
inhibitor, partially inhibited simvastatin relaxation ~20% (figure 2.21 
A&B). A combination of rotenone and myxothiazol caused further inhibition 
of the relaxation to simvastatin ~30% (figure 2.22 A&B & 2.23).  On the 
other hand, antimycin A (10 ǋM), another complex III inhibitor did not 
modify the relaxant effect of simvastatin (figure 2.24 A&B). The complex II 
inhibitors 4,4,4-trifluoro-1-(2-thienyl)-1,3-butanedione (TTFA), 3-
nitropropionic acid (3-NP) (both 10 µM) and malonate 1 mM had no effect 
on the simvastatin response (figure 2.25, 2.26 & 2.27). Concentrations of 
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the inhibitors were chosen according to previous studies to achieve a 
complete inhibition of specific electron transport sites in each complex.  
A- 
 
B- 
 
Figure 2.20. (A) Effect of rotenone (10 µM) on relaxations to simvastatin 
(10 µM) in porcine coronary artery rings pre-contracted with U46619. Data 
are expressed as a percentage relaxation of the U46619-induced 
contraction and are mean ± SEM from 10 different animals. (B) Original 
organ bath trace for simvastatin induced porcine coronary relaxation in the 
presence of rotenone (10 µM) : KCl (60 mM) bath concentration were 
obtained for standardization, after about 10-15 min the tissue was washed 
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out with Kreb-Henseleit, and then left to re-stabilize to baseline. rotenone 
(10 µM) was added to one segment and compared with the control 
segment (DMSO). Then a cumulative addition of U46619 was added to 
stimulate tissue contraction to about 50-70% of KCl contraction before the 
addition of a single concentration of simvastatin (10 µM).  
A- 
 
B- 
 
Figure 2.21. (A) Effect of myxothiazol (10 µM) on relaxations to 
simvastatin (10 µM) in porcine coronary artery rings pre-contracted with 
U46619. Data are expressed as a percentage relaxation of the U46619-
induced contraction and are mean ± SEM from 12 different animals. (B) 
Original organ bath trace for simvastatin induced porcine coronary 
relaxation in the presence of myxothiazol (10 µM) : KCl (60 mM) bath 
concentration were obtained for standardization, after about 10-15 min the 
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tissue was washed out with Kreb-Henseleit, and then left to re-stabilize to 
baseline. myxothiazol (10 µM) was added to one segment and compared 
with the control segment (DMSO). Then a cumulative addition of U46619 
was added to stimulate tissue contraction to about 50-70% of KCl 
contraction before the addition of a single concentration of simvastatin (10 
µM).   
 
A- 
 
B- 
 
Figure 2.22. (A) Effect of rotenone (10 µM) and myxothiazol (10 µM) 
combination on relaxations to simvastatin (10 µM) in porcine coronary 
artery rings pre-contracted with U46619. Data are expressed as a 
percentage relaxation of the U46619-induced contraction and are mean ± 
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SEM from 7 different animals. (B) Original organ bath trace for simvastatin 
induced porcine coronary relaxation in the presence of rotenone and 
myxothiazol (10 µM each): KCl (60 mM) bath concentration were obtained 
for standardization, after about 10-15 min the tissue was washed out with 
Kreb-Henseleit, and then left to re-stabilize to baseline. rotenone and 
myxothiazol (10 µM each) were added to one segment and compared with 
the control segment (DMSO). Then a cumulative addition of U46619 was 
added to stimulate tissue contraction to about 50-70% of KCl contraction 
before the addition of a single concentration of simvastatin (10 µM). 
 
 
Figure 2.23. Effect of rotenone (10 µM) and myxothiazol (10 µM) 
combination on relaxations to simvastatin (10 µM) in porcine coronary 
artery rings, comparing the effect of the inhibitors in 4 segments from the 
same animal, pre-contracted with U46619. Data are expressed as a 
percentage relaxation of the U46619-induced contraction and are mean ± 
SEM from 6 different animals. 
A- 
  
B- 
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Figure 2.24. (A) Effect of antimycin A (10 µM) on relaxations to 
simvastatin (10 µM) in porcine coronary artery rings pre-contracted with 
U46619. Data are expressed as a percentage relaxation of the U46619-
induced contraction and are mean ± SEM from 6 different animals. (B) 
Original organ bath trace for simvastatin induced porcine coronary 
relaxation in the presence of antimycin (10 µM): KCl (60 mM) bath 
concentration were obtained for standardization, after about 10-15 min the 
tissue was washed out with Kreb-Henseleit, and then left to re-stabilize to 
baseline. antimycin (10 µM) was added to one segment and compared with 
the control segment (DMSO). Then a cumulative addition of U46619 was 
added to stimulate tissue contraction to about 50-70% of KCl contraction 
before the addition of a single concentration of simvastatin (10 µM).  
 
 
Figure 2.25. Effect of TTAF (10 µM) on relaxations to simvastatin (10 µM) 
in porcine coronary artery rings pre-contracted with U46619. Data are 
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expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 5 different animals.  
 
 
Figure 2.26. Effect of 3NP (10 µM) on relaxations to simvastatin (10 µM) 
in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 11 different animals.  
 
Figure 2.27. Effect of malonate (1 mM) on relaxations to simvastatin (10 
µM) in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 5 different animals.  
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2.4.5.2 Effect of Mitochondrial uncouplers on Simvastatin-induced 
relaxations. 
 
The presence of the respiratory chain uncoupler FCCP (1 ǋM) enhanced the 
relaxation responses to simvastatin (figure 2.28 A&B).  
A- 
 
 
B- 
 
Figure 2.28. (A) Effect of FCCP (1 µM) on relaxations to simvastatin (10 
µM) in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 15 different animals. (B) Original organ bath 
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trace for simvastatin induced porcine coronary relaxation in the presence 
of FCCP (1 µM): KCl (60 mM) bath concentration were obtained for 
standardization, after about 10-15 min the tissue was washed out with 
Kreb-Henseleit, and then left to re-stabilize to baseline. FCCP (1 µM) was 
added to one segment and compared with the control segment (DMSO). 
Then a cumulative addition of U46619 was added to stimulate tissue 
contraction to about 50-70% of KCl contraction before the addition of a 
single concentration of simvastatin (10 µM). 
 
As a comparison with statins, the effects of myxothiazol and FCCP on 
relaxations to pioglitazone were determined. Myxothiazol and FCCP had no 
effect on pioglitazone relaxations (figure 2.29 & 2.30 respectively).  
 
Figure 2.29. Effect of myxothiazol (10 µM) on relaxations to pioglitazone 
(10 µM) in porcine coronary artery rings pre-contracted with U46619. Data 
are expressed as a percentage relaxation of the U46619-induced 
contraction and are mean ± SEM from 5 different animals.  
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Figure 2.30. Effect of FCCP (1 µM) on relaxations to pioglitazone (10 µM) 
in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 6 different animals.   
 
2.4.5.3 Effect of Mitochondrial ATPase inhibitor on Simvastatin-induced 
relaxations. 
 
The presence of the mitochondrial ATPase inhibitor oligomycin (10 µM; 
figure 2.31) did not alter the relaxation responses to simvastatin. 
 
 
Figure 2.31. Effect of oligomycin (10 µM) on relaxations to simvastatin 
(10 µM) in porcine coronary artery rings pre-contracted with U46619. Data 
are expressed as a percentage relaxation of the U46619-induced 
contraction and are mean ± SEM from 7 different animals.  
  
2.4.5.4 Role of mitochondrial KATP channels:  
 
Inhibition of mitochondrial KATP channels with 5-hydroxdecanoate 5-HD 1 
mM had no effect on simvastatin-induce relaxations (figure 2.32). Such 
concentration has been shown effective in mitochondrial KATP blockade 
(Ghosh et al., 2000). 
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Figure 2.32. Effect of 5HD (1 mM) on relaxations to simvastatin (10 µM) 
in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 7 different animals.  
 
2.4.6 Role of Reactive Oxygen Species in the Relaxation Response to 
Simvastatin: 
2.4.6.1 Reactive oxygen species of mitochondrial origin  
 
Inhibition of mitochondrial electron transfer chain can lead to increases in 
production of reactive oxygen species, which may mediate the relaxation 
response. Indeed the simvastatin induced relaxation in aortic rings of rats 
was sensitive to superoxide dismutase and catalase (Alvarez De Sotomayor 
et al., 2000, de Sotomayor et al., 2005). Thus the effect of ebselen, 
hydrogen peroxide scavenger, (10 µM) alone or in combination with PEG-
catalase (300 Uml-1), which metabolises hydrogen peroxide, and PEG-
superoxide dismutase (100 Uml-1), which metabolises superoxide was 
examined. Neither ebselen on its own (figure 2.33 and 2.34), nor a 
combination of ebselen, PEG-catalase and PEG-superoxide dismutase had 
an effect on the relaxation response to simvastatin (10 µM) in the porcine 
coronary artery (figure 2.35).   
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Figure 2.33. Effect of ebselen on relaxations to simvastatin (10 µM) in 
porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 8 different animals. 
 
 
Figure 2.34. Effect of ebselen on relaxations to simvastatin (10 µM) in 
porcine coronary artery rings pre-contracted with KCl. Data are expressed 
as a percentage relaxation of the KCl-induced contraction and are mean ± 
SEM from 5 different animals. 
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Figure 2.35. Effect of PEG-SOD, PEG catalase and Ebselen combination on 
relaxations to simvastatin (10 µM) in porcine coronary artery rings pre-
contracted with U46619. Data are expressed as a percentage relaxation of 
the U46619-induced contraction and are mean ± SEM from 6 different 
animals. 
 
Superoxide dismutase activity is necessary for NO-mediated vascular 
relaxation (Wambi-Kiesse and Katusic, 1999); by SOD inhibition the level 
of superoxide increased with resultant attenuation of vasorelaxation (Omar 
et al., 1991). In our study, the inhibition of SOD with 10 mM DETCA had 
no effect on the relaxation response to simvastatin 10 µM (figure 2.36). 
 
 
Figure 2.36. Effect of DETCA (10 mM) on relaxations to simvastatin (10 
µM) in porcine coronary artery rings pre-contracted with KCl. Data are 
expressed as a percentage relaxation of the KCl-induced contraction and 
are mean ± SEM from 6 different animals. 
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2.4.6.2 Effect of NADPH oxidase inhibition on simvastatin mediated coronary 
relaxation: 
 
Previous studies have suggested that statins regulate reactive oxygen 
species production through effects on NADPH oxidase (Wassmann et al., 
2002, Erdos et al., 2006, Chen et al., 2008). Furthermore, studies have 
shown that regulation of coronary vascular tone may require NADPH 
oxidase-derived ROS to activate phosphatidylinositol 3-kinase-Akt-
endothelial NO synthase axis (Larsen et al., 2009, Feng et al., 2010). 
Therefore, this present study determined whether inhibition of NADPH 
oxidase alters simvastatin-induced relaxations. Incubation with the non-
selective NADPH oxidase inhibitor DPI (10 µM, a concentration used to 
inhibit vascular ROS production (Wind et al., 2010), had no effect on the 
simvastatin induced pig coronary relaxation (figure 2.37).  
 
 
 
 
 
 
 
 
 
Figure 2.37. Effect of DPI (10 µM) on relaxations to simvastatin (10 µM) 
in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 7 different animals.  
 
2.4.6.3 Role of peroxynitrite 
 
Superoxide reacts with NO and forms peroxynitrite, the latter produces 
dilatation in several vascular beds, including coronary vessels (Liu et al., 
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1994). Therefore, this study examined the effect of uric acid (100 µM) as a 
peroxynitrite scavenger (Ohashi et al., 2005). As shown in figure 2.38, uric 
acid had no effect on the simvastatin relaxation in porcine coronary 
vessels.    
 
 
 
Figure 2.38. Effect of uric acid (100 µM) on relaxations to simvastatin (10 
µM) in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 7 different animals.  
 
2.4.7. Effect of the antioxidant quercetin on simvastatin relaxation:   
 
The flavonoid quercetin has anti-oxidant properties (Duarte et al., 2001). A 
previous study by Cristian et al has shown that quercetin (5±10 µM) could 
EHKDYHDVD µµFRHQ]\PH4-PLPHWLF¶¶PROHFXOHDOORZLQJDQRUPDOHOHFWURQ
flow and protecting mitochondrial function (Sandoval-Acuna et al., 2012). 
Quercetin also protected mitochondrial function against the side effects of 
atorvastatin in rats (Bouitbir et al., 2012). Therefore, the effect of 
quercetin on the relaxation response to simvastatin in the porcine coronary 
artery was determined. As shown in figure 2.39, quercetin (10 µM) had no 
significant effect on simvastatin relaxation.  
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Figure 2.39. Effect of quercetin (10 µM) on relaxations to simvastatin (10 
µM) in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 14 different animals.  
 
2.4.8 Effect of DTT on simvastatin relaxation: 
 
A previous study has shown that thiol oxidation was observed to cause 
concentration-dependent relaxation of endothelium- removed bovine 
coronary arteries, such relaxation was reversed by a thiol reductant, 1 mM 
DTT, (Iesaki and Wolin, 2000). Results have also shown that NO has 
opposing effects on the motility of the gall bladder smooth muscle strips, it 
acts as a relaxant agent when NO࣭is formed or a contractile agent when 
peroxynitrite species are formed (Alcon et al., 2001). However, our study 
shows that a reducing environment created by DTT has no effect on 
simvastatin-mediated porcine coronary relaxation (figure 2.40). 
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Figure 2.40. Effect of DDT (1 mM) on relaxations to simvastatin (10 µM) 
in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 5 animals. 
 
2.4.9. Role of H2S in simvastatin-induced coronary relaxation: 
 
H2S mediates relaxation of vascular smooth muscle. A previous study has 
demonstrated that simvastatin increases the release of H2S from 
perivascular fat (Wojcicka et al., 2011). Therefore, in this study, the effect 
of the H2S synthesis inhibitors amino-oxyacetic acid (AOAA, 100 µM) and 
propargylglycine (PPG, 10 µM) on the relaxation responses to simvastatin 
were determined.  As shown in figure 2.41, H2S inhibition had no 
significant effect on simvastatin 10 µM relaxation in PCA. 
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Figure 2.41. Effect of H2S inhibition on relaxations to simvastatin (10 µM) 
in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 6 different animals. 
 
2.4.10. Effect of Na+/K+ pump inhibition on Simvastatin-induced 
relaxations. 
 
Na+-K+ ATPase pump activation have been suggested as mechanism for 
cerivastatin relaxation in rat aortic rings (Sonmez Uydes-Dogan et al., 
2005). Therefore, this present study determined the effect of the Na+-K+ 
ATPase pump inhibitor ouabain on the simvastatin relaxations. Ouabain 
(100 nM), had no effect on simvastatin (10 µM) induced relaxation of 
porcine coronary artery (figure 2.42 & 2.43). Ouabain at 100 nM 
concentration has been shown to be effective at inhibiting the Na+-K+ 
pump block in our experiments (see chapter III).  
   
 
Figure 2.42. Effect of ouabain (100 nM) on relaxations to simvastatin (10 
µM) in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 6 different animals. 
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Figure 2.43. Effect of ouabain (10 µM) on relaxations to simvastatin (10 
µM) in porcine coronary artery rings pre-contracted with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 6 different animals.   
 
2.4.11 Acute effects of Simvastatin on Mitochondrial Membrane Potential. 
2.4.11.1 Effect of simvastatin on Membrane Potential of the isolated 
mitochondria 
 
Previous studies in other cell types have demonstrated that simvastatin 
has an effect on the mitochondrial electron transport chain, altering 
mitochondrial membrane potential (Sirvent et al., 2005b, Dai et al., 2010, 
Tolosa et al., 2014). This study aimed to determine whether simvastatin 
has a direct effect on mitochondria isolated from a pig heart. Simvastatin 
and Lovastatin (10 µM each) produced an increase in total fluorescence in 
the isolated mitochondria from a pig heart loaded with Rh123 (figure 2.44 
& 2.45 respectively). By contrast, pravastatin had no effect of the 
mitochondrial potential (figure 2.46).    
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Figure 2.44. Typical trace showing the effect of simvastatin (10 µM) on 
Rh123 fluorescence in mitochondria isolated from pig hearts. 
 
 
 
Figure 2.45. Typical trace showing the effect of lovastatin (10 µM) on 
Rh123 fluorescence in mitochondria isolated from pig hearts. At the end of 
the experiment FCCP was added to depolarize the mitochondria 
completely.  
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Figure 2.46. Typical trace showing the effect of pravastatin (10 µM) on 
Rh123 fluorescence in mitochondria isolated from pig hearts. Simvastatin 
(10 µM) was added after pravastatin for comparison. At the end FCCP (1 
µM) added to get the maximum depolarization.   
 
2.4.11.2. Acute effects of Simvastatin on Mitochondrial Membrane Potential 
in human aortic smooth muscle cells 
 
In cultured human aortic vascular smooth muscle cells, 10 µM simvastatin, 
but not pravastatin, increased the fluorescence in Rh123-loaded cells 
(figure 2.47 a & b). In smooth muscle cells, a longer period of simvastatin 
perifusion was required to depolarize the mitochondria in comparison with 
SDQFUHDWLF ǃ-cell (chapter V). Because of the bleaching effect of the dye 
with continuous perfusion, results were collected with simvastatin (10 µM) 
(figure 2.48 & 2.49). Such a property could be due to the unusual Rh123 
retention by the smooth muscle cells (Summerhayes et al., 1982).   
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A- 
 
 
B- 
 
Figure 2.47. Representative effect of simvastatin on Rh 123 
fluorescence: Typical trace showing the effect simvastatin and DMSO on 
Rh123 fluorescence in cultured human aortic smooth muscle. Simvastatin 
was applied for the duration of the bars. FCCP 1 µM was perfused as 
positive control to get the maximum fluorescence. A- Simvastatin (10 µM) 
B- DMSO as a solvent control.  
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A-                                       B- 
      
C- 
 
 
 
 
Figure 2.49. Cumulative fluorescence data from human aortic smooth 
muscle cells loaded with Rh123 in the presence of simvastatin (10 µM), 
pravastatin (10 µM), or vehicle control (0.1% v/v DMSO). Data are 
expressed as a percentage of the response to 1 µM FCCP in the same cells 
Figure 2.48. Typical fluorescence 
images from human aortic 
smooth muscle cells loaded with 
Rh123: A- in the absence (basal), B- 
presence of simvastatin (10 µM) or 
C- presence of FCCP (1 µM). 
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and are mean ± SEM from n=15 separate experiments. *** indicates 
p<0.001, one-way ANOVA, followed by Tukey's multiple comparisons test.  
 
2.4.11.3. Acute effects of Simvastatin on Mitochondrial Membrane Potential 
in segments of porcine coronary artery  
 
In order to determine the effects of simvastatin on mitochondrial 
membrane potential in intact blood vessels. The tissue was incubated with 
Rh123 and placed in a cuvette in a fluorometer (Hitachi F-2500) at 37 °C 
as explained in the method. Fluorescence signals were allowed to stabilise 
before the addition of simvastatin (10 µM). As shown in (figure 2.50), a 
similar effect was observed in intact blood vessels, with an increase in 
Rh123 fluorescence.   
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Figure 2.50. Typical trace showing the effect of simvastatin (10 µM) on 
Rh123 fluorescence in an intact segment of porcine coronary artery. 
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2.5 DISCUSSION 
 
Statins inhibit HMG-CoA reductase, leading to a reduction in synthesis of 
mevalonate and hence cholesterol. As such they reduce plasma cholesterol 
levels. Statins also exhibit other beneficial effects within the cardiovascular 
system, including vasodilatation. Recent evidence suggests that the 
cardiovascular pleiotropic effects of statins are predominantly independent 
of reduction in plasma cholesterol (Liao and Laufs, 2005). A number of 
mechanisms have been put forward to explain the vasodilator effect of 
statins including an increase in NO bioavailability (Rikitake and Liao, 
2005), direct effects on K+ channels (Lopez et al., 2008), or inhibition of 
calcium channels (see chapter III) (Bergdahl et al., 2003). In this study we 
have demonstrated that simvastatin stimulates relaxation of the porcine 
coronary artery, and this effect is dependent, at least in part, on 
mitochondrial function. 
Simvastatin produces a concentration dependent relaxation of the porcine 
coronary artery. The onset of the relaxation usually started within minutes 
after addition. However the relaxation was slow with a maximum response 
occurring after around 120 min. Indeed at lower concentrations (300 nM) 
the relaxation response did not become significant until around 120 min. 
The relaxation may be dependent upon the lipophilicity of statins. 
Simvastatin, which is 195 times more lipophilic than pravastatin produced 
a greater relaxation of the porcine coronary artery than slightly less-
lipophilic lovastatin (85 times more lipophilic than pravastatin) (Joshi et 
al., 1999). On the other hand, the hydrophilic pravastatin, and the sodium 
salt of simvastatin failed to produce a relaxation. Similar effects have been 
shown in other studies, including the bovine coronary artery (Lorkowska 
and Chlopicki, 2005). However, previous studies have shown that the 
hydrophilic pravastatin induced endothelium-dependent relaxation in rat 
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aortic and mesenteric vessels (Kaesemeyer et al., 1999, Ghaffari et al., 
2011). The difference in response to pravastatin might be due to 
differences in species (Sonmez Uydes-Dogan et al., 2005), the presence of 
a statin transporter on endothelial cells, which may be blood vessel specific 
(Ohtawa et al., 1999), or alternatively endothelium-dependent responses 
may only be seen in tissues expressing scavenging receptor SR-B1 with 
resultant endothelial nitric oxide synthase activation (Datar et al., 2010). 
Thus, the exact mechanism of pravastatin endothelium-dependent 
relaxation needs to be reassessed in further studies.  
The relaxation to simvastatin was independent of the pre-contractile agent 
as a similar relaxation was obtained after pre-contraction with endothelin-1 
or KCl. Previous studies have suggested that the relaxation response to 
statins was dependent upon NO (Rikitake and Liao, 2005, Lopez-Canales et 
al., 2011, Mukai et al., 2003, Mraiche et al., 2005). However, in the 
current study we have shown that NO is not involved in simvastatin 
relaxation; this is possibly related to differential tissue response to NO 
(Christie et al., 1989). Interestingly, results have shown that vasodilation 
in coronary arteries during increased myocardial oxygen demand is 
mediated by metabolic mechanisms rather than by endothelium-dependent 
production of NO (Lefroy et al., 1993, Nishikawa and Ogawa, 1997). A 
mechanism independent NO has been similarly suggested by Budzyn et al, 
(Budzyn et al., 2004).  
The role of PGI2 as a mediator of the simvastatin-induced relaxation was 
tested by incubation with the cyclooxygenase inhibitor indomethacin and 
the results clearly indicate that cyclooxygenase metabolites have no role in 
the coronary relaxation. Similar results have been reported by De 
Sotomayor et al (de Sotomayor et al., 2005). Indeed, lovastatin decreased 
basal prostacyclin production in cultured endothelial cells (Zhou et al., 
2009). Conversely Lorkowska et al suggested a role for PGI2 in simvastatin 
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mediated bovine coronary relaxation (Lorkowska and Chlopicki, 2005). 
Such differences may be related to species differences. The current study 
also demonstrates that the relaxation to simvastatin in the porcine 
coronary artery is endothelium-independent.  
Previous studies have demonstrated that K+ channel activation is involved 
in simvastatin relaxation. Specifically, KATP potassium channels and Kv 
potassium channels have been implicated in the relaxation response to 
cerivastatin in the rat aorta (Mukai et al., 2003, Sonmez Uydes-Dogan et 
al., 2005). Our results revealed that neither KATP channels nor Kv channels 
are involved in the relaxation to simvastatin in the porcine coronary artery. 
Indeed, neither TEA, a non-selective inhibitor of K+ channels, nor high K+ 
altered the simvastatin relaxation, suggesting activation of K+ channels is 
not involved in the relaxation response. In fact, a previous study in our 
laboratory demonstrated that simvastatin inhibits K+ channel-mediated 
relaxations in the porcine coronary artery (Uhiara et al., 2012).  
Simvastatin has been shown to inhibit the Na+-Ca2+ exchanger in the 
cardiomyocytes (Bastiaanse et al., 1994) and endothelial cells (Alvarez de 
Sotomayor et al., 1999). Sonmez et al (2005) also suggested activation of 
the Na+-K+ ATPase pump as a mechanism in cerivastatin-induced 
relaxation in isolated rat aorta. This study determined the effect of ouabain 
on the simvastatin relaxation. Our results demonstrated that ouabain had 
no effect on simvastatin relaxation, thus the Na+-K+ pump plays no role in 
the acute vascular relaxant effects of simvastatin in isolated porcine 
coronary artery.  
H2S has been shown to be produced endogenously from L-cysteine through 
WKHDFWLRQVRIF\VWDWKLRQLQHǃ-V\QWKDVHDQGF\VWDWKLRQLQHǄO\DVH(Kimura, 
2011). Previous studies have demonstrated that simvastatin increases the 
production of H2S from perivascular tissue. However, this can be ruled out 
as a mechanism of the acute simvastatin induced relaxation in PCA since 
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inhibition of H2S synthesis with AOAA and PPG had no effect on the 
relaxation response. 
The findings presented here suggest that the relaxation in pig coronary 
artery segments is dependent upon the ability of the drug to penetrate 
across the plasma membrane of the smooth muscle cell and suggest that 
the site of action of simvastatin is not extracellular. Interestingly, an in 
vitro study by Skottheim et al. suggested that lactone forms of statins 
induce myotoxicity in human skeletal muscle cells more than the 
respective acid forms, such differences may be explained by lipophilicity 
since the lactone forms reach intracellular sites to different extent than the 
acid forms (Skottheim et al., 2008). These observations are consistent 
with previous data demonstrating that lipophilic statins, but not hydrophilic 
statins, like pravastatin, induce acute vasodilator effects (Mukai et al., 
2003, Lorkowska B, 2005). One possible intracellular target for statins is 
the mitochondria. Previous studies have demonstrated that simvastatin at 
20 times higher concentration than those used in this current study is able 
to alter mitochondrial membrane potential in intact hepatocytes, whereas a 
similar phenomenon was observed in permeabilized skeletal muscle cells 
with an EC50 of ~2 µM (Sirvent et al., 2005b, Abdoli et al., 2013). There is 
a growing consensus that mitochondria play an important role in the 
regulation of vascular tone. For example, flow-induced dilation involves 
generation of reactive oxygen species originating from mitochondria in 
endothelial cells (Bubolz et al., 2012). Therefore, we investigated whether 
the relaxation response was dependent upon mitochondrial activity. 
Inhibition of complex I with rotenone and complex III with myxothiazol 
caused significant inhibition of the simvastatin relaxation. A combination of 
the two produced a greater inhibition of the relaxation. On the other hand, 
the mitochondrial uncoupler FCCP enhanced the relaxation. Antimycin A, 
another complex III inhibitor, and inhibition of complex II had no effect. 
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Antimycin A and myxothiazol act at different parts of complex III, with 
myxothiazol acting at the Qo site, whereas antimycin A acts at the Qi site, 
which probably explains the different effects with these two compounds 
(Wu et al., 2010). The effects of rotenone and myxothiazol on the 
simvastatin relaxation are unlikely to be due to non-specific effects caused 
by inhibition of mitochondrial function since other complex inhibitors 
(antimycin A and complex II inhibitors), the ATP synthase inhibitor 
oligomycin, and the mitochondrial uncoupling agent FCCP had no inhibitory 
effect on the vasorelaxation. 
Simvastatin produced an increase in Rh123 fluorescence in isolated 
mitochondria, which is indicative of a change in mitochondrial membrane 
SRWHQWLDOƩǓm). This was also seen in cultured aortic smooth muscle cells, 
demonstrating that simvastatin can depolarize the mitochondrial 
membrane potential in whole cells. By contrast pravastatin had no effect 
on the mitochondrial potential in smooth muscle cells, which correlates 
with the lack of relaxation with pravastatin. Similar effects on Rh123 
fluorescence were found in intact blood vessels, suggesting that the effect 
of simvastatin on porcine coronary artery tone could be through effects on 
mitochondria. In combination with the relaxation studies, these 
experiments indicate that simvastatin does have an effect on vascular 
smooth muscle mitochondria. As the relaxation to simvastatin was reduced 
by complex I and complex III inhibition, but not complex II, these data 
indicate that the relaxation to simvastatin is dependent upon complex I 
and III activity. 
Although studies demonstrate that simvastatin inhibits mitochondrial 
function, the mechanism by which it does this is unknown. Previous studies 
in skeletal muscle have suggested that simvastatin inhibits complex I 
(Sirvent et al., 2005a).  Other studies have hypothesized that the effect on 
mitochondria is due to a reduction in the expression of co-enzyme Q10, 
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which is part of complex III (Vaughan et al., 2013, Tavintharan et al., 
2007, Larsen et al., 2013). However, this is more likely to be due to long-
term incubation with statins, rather than the acute exposure in this present 
study. Other studies have suggested that simvastatin increases 
mitochondrial KATP channel activity (Zhao et al., 2006, Jones et al., 2003a). 
However, the mitochondrial KATP channel blocker 5-hydroxydecanoate had 
no effect on the relaxation, ruling this out as a mechanism. 
Mitochondria are a major source of ROS within cells (Carreras et al., 
2004). The major sources of ROS in the electron transport chain (ETC) are 
thought to be complex I and complex III (Carreras et al., 2004). Antimycin 
A and myxothiazol both increase production of ROS from complex III 
(Starkov and Fiskum, 2001, Mattiasson, 2004), and both compounds 
relaxed the porcine coronary artery (see Chapter IV). Release of ROS from 
the mitochondria into the cytosol can cause vasodilatation (Katakam et al., 
2014) and can inhibit L-type calcium channels (Fearon, 2006, Scragg et 
al., 2008). Therefore, this study investigated whether ROS underlie the 
effect of simvastatin on vascular tone. A combination of the hydrogen 
peroxide scavenger ebselen, catalase, which metabolizes hydrogen 
peroxide, and superoxide dismutase, which metabolizes superoxide had no 
effect on the simvastatin relaxation. Furthermore, diethylthiocarbamate 
which inhibits superoxide dismutase, uric acid, peroxynitrite scavenger, 
and quercetin, flavonoid anti-oxidant (Wambi-Kiesse and Katusic, 1999) 
had no effect on the simvastatin relaxation. These data indicate that an 
increase in ROS production from the mitochondria does not play a role in 
the simvastatin-induced relaxation.  NADPH oxidase (Nox) is a relevant 
source of H2O2 that mediates dilation of coronary arteries (Larsen et al., 
2009) and mitochondrial superoxide could stimulate cytoplasmic Nox2, 
which has been linked to the development of endothelial oxidative stress 
and even hypertension (Nazarewicz et al., 2013). Our results with DPI, a 
109 
 
commonly used Nox enzyme inhibitor (Wind et al., 2010), suggest that 
Nox inhibition has no role in the simvastatin relaxation.  
The effects of simvastatin on vascular tone in the porcine coronary artery 
occur at concentrations that are very close to the estimated therapeutic 
plasma concentration (from 0.01 to 1 µM in patients treated with a dosage 
range of 20 to 60 mg daily) (Laufs et al., 1998, Lilja et al., 1998, Kantola 
et al., 1998), although higher concentrations were required for maximum 
effect. We hypothesise that lipophilic statins accumulate within the 
mitochondria. Lipophilic compounds can easily pass through the 
mitochondrial membrane and, as the pH in the mitochondrial matrix is 
higher than the pH in the cytosol, these lipophilic compounds can become 
charged. As a consequence mitochondria can trap lipophilic compounds 
(Rashid and Horobin, 1991). Therefore, the concentration of statin within 
the mitochondria may be higher than that measured in the plasma. The 
time taken for uptake into the mitochondria would explain why the 
relaxation to simvastatin was slow; at the lowest concentration of 
simvastatin used (300 nM); the relaxation did not reach significance until 
around 145 minutes after addition. 
In summary, this study has demonstrated that simvastatin alters 
mitochondrial membrane potential in vascular smooth muscle and the 
relaxation to simvastatin in the porcine coronary artery is dependent, in 
part, upon mitochondrial activity. The mechanism by which inhibition of 
mitochondria leads to relaxation of the porcine coronary artery is unknown. 
One possibility is that alteration of mitochondrial membrane potential by 
simvastatin may lead to inhibition of calcium influx, hence stimulation of 
relaxation, and this will be investigated in the next chapter.  
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CHAPTER III: EFFECT OF SIMVASTATIN ON Ca2+ INFLUX IN 
PORCINE CORONARY ARTERY       
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3.1. Introduction 
 
Cytosolic free Ca2+ appears to play a fundamental part in the control of cell 
function (Hill-Eubanks et al., 2011). In vascular smooth muscle cells, Ca2+ 
has been implicated in cell proliferation and smooth muscle contraction 
(Karaki et al., 1997). When the intracellular Ca2+ increases, it combines 
with calmodulin. This complex activates myosin light chain kinase (MLCK) 
to phosphorylate the light chain of myosin. Smooth muscle relaxation is 
brought about by the removal of Ca2+, which results in dissociation of the 
Ca2+-calmodulin complex and dephosphorylation of myosin by myosin light 
chain phosphatase (Webb, 2003). The regulation of cytosolic Ca2+ is 
complex and depends, partly, on Ca2+ entry from the extracellular space 
through voltage-activated or receptor-operated Ca2+ channels, or both 
(Ren et al., 2010, Weirich et al., 2005). However a significant contributor 
to cytoplasmic free Ca2+ regulation in smooth muscle cell is the release of 
Ca2+ from internal stores by inositol 1,4,5-triphosphate (Yang et al., 2013, 
Yamamura et al., 2012). The regulation of these mechanisms is important 
for the maintenance of vascular tone (Marche and Stepien, 2000, 
Kamishima et al., 2000).   
Simvastatin is a drug widely used in the treatment of 
hypercholesterolemia. This drug is an inhibitor of the rate-determining 
enzyme in the biosynthesis of cholesterol, 3-hydroxy-3-methylglutaryl-
coenzyme A HMG-CoA reductase (Istvan and Deisenhofer, 2001, Istvan, 
2002), and has proved useful in the reduction of plasma low-density 
lipoprotein LDL Level. Mounting clinical and experimental evidence 
suggests that the protective effects of statins on vascular disease relate 
not only to improving lipid profiles (Cheung et al., 2004, Davignon, 2004, 
Bonetti et al., 2003). In fact, HMG-CoA reductase provides the necessary 
building blocks for both cholesterol, and  the isoprenoids farnesyl and 
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geranylgeranyl pyrophosphate, these are used for post-translational 
modification of Ras and Rho GTPases, respectively (Buhaescu and 
Izzedine, 2007). Reduced isoprenylation impairs Ras and Rho activation 
which play important roles in smooth muscle cell proliferation and 
contraction (Rattan, 2010, Corsini et al., 1991).  
Not only chronic treatment, but also acute exposure to simvastatin is able 
to induce coronary relaxation (Wassmann et al., 2003, Takagi et al., 
2006). There is increasing evidence that the actions of HMG CoA reductase 
inhibitors in the vasculature are attributable to more than their cholesterol-
lowering function (Sadowitz et al., 2010a).  
Simvastatin could affect Ca2+ release from intracellular pools, as described 
earlier in vascular smooth muscle cells (Tesfamariam et al., 1999, 
Escobales et al., 1996a), Capacitative Ca2+ entry is also affected as 
confirmed by the inhibition of contraction due to CaCl2 after noradrenaline 
stimulation (Alvarez de Sotomayor et al., 2001).   
The alteration of intracellular Ca2+ calcium homeostasis by statins was 
already discovered by other groups in different cell types; in cardiac cells, 
the activation of Ca2+ channels by high K+ or Bay K8644 was completely 
abolished in mevinolin-treated cells (Renaud et al., 1986). Studies also 
have reported a blockade of L-type Ca2+ channels by simvastatin in rat 
islet ǃ-cells (Yada et al., 1999) and rat glomerular mesangial cells 
(Ishikawa et al., 1995). Simvastatin could also inhibit catecholamine 
secretion induced by 56 mM K+ through Ca2+ channels (Matsuda et al., 
2008). Other HMG-CoA reductase inhibitors like fluvastatin, cerivastatin 
and pravastatin, markedly suppressed intracellular Ca2+ mobilization and 
nonselective cation current evoked by LPC in human aortic endothelial cells 
(Yokoyama et al., 2002). Rosuvastatin also attenuates the increase in 
intracellular free calcium and superoxide anion during L-glutamate 
application in cortical neurons (Domoki et al., 2010). On the other hand, 
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simvastatin induced an increase in cytosolic calcium Ca2+ in bovine aortic 
endothelial cells, by releasing Ca2+ from intracellular stores sensitive to 
thapsigargin and ryanodine, and increasing Ca2+ entry as a consequence of 
intracellular Ca2+ store depletion by a mechanism which does not occur via 
L-type Ca2+ channels (Alvarez de Sotomayor and Andriantsitohaina, 2001). 
In parallel, lovastatin exposure for more than 24 hours increased basal 
Ca2+ with increased vasoconstriction response induced by noradrenaline in 
isolated rat aortic and mesenteric arteries (Roullet et al., 1995, Roullet et 
al., 1993). Indeed it has been found that co-administration of Ca2+ channel 
blockers with statins has beneficial effects by inhibiting the progression of 
coronary atherosclerosis (Martin-Ventura et al., 2008, Bangalore et al., 
2007, Clunn et al., 2010). However, a combination of nifedipine and statin 
may also result, in certain cases, in worsening of cardiac performance. This 
may suggest another mechanism of drug-drug interaction than the one 
based on liver metabolism i.e. nifedipine may interact with simvastatin by 
inhibiting cytochrome P-450 mediated biotransformation (Jasinska et al., 
2006).       
Mitochondria within the smooth muscle cell might be directly involved in 
taking up Ca2+ load from the cytosol following stimulation (Drummond and 
Fay, 1996). Recent studies are providing evidence that mitochondrial 
inhibition influences Ca2+ waves due to the spatial relationship between 
mitochondria and the sarcoplasmic reticulum (Sward et al., 2002). Ca2+ 
channel current could also be modulated by ROS generated at complex III 
of the mitochondrial electron transport chain (Fearon, 2006, Hsieh et al., 
2001). We have shown in chapter 2 that simvastatin depolarizes 
mitochondria in smooth muscle cells. Thus, the aim of the present study 
was to examine the involvement of Ca2+ influx, as a potential mechanism, 
in simvastatin-induced relaxation of porcine coronary artery. Also, the 
effect of simvastatin on the Ca2+ influx induced by membrane 
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depolarization was studied in freshly isolated porcine coronary smooth 
muscle cells. Lastly, possible involvement of mitochondria in modulating 
Ca2+ influx was examined by incubation with mitochondrial respiratory 
chain inhibitors (Kamishima and Quayle, 2002, McCarron et al., 2013).  
3.2 Materials and Methods 
3.2.1 Materials  
 
General laboratory reagents are listed in chapter 2, reagents specific to 
this chapter were purchased from the following sources: simvastatin was 
obtained from Tocris Cookson, Bristol UK. Rotenone, FCCP, U46619, 
cyclopiazonic acid and nifedipine were obtained from Sigma-Aldrich, Poole, 
UK. DABCO fluorescent mounting medium contains: 1-4-Diazabicyclo-2-2-
2-octane (DABCO), Phosphate buffered saline (PBS) and glycerol.  
Dulbecco Modified Eagle Medium (DMEM) with D-valine and fetal bovine 
serum (SFBS). Antibiotic, antimycotic solution (sigma) at 10 mL/L which 
FRQWDLQV  XQLWV SHQLFLOOLQ  PJ VWUHSWRP\FLQ DQG  ǋJ
amphotericin B per mL. 
3.2.2. Preparation and characterization of the smooth muscle cells (SMCs) 
3.2.2.1. Preparation of the SMCs 
3.2.2.1.1. Primary Vascular Smooth Muscle Cell Cultures (Explant Method) 
 
Explant culture of medial tissue is the simplest and most reliable method of 
obtaining VSMC cultures. Porcine coronary arteries were obtained from a 
local abattoir as before. Arteries were dissected out of the heart. After 
connective tissue removal from around the artery, the vessel was washed 
with sterile saline. The artery was then placed on a sterile dissection board, 
in a hood, and covered with normal saline to keep it moist. The arteries 
were cut open longitudinally using sterile forceps and scissors, and the 
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luminal side of the vessel freed of endothelium by gently scraping the 
surface using forceps. The medial layers were placed in a separate Petri 
dish and cut carefully using a scalpel blade into approximately 1 × 1-cm 
pieces. These explants were then carefully placed into six-well plates. A 
coverslip was placed on top of the explants and covered with medium. The 
medium consisted of Dulbecco Modified Eagle Medium (DMEM) with D-
valine and fetal bovine serum (SFBS). In addition the media contain 
antibiotic, antimycotic solution (sigma) at 10 mL/L which contains 10,000 
XQLWVSHQLFLOOLQPJVWUHSWRP\FLQDQGǋJDPSKRWHULFLQ%SHUP/The 
segments were incubated for 24 h at 37°C in a humidified atmosphere of 
5% CO2±95% air. Medium was changed after 24 h and then every 3±4 
days. Cells started to grow out radially from the explants within 1 week of 
the culture.  
3.2.2.1.2. Isolation of Smooth Muscle Cells by Enzyme dispersal method 
 
Enzyme dispersion of the medial layer does not yield as many cells as the 
explant method, but the advantage is that the whole population of VSMCs 
is represented, rather than selecting for those capable of migrating from 
the tissue. In addition, the cells isolated by enzyme dispersion may 
represent a phenotype more closely related to that in the vessel wall 
because the time to isolation is much quicker 2 h as opposed to 2±3 
weeks. The vessels were prepared as for the explant method. However, in 
this case, explants were placed in a sterile conical flask and incubated in 
serum-free digestion medium containing collagenase (2 mg/mL). Explants 
were incubated in a shaking water bath at 37°C for 30-45 minutes, with 
occasional dispersion using a wide-mouthed pipette. The dispersed cells 
were removed by centrifugation type (1,000 rpm for 5 min) and the 
remainder left to disperse further. The dispersed cells were centrifuged 
again and re-suspended in fresh Dulbecco Modified Eagle Medium (DMEM) 
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with D-valine and fetal bovine serum (SFBS) with antibiotic and 
antimycotic solution (10,000 units penicillin, 10 mg streptomycin and 25 
ǋJ$PSKRWHULFLQ%SHUP/). 
3.2.2.2. Immunohistochemistry: Characterization of the Smooth Muscle Cells 
 
Confluent monolayers of vascular smooth muscle cells exhibited a 
FKDUDFWHULVWLFµKLOODQGYDOOH\¶PRUSKRORJ\LQFXOWXUH,VRODWHGSULPDU\FHOOV
were identified by their positive reaction with antibodies against smooth 
muscle actin, which has been shown to be a specific marker for smooth 
muscle cells.   
Cells were fixed using 4% paraformaldehyde for 20 min at room 
temperature. They were then permeabilized using PBS + 0.1% BSA + 
0.15% Triton ×-100 (100 ml PBS + 100 mg BSA +15 µL Triton) at room 
temperature for 20 min. Cells were then blocked using dried powder milk 
(1.5 g in 30 ml) at room temperature. The blocking solution was then 
removed and replaced with the primary antibody Į-Actin primary mouse, 
sigma), (6 µL in 1200 µL), and incubated overnight in a humidifier at 4°C.    
The following day, the primary antibody was removed and cells washed in 
PBS. After washes, cells were incubated with the secondary TRITC anti-
mouse secondary antibody in PBS+0.1% BSA (6 µL in 1200 µL of PBS) and 
incubated at 37°C for 30 min  
After this time, cells were washed with PBS. The nuclear stain DAPI (1 in 
1000) was then added for 5 min, and cells washed again in PBS. Mounting 
solution was then added and a cover slip put on top of the cells. 
Micrographs were captured with DMRB Fluorescence Microscope Luca EM. 
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3. 3 Data Analysis 
 
The relaxation responses were expressed as a percentage change from the 
agonist-induced pre-contraction over time. Values for all figures refer to 
mean ± SEM. Relaxation responses over time were compared by using 
two-way analysis of the variance (ANOVA) followed by a Bonferroni post-
hoc test. Differences were considered to be significant when the P value 
was < 0.05. Changes in Fluo-4 fluorescence were analyzed by one-way 
ANOVA, followed by Tukey's multiple comparisons test. 2-tailed unpaired t- 
test was used to determine statistical significance where P<0.05 was 
FRQVLGHUHG VWDWLVWLFDOO\ VLJQLILFDQW :KHUH ³Q´ LQGLFDWHV WKH QXPEHU RI
independent experiments for each treatment. Asterisks indicate statistically 
differences from control.    
3.4 Experimental protocol  
3. 4.1 organ bath isometric studies  
 
Porcine coronary arteries were set up in isolated tissue baths as previously 
described (Uhiara et al., 2012) see chapter II. Tissues were pre-contracted 
submaximally with KCl or U46619, in the presence of various inhibitors: L-
NAME (300 µM) to inhibit nitric oxide synthase; cyclopiazonic acid (10 ǋM; 
CPA) to inhibit the sarcoplasmic reticulum Ca2+-ATPase;  rotenone (10 µM) 
to inhibit complex I, FCCP (1 µM) to uncouple to mitochondria. 
Alternatively, tissues were exposed to calcium-free Krebs buffer containing 
(2 mM) EGTA. After the tissues had reached a steady contraction, 10 µM 
simvastatin was added and tone measured over 2 hours. In other 
experiments, tissues pre-contracted with KCl were exposed to nifedipine (1 
µM) with or without simvastatin (10 µM).   
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Porcine coronary arteries were set up in isolated tissue baths as before. 
Tissues were exposed to Krebs-Henseleit buffer without calcium, and then 
exposed to 60 mM KCl. Concentration-response curves to CaCl2 (1 µM to 3 
mM) were then performed, in the absence or presence of simvastatin (3 to 
10 µM). Control tissues were treated with DMSO as a solvent control. In 
some experiments, tissues were also exposed to mevalonate (10 mM) or 
rotenone (10 µM) prior to addition of simvastatin. 
3.4.2. Effect of simvastatin on calcium influx in freshly isolated smooth 
muscle cells. 
 
The concentration of intracellular calcium, [Ca2+]i, was monitored with 
Fluo-4 using standard epifluorescent imaging techniques similar to those 
described by (Smith et al., 1999). Smooth muscle cells were isolated from 
proximal coronary artery segments by incubation with type II collagenase 
(2 mg/mL) for 30 min, and then plated on glass coverslips. Cells were then 
loaded with the Ca2+-sensitive fluorophore fluo-4 AM (5 µmol/L) in HEPES-
buffered Hanks solution which contained (in mM): 138 NaCl, 4.2 NaHCO3, 
1.2 NaH2PO4, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, 10 HEPES (pH 7.4 with NaOH) 
with 5 mmol/L glucose for 1 hour at room temperature. The cells were 
then washed with Hanks buffer to remove extracellular dye before leaving 
them at room temperature for 15 minutes for complete de-esterification of 
the dye. Coverslips were then superfused with Hanks buffer at 37°C for 5 
min for basal recording. The Hanks buffer was then replaced with high K+ 
(50mM) Hanks containing (in mM) 50 KCl, 92.6 NaCl, 4.2 NaHCO3, 1.2 
NaH2PO4, 2.6 CaCl2, 1.2 MgCl2, 10 glucose, and 10 HEPES [pH 7.4], which 
elicited a sustained increase in the fluorescence. Subsequently simvastatin 
(10 µM), or DMSO (0.1% v/v) as a control, was added to the perfusion 
media. Loaded cells were imaged using an inverted Axiovert 135TV 
microscope fitted with a 20x Fluo objective (Carl Zeiss Ltd, Welwyn Garden 
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City, UK). To monitor [Ca2+]i, cells were continuously illuminated at an 
excitation wavelength of 450-490 nm. The images were bandpass filtered 
at 515-565 nm, detected using a Photonics Science ISIS camera and 
captured at 1Hz with an 8-bit frame grabber (DT3155, Data Translation, 
Basingstoke, UK) and Imaging Workbench software (Indec Biosystems, 
Santa Clara, CA, USA). For image analysis, a region of interest (ROI) was 
drawn around each cell, the background fluorescence substracted, and the 
time course of its mean fluorescence intensity calculated. Data was 
analysed using Microcal ORIGIN 5.0 (Microcal Software Inc., Northampton, 
MA). Macros were created (see Appendices for the macro scripts). 
3.5. RESULTS 
3.5.1. Simvastatin inhibits KCl-induced contraction in porcine coronary 
arteries 
 
As shown in figure 3.1, acute application of simvastatin elicited time 
dependent relaxation in pig proximal coronary artery pre-contracted 
submaximally with KCl (fig. 1). 
 
 
Figure 3.1. Acute effects of simvastatin (10 ǋM) in porcine coronary artery 
rings precontracted submaximally with KCl. Data are expressed as a 
percentage relaxation of the KCl-induced contraction and are mean ± SEM 
from 8 different experiments. *** indicates p<0.001, (2- way ANOVA 
followed by a Bonferroni post-hoc test) versus values obtained from the 
solvent control DMSO (0.1% v/v). 
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3.5.2. Role of endothelium-derived vasodilator factors in the relaxation 
response to simvastatin. 
 
Pre-treatment of the porcine coronary rings with a nitric oxide synthase 
inhibitor, L-NAME (300 µM), had no significant effect on the relaxation to 3 
µM simvastatin (figure 3.2). Similar results with L-NAME (300 µM) on 
simvastatin 10 µM have been shown in chapter II. 
 
  
Figure 3.2. Acute effects of simvastatin (3 ǋM) in porcine coronary artery 
rings precontracted with KCl in the presence or absence L-NAME (300 ǋM). 
Data are expressed as a percentage relaxation of the KCl-induced 
contraction and are mean ± SEM from 5 different experiments. (2- way 
ANOVA followed by a Bonferroni post-hoc test).  
 
3.5.3. Role of Sarcoplasmic reticulum Ca2+ -ATPase in acute simvastatin 
relaxation: 
 
A possible mechanism of simvastatin relaxation could involve inhibition of 
the Ca2+- ATPase and thus inhibition of SR calcium sequestration 
(Escobales et al., 1996a). CPA inhibits Ca2+-ATPase. Thus, we examined 
CPA (10 µM) for its ability to block the relaxant effect of 10 ǋM 
simvastatin. Figure (3.3) clearly shows that CPA had no effect on 
simvastatin relaxation.   
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Figure 3.3. Acute effects of simvastatin (10 ǋM) in porcine coronary artery 
rings precontracted with KCl in the presence or absence cyclopiazonic acid 
(10 ǋM). Data are expressed as a percentage relaxation of the KCl-induced 
contraction and are mean ± SEM from 5 different experiments. (2- way 
ANOVA followed by a Bonferroni post-hoc test).   
 
3.5.4. Simvastatin relaxation in Ca2+-free Krebs: 
 
In separate experiments, tissues were incubated in calcium-free Krebs-
Henseleit buffer. Under these conditions, the acute relaxation to 
simvastatin was significantly reduced, although not abolished completely 
(figure 3.4).  
  
 
Figure 3.4. Acute effects of simvastatin (10 ǋM) in porcine coronary artery 
rings precontracted with U46619 in Ca2+-free Krebs or normal Krebs.  Data 
are expressed as a percentage relaxation of the U46619-induced 
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contraction and are mean ± SEM from 6 different experiments. (2-way 
ANOVA followed by a Bonferroni post-hoc tesWLQGLFDWHV3 
 
3.5.5. Simvastatin suppressed Ca2+-induced contraction in coronary 
arteries: 
 
In these experiments, simvastatin was added prior to contraction. The 
addition of simvastatin (10 µM) did not affect the base line tone in these 
arteries. In Ca2+-free, 60 mM K+-containing Krebs solution, CaCl2 produced 
concentration-dependent contractions in porcine coronary arteries (Figure 
3.5 & 3.6). Treatment with 3 µM or 10 µM simvastatin for 60 min 
suppressed CaCl2-induced contractions (Figure 6).  
A- 
 
B- 
 
 
Figure 3.5. Representative organ bath tracing of contractile responses in 
segments of porcine coronary artery to Ca2+ re-introduction in a Ca2+ free, 
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high K+ buffer in the presence of A- simvastatin 10 ǋ0and B- DMSO as a 
vehicle control. 
 
 
 
Figure 3.6. Contractile response to the reintroduction of calcium in a 
calcium IUHHKLJKSRWDVVLXP.UHEV¶VROXWLRQLQWKHcoronary artery in the 
presence of simvastatin for 1h (10 µM, n=9) and (3 µM, n=5). Data are 
expressed as a percentage relaxation of the KCl-induced contraction and 
are mean ± SEM. *** indicates p < 0.001 (2- way ANOVA followed by a 
Bonferroni post-hoc test).   
 
Incubation of the porcine coronary rings with mevalonate 10 mM, the 
maximum  concentration that has been used in previous studies to inhibit 
statin relaxation (Roullet et al., 1995, Alvarez de Sotomayor et al., 2001, 
Bergdahl et al., 2003), for 60 min had no effect on the simvastatin 
suppressant effect in CaCl2-induced contractions (figure 3.7). 
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Figure 3.7. Contractile response to the reintroduction of calcium in a 
FDOFLXPIUHHKLJKSRWDVVLXP.UHEV¶VROXWLRQLQWKHFRURQDU\DUWHU\ LQWKH
presence of simvastatin with mevalonate (10 mM) both for 1h (n=5). Data 
are expressed as a percentage relaxation of the KCl-induced contraction 
and are mean ± SEM. (2- way ANOVA followed by a Bonferroni post-hoc 
test).    
 
3.5.6. Role of voltage-gated Ca2+ channel in the acute simvastatin relaxation 
 
The involvement of voltage-gated calcium channels in the relaxation to 
simvastatin was examined by incubation with nifedipine (1 µM) (Figure 
3.8). Nifedipine on its own induced significant relaxation of the KCl 
precontracted coronary vessels within 10 min (figure 3.11). This was 
unaltered by the presence of rotenone (10 µM). 
 
 
            
125 
 
Figure 3.8. Acute effects of simvastatin (10 ǋM) in porcine coronary artery 
rings precontracted with U46619 in the presence and absence of nifedipine 
(1 ǋM). Data are expressed as a percentage relaxation of the U46619-
induced contraction and are mean ± SEM from 6 different experiments. (2- 
way ANOVA followed by a Bonferroni post-hoc test). 
 
3.5.7. Effect of complex I mitochondrial inhibitor, rotenone, on simvastatin 
relaxation in porcine coronary segments precontracted submaximally with 
KCl:  
 
The presence of rotenone 10 µM inhibited the relaxation to simvastatin 
after pre-contraction with KCl (figure 3.9 A&B). In comparison, FCCP 1 µM 
had no significant effect on the relaxation to simvastatin in the presence of 
KCl (figure 3.10). On the other hand, rotenone had no effect on the 
relaxation to nifedipine (figure 3.11), suggesting that rotenone is not 
acting directly at L-type calcium channels. 
A- 
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B-
 
Figure 3.9. (A) Acute effects of simvastatin (10 ǋM) in porcine coronary 
artery rings precontracted submaximally with KCl in the presence or 
absence of rotenone (10 ǋM). Data are expressed as a percentage 
relaxation of the KCl-induced contraction and are mean ± SEM from 9 
different experiments. *** indicates p < 0.001, (2- way ANOVA followed 
by a Bonferroni post-hoc test) versus values obtained from the solvent 
control DMSO (0.1% v/v). (B) Original organ bath trace for simvastatin 
induced porcine coronary relaxation in the presence of rotenone (10 µM): 
KCl (60 mM) bath concentration were obtained for standardization, after 
about 10-15 min the tissue was washed out with Kreb-Henseleit, and then 
left to re-stabilize to baseline. rotenone (10 µM) was added to one 
segment and compared with the control segment (DMSO). Then another 
addition of KCl (60 mM) was added to stimulate tissue contraction before 
the addition of a single concentration of simvastatin (10 µM).  
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Figure 3.10. Acute effects of simvastatin (10 ǋM) in porcine coronary 
artery rings precontracted with KCl in the presence or absence of FCCP (1 
ǋM). Data are expressed as a percentage relaxation of the KCl-induced 
contraction and are mean ± SEM from 4 different experiments. (2- way 
ANOVA followed by a Bonferroni post-hoc test).  
 
  
Figure 3.11. Effects of nifedipine (1 ǋM) in porcine coronary artery rings 
precontracted with KCl in the presence of (10 µM) rotenone. Data are 
expressed as a percentage relaxation of the KCl-induced contraction and 
are mean ± SEM from 5 different experiments. (2- way ANOVA followed by 
a Bonferroni post-hoc test). 
 
Although the complex I inhibitor rotenone had no significant effect on the 
calcium-induced contraction in the porcine coronary artery (see chapter 4), 
it did partially prevent the inhibitory effect of simvastatin on the contractile 
responses in segments of porcine coronary artery to Ca2+ re-introduction in 
a Ca2+ free, high K+ (Figure 3.12). 
 
 
128 
 
Figure 3.12. Contractile response to the reintroduction of calcium in a 
FDOFLXPIUHHKLJKSRWDVVLXP.UHEV¶VROXWLRQLQWKHFRURQDU\DUWHU\ LQWKH
presence of simvastatin and rotenone (10 µM) both for 1 h (n=6). Data are 
expressed as a percentage relaxation of the KCl-induced contraction and 
are mean ± SEM. * indicates P<0.05, *** indicates p < 0.001 (2- way 
ANOVA followed by a Bonferroni post-hoc test). 
 
3.5.8. Simvastatin inhibited Ca2+ rise in isolated coronary porcine smooth 
muscle cells: 
3.5.8.1 SMC in Cultures  
 
Coronary smooth muscle cells grew like other smooth muscle cells in a 
µKLOO-and-YDOOH\¶-like pattern which is characteristic of smooth muscle cell 
growth (Figure 3.13). As soon as the cells became confluent, they were 
characterized by immunofluorescence staining for Į-smooth muscle actin 
to differentiate smooth muscle cells from fibroblasts. The cells reacted 
intensely and the staining was exclusively in long, straight fibrils scattered 
densely throughout the cytoplasm. The nucleus stained with DAPI (Figure 
3.14). However, using these cells, no change in intracellular Ca2+ could be 
detected in response to KCl-induced depolarization, thus the imaging 
experiments were done using freshly isolated coronary smooth muscle 
cells.   
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 (A)  SMC growth after 10 days 
 
(B) SMC growth after 17 days 
 
Figure 3.13. Coronary Smooth muscle cells in culture A- after 10 days B- 
after 17 days ZLWKD µKLOO-and-YDOOH\¶-like pattern which is characteristic of 
smooth muscle cell growth. Micrographs were captured with light 
microscope. The magnification is 10X.  
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Figure 3.14. ,PPXQRIOXRUHVFHQW LPDJH IRU IL[HG Į-smooth muscle cells 
actin grown from porcine coronary vessels, 3-weeks in culture. The cells 
were fixed in 4% PFA, and then immunohistochemistry performed. 
Micrographs were captured with DMRB Fluorescence Microscope Luca EM, 
magnification 63XVFDOHEDUǋP  
 
3.5.8.1 Freshly isolated smooth muscle cells 
 
Unlike cultured primary smooth muscle cells, freshly isolated smooth 
muscle cells produced an increase in intracellular calcium in response to 
KCl (figure 3.15 A). In the presence of 10 µM simvastatin, this response 
was significantly reduced (figure 3.15 B & C). 
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A) 
 
     
 
B) 
 
1 2 
3 
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C) 
 
Figure 3.15. (A) Example images showing changes in fluo-4 fluorescence 
in freshly isolated coronary artery smooth muscle cells (cell clumps of 25±
50 cells were often found). Before depolarization (basal fluorescence), 
after addition of 50 mM KCl (depolarized SMC), and after perfusion of 10 
ǋ0VLPYDVWDWLQ(B) time-response traces and (C) bar chart of mean data 
± SEM from 239 (DMSO) and 291 (simvastatin) cells showing the changes 
in fluo-4 fluorescence in response to 50 mM KCl in the presence of 0.1 % 
YY '062 RU ǋ0 VLPYDVWDWLQ * indicates p<0.0001 v DMSO, 2-
tailed, unpaired t-test.  
  
3.6. Discussion  
 
The present study provides evidence that simvastatin induces a 
concentration- dependent relaxation in the isolated proximal porcine 
coronary artery segments after pre-contraction with KCl depolarization. 
The relaxation is likely to arise from the ability of the simvastatin to inhibit 
Ca2+ influx. The effect of simvastatin on Ca2+ channels was supported by 
two observations. First, simvastatin inhibited coronary artery contraction in 
response to increasing concentrations of CaCl2 in a Ca
2+ free, high K+ 
containing solution. Second, simvastatin hindered the increase in 
intracellular Ca2+ in vascular smooth muscle isolated from porcine coronary 
arteries, as indicated by fluo-4. 
The relaxation induced by simvastatin after pre-contraction with KCl was 
similar to that seen after pre-contraction with U46619, and endothelin-1 
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(see chapter II), indicating that the relaxant effect of simvastatin was not 
due to an interaction with K+ channels. Similarly, treatment with L-NAME 
did not affect simvastatin-induced responses, thus ruling out the 
involvement of NO. Agonist-induced calcium signal is provisioned by 
extracellular calcium influx through voltage operated calcium channel 
(VOCC), store-operated calcium channel (SOCC), or release from 
intracellular calcium store (Goto et al., 1989, Tosun et al., 1998b, Miwa et 
al., 2005, Pang et al., 2005). In this context, it is perhaps easier to 
hypothesize for KCl stimulation to narrow down the mechanism of calcium 
blockade, since there is a general consensus for KCl mechanism of 
activation of contraction (Ratz et al., 2005). Elevation of K+ is known to 
activate L-type Ca2+ channels with an increase in Ca2+ via membrane 
depolarization in vascular smooth muscle (Fransen et al., 2012). Effects of 
Ca2+-induced Ca2+ release by the sarcoplasmic reticulum might also be 
involved (Fernandez-Tenorio et al., 2011). However, incubation with CPA, 
a Ca2+ ATPase inhibitor (Seidler et al., 1989) had no effect on simvastatin 
relaxation, ruling out an effect of simvastatin on calcium uptake into 
intracellular stores as a possible mechanism for relaxation (Zheng et al., 
1993, Moritoki et al., 1996). Consistent with our data, Bergdahl et al study 
provided evidence that lipophilic statins inhibit L-type Ca2+ current and 
attenuate contraction in cerebral vascular smooth muscle (Bergdahl et al., 
2003). Similarly, simvastatin inhibited Ca2+ increase by KCl in rat islet 
SDQFUHDWLF ǃ-cells (Yada et al., 1999). Furthermore, simvastatin, 
cerivastatin, and fluvastatin blocked the hypoxia-induced Ca2+ rise in 
human umbilical cord endothelial cells (Schaefer et al., 2006). However, 
simvastatin (50 µM)-treated rat aortic smooth muscle cells showed a slight 
increase in basal Ca2+ compared with control (Tesfamariam et al., 1999), 
which could be related to the high concentration of simvastatin used.   
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On the other hand, incubation of human umbilical vein endothelial cells for 
24 hours with cerivastatin or fluvastatin (1 µM) significantly increased the 
resting Ca2+ (Heinke et al., 2004). Similarly Lorkowska (2004) proved that 
incubation of bovine aortic endothelial cells with atorvastatin, cerivastatin, 
simvastatin, lovastatin, but not pravastatin, at a concentration of 10±30 
ǋ0 LQGXFHDQ LPPHGLDWH LQFUHDVH LQCa2+ and such effect may correlate 
with the immediate release of NO and PGI2 by these drugs (Luckhoff et al., 
1988, Lorkowska et al., 2004). Collectively, such findings suggest that 
vascular effects of simvastatin involve both mobilization of Ca2+ from 
intracellular stores and/or extracellular Ca2+ entry via membrane cation 
channels (Su et al., 2014), which may be induced as a consequence of 
intracellular Ca2+ store depletion (Alvarez de Sotomayor and 
Andriantsitohaina, 2001). On the other hand, blockade of extracellular Ca2+ 
entry into smooth muscle. The latter promotes relaxations independent of 
the presence of endothelium (Alvarez de Sotomayor et al., 2001). The data 
in isolated smooth muscle confirmed that simvastatin inhibits the increase 
in intracellular calcium as a result of exposure to KCl. It is worth 
mentioning that Ca2+ influx could not be elicited in cultured porcine 
vascular smooth muscle cells by KCl-induced depolarization, suggesting 
that the culturing conditions result in loss of calcium channel expression 
(Kuga et al., 1996, Gollasch et al., 1998). The same phenomenon has been 
reported previously (Clunn et al., 1997). Therefore, freshly isolated cells 
were used for measuring changes in intracellular calcium levels.  
The mechanism by which statins may inhibit Ca2+ influx is not clear; the 
high K+ depolarization was completely abolished by a selective L-type Ca2+ 
channel blocker, nifedipine (1 µM). However, the same concentration of 
nifedipine failed to inhibit the simvastatin relaxation in U-46619 pre-
contracted arteries. Such effect could point to the indirect inhibition of Ca2+ 
influx by simvastatin. 
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NO may inhibit calcium efflux (Collins et al., 1986, Blatter and Wier, 1994). 
However, this study has shown that NO inhibition had no effect on 
simvastatin relaxation, thus ruling this out as a mechanism. 
Rho-kinase can be seen as a major player for receptor-mediated, but not 
for KCl stimulation (Nobe and Paul, 2001). It is worth mentioning that 
voltage-gated calcium channels not only mediate the Ca2+ influx that 
triggers contraction, but also metabotropically regulate intracellular Ca2+ 
release and RhoA activation to sensitize the contractile machinery 
(Fernandez-Tenorio et al., 2011, Urena and Lopez-Barneo, 2012). Thus, 
the involvement of Rho in vasorelaxation mediated by simvastatin cannot 
be discounted, and it remains to be investigated.  
Previous studies have shown that pre-incubation with mevalonate restored 
the CaCl2 -induced contraction (Alvarez de Sotomayor et al., 2001) and 
reverse the changes induced by simvastatin on Ca2+ signal after 
stimulation with noradrenaline (Alvarez de Sotomayor et al., 2001) and 
vasopressin (Ng et al., 1994). This study has shown that mevalonic acid 
incubation for one hour had no effect on simvastatin relaxation, suggesting 
that the acute effects of simvastatin involves direct actions at Ca2+ pools 
unrelated to mevalonate products (Bergdahl et al., 2003). Longer 
incubation, up to 48 h with mevalonic acid might have different effects 
which in turn might explain the discrepancy with other studies (Clunn et 
al., 1997). However, Escobales et al have shown that the inhibitory effect 
of simvastatin was reduced 50% by 30 min incubation with mevalonic acid 
in rat aortic rings (Escobales et al., 1996b).  
Membrane cholesterol plays a role in regulating L-type calcium current, 
both under basal conditions and in response to selected agonists (Bialecki 
et al., 1991). Several published observations seem to refute the possibility 
that the acute effects of simvastatin on vascular tone and Ca2+ influx are 
due to reduced cholesterol content. For examples, cyclodextrin reduced the 
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arterial contents of cholesterol by 20%, but was without any effect on 
contraction induced by depolarisation (Lohn et al., 2000). Enrichment of 
cholesterol, on the other hand, leads to increased L-type current (Sen et 
al., 1992), which may involve incorporation of cholesterol into membrane 
domains where it is not normally present (Sen et al., 1992). Thus, 
inhibition of Ca2+ influx by simvastatin is likely to be independent of 
cholesterol biosynthesis.    
Acute application of simvastatin on human skeletal muscle fibres triggers a 
large release of Ca2+ from the SR as an early event for myotoxicity. The 
Ca2+ release results from alterations in mitochondrial function with 
subsequent mitochondrial membrane depolarization and Ca2+ efflux to the 
cytoplasm (Sirvent et al., 2005b). Mitochondria appeared as the cellular 
structure responsible for the earlier event leading to a subsequent large 
sarcoplasmic reticulum Ca2+ release (Liantonio et al., 2007, Pierno et al., 
2009). Because of the structural proximity between the mitochondria and 
the sarcoplasmic reticulum, mitochondria ensure efficient sarcoplasmic 
reticulum refilling and minimize cytosolic Ca2+ elevations (Poburko et al., 
2009, Restini et al., 2006). Furthermore, the principal internal Ca2+ stores 
within vascular smooth muscle cells are the sarcoplasmic reticulum (SR) 
and mitochondria (Drummond and Fay, 1996). Accordingly, mitochondrial 
inhibition produces a small, transient increase in Ca2+ as a result of 
mitochondrial Ca2+ efflux. On the other hand, mitochondrial inhibition 
reduces the amount of Ca2+ released by IP3 (McCarron and Muir, 1999). 
Indeed, IP3 receptors became inoperative during mitochondrial 
depolarization and were reversible upon repolarization of mitochondria, the 
latter is considered as a protective mechanism to prevent Ca2+ dependent 
apoptosis (Collins et al., 2000). A previous study by Escobales et al could 
not prove the precise mechanism by which simvastatin releases calcium 
from IP3-sensitive pools (Escobales et al., 1996a). Our study suggests that 
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simvastatin effects on vascular smooth muscle involve Ca2+ release from 
intracellular stores by mitochondrial depolarization while on the same time 
blockade of extracellular Ca2+ entry. However, the involvement of 
mitochondria needs more studies to confirm the hypothesis.  
Application of the complex I inhibitor rotenone (10 ǋM) completely 
inhibited Ca2+ waves with accompanied increase in basal Ca2+ in interstitial 
cells from rabbit urethra (Sergeant et al., 2008). Rotenone (10 ǋM) also 
reduced Ca2+ spark and wave frequency and elevated global Ca2+ in 
smooth muscle cells of intact arteries (Cheranov and Jaggar, 2004) and  
induced a rapid increase in Ca2+ in the presence of extracellular Ca2+ but 
not in the absence of extracellular Ca2+ (Wyatt and Buckler, 2004). This 
suggests that mitochondrial inhibition might influence Ca2+ wave activity, 
possibly due to a close spatial relationship of mitochondria and the 
sarcoplasmic reticulum. On the other hand, It has been found that 
rotenone inhibits dilation in human coronary vessels by suppression of O± 
and H2O2 formation (Liu et al., 2003). This mechanism has been discussed 
in chapter I.  
In the present study, rotenone prevented the inhibitory effect of 
simvastatin on the calcium-induced contraction (figure 3.12). Rotenone 
also inhibited the relaxation to simvastatin after pre-contraction to KCl 
(figure 3.9) which is likely to be due to inhibition of calcium influx. Previous 
study has shown that rotenone inhibited acetylcholine-induced, 
endothelium-dependent relaxation of rat and rabbit aorta by inhibiting NO 
production (Weir et al., 1991). However, in our study, NO synthase 
inhibition with L-NAME had no effect on relaxation induced by simvastatin, 
ruling this out as a mechanism. Furthermore, uncoupling of the 
mitochondria with FCCP had no effect on simvastatin relaxation in KCl pre-
contracted vessels (figure 3.10) indicating that the inhibitory effect of 
rotenone is unlikely to be due to a non-selective effect of inhibition of 
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mitochondrial function. It is also worth mentioning that the relaxation 
induced by nifedipine on KCl-contracted coronary rings was unaffected, 
unlike simvastatin, by rotenone incubation. This provides further support 
to the suggestion that the inhibitory effect of rotenone on the simvastatin 
relaxation is not due to a non-specific effect of rotenone.  
A Previous study has shown that reactive oxygen species generated from 
complex III of the mitochondria result in Ca2+ channel inhibition in cardiac 
cells (Scragg et al., 2008), other studies have shown that oxidized LDL 
enhance Ca2+ current via mitochondrial reactive species(Fearon, 2006). 
These differential responses may relate to the concentration and type of 
ROS, species differences and experimental conditions. The locus of 
increased superoxide was suggested to be beyond complex I. To examine 
whether Complex III was the site of enhanced superoxide production 
pharmacological inhibition of the individual mitochondrial complexes was 
used, inhibition of the respiratory chain by rotenone or myxothiazol block 
electron flow at the Qo superoxide site of complex III (Viola and Hool, 
2010). Both compounds successfully attenuated the increase in 
superoxide, thus inhibit complex III ROS generation and prevent the 
effects of ROS on Ca2+ channels. Therefore inhibition of complex III by 
simvastatin would no longer have any effect. 
The data presented here suggest that simvastatin acts as inhibitor of 
complex III. If the effects of simvastatin are mediated through inhibition of 
complex III, then the effects of simvastatin on vascular tone should be 
mimicked by a complex III inhibitor. Thus, the effects of the mitochondrial 
inhibitors on the precontracted porcine coronary segments, with special 
reference to antimycin A as complex III inhibitor, will be investigated in the 
next chapter. 
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FIGURE 3.16. Role of mitochondria in simvastatin induced porcine 
coronary relaxation. The three complexes of the mitochondrial (inner) 
membrane that form the proton gradient (I, III, and IV) are indicated, and 
two established inhibitors of electron flow are shown, rotenone and 
myxothiazol. The sites of simvastatin action proposed by our study, as 
indicated by red arrow, are mitochondrial complex III thereby causing 
mitochondrial depolarization. Furthermore simvastatin inhibits Ca2+ influx 
with subsequent relaxation. Mitochondrial depolarization may be the 
upstream for AMPK stimulation and NO production proposed by other 
studies. Simvastatin blocks KATP channels thus they have no role in 
simvastatin relaxation. Our proposal includes also ROS generation as a 
result of complex III inhibition, in-turn ROS may inhibit Ca2+ channels (as 
indicated by ?), however more studies are recommended to confirm the 
mechanism of simvastatin induced Ca2+ channels inhibition.  
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CHAPTER IV: Effect of complex III inhibition with antimycin 
A on porcine coronary tone: mechanism of action & 
comparison with other mitochondrial inhibitors  
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4.1 Introduction 
 
Traditionally mitochondria are known as the energy generating centre of 
the cells, However, there is growing consensus demonstrating that 
mitochondria actively participate in intracellular signalling, such as 
production of ROS and regulation of the intracellular Ca2+ concentration  
(Michelakis et al., 2002). The process of ROS generation is  tightly 
regulated (Sena and Chandel, 2012). In the mitochondrial matrix, 
superoxide (O2
āí) is converted to hydrogen peroxide (H2O2) by superoxide 
dismutase. H2O2 then diffuses across the mitochondrial membranes. In the 
cytosol H2O2 can be further be metabolized to water (H2O) by glutathione 
peroxidases (Zhang and Gutterman, 2007, Xi et al., 2005). Mitochondrial 
superoxide is mainly produced by complexes I and III of the electron 
transport chain (Chen et al., 2003). The oxidant generation can be 
modulated by mitochondrial potential and intracellular Ca2+ (Camello-
Almaraz et al., 2006a). Antimycin A (a complex IIIQi inhibitor) is known to 
increase O2
āí generation, and myxothiazol (a complex IIIQo inhibitor) has 
the same effect (Starkov and Fiskum, 2001). With rotenone (a complex I 
inhibitor) this point is controversial. While inhibition of complex I with 
rotenone reduced mitochondrial ROS in intact human coronary arterioles 
(Liu et al., 2003), increased mitochondrial ROS was observed in isolated 
mitochondria (Andreyev et al., 2005). On the other hand, uncoupling 
oxidative phosphorylation with (FCCP) reduces O2
āí production (Saitoh et 
al., 2006).  
The increase in ROS production has been considered a pathological 
response since excess O2
āí generation influences vasomotor tone by 
quenching NO. However, recent findings suggest that ROS can play an 
important supportive role in the control of a large variety of vascular cell 
signalling processes including activation of nitric oxide synthase (NOS), 
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modulation of intracellular Ca2+, and AMP kinase activation (Cardaci et al., 
2012). AMP kinase in turn can increase NO bioavailability (Rossoni et al., 
2011) and modulates vascular tone (Mackenzie et al., 2013).  In small 
coronary arterioles, complex I and III ±derived H2O2 is found to be 
responsible for flow-mediated vasodilatation that is independent of NO (Liu 
et al., 2003, Cai, 2005). Rotenone and myxothiazol markedly attenuated 
flow-induced dilation and associated O2
āí and H2O2 generation in the 
coronary circulation (Liu et al., 2003). On the other hand, mitochondrial 
depolarization using nanomolar concentrations of the protonophore CCCP 
induces ROS elevation with an increase in calcium spark frequency, which 
in turn stimulates calcium-activated K+ channels, resulting in cerebral 
artery vasodilation (Xi et al., 2005). By contrast, marked depolarization 
using micromolar CCCP or rotenone reduces calcium spark activity thereby 
reducing opening of calcium-activated potassium channels (Cheranov and 
Jaggar, 2004, Xi et al., 2005).   
Previous studies have demonstrated that inhibiting the mitochondrial 
electron transfer chain leads to vasodilatation (Qamirani et al., 2006, Hao 
et al., 2006, Sward et al., 2002, Weissmann et al., 2003). However, other 
studies have demonstrated opposing actions in different blood vessels e.g. 
inhibition of complex I constricted the pulmonary artery, but stimulated 
dilation of the renal artery (Michelakis et al., 2002). Such differences of the 
mitochondrial inhibitors on the vascular tone could be related to 
mitochondrial diversity between different vascular beds (Michelakis et al., 
2002).   
It is now well recognised that the large negative potential across the inner 
membrane (up to í180 mV) accumulates Ca2+ very efficiently and rapidly 
(McCarron et al., 2013, Szabadkai and Duchen, 2008). The uptake of Ca2+ 
into mitochondria is proposed to stimulate mitochondrial ATP production, 
thereby providing a means for matching increased energy demand. Despite 
143 
 
reports of their high-capacity and low affinity for Ca2+, mitochondria are 
also accepted as being important regulators of intracellular Ca2+ 
concentration, thereby regulating smooth muscle tone. Mitochondria could 
be transiently exposed to local Ca2+ concentrations much higher than those 
measured in the bulk cytosol sufficient to activate their low-affinity Ca2+ 
uptake (McCarron et al., 2012). In arterial smooth muscle cells, the results 
suggested that mitochondrial Ca2+ uptake is important over low Ca2+ range 
(Kamishima and Quayle, 2002).  
Chapters 2 and 3 have indicated that simvastatin produces a relaxation 
response, which we hypothesise is through an effect on complex III of the 
mitochondria. If this is the case, then inhibition of complex III should 
produce similar effects. The direct impact of the mitochondrial inhibitors on 
the vascular tone of the coronary vessels is unknown. Therefore the goals 
of the present chapter were to determine the effects of antimycin A as a 
complex III inhibitor, in comparison with other mitochondrial inhibitors, on 
the vascular tone of the isolated porcine coronary artery and to elucidate 
the underlying signalling pathways involved.  
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4.2. Materials and mehods  
4.2.1. Materials  
 
Rotenone, antimycin A, 3-nitropropionic acid (3-NP), 4,4,4-trifluoro-1-(2-
thienyl)-1,3-butanedione (TTFA), FCCP, oligomycin, TEA, 4-aminopyridine, 
ebselen, PEG-SOD, PEG-catalase, diethylthiocarbamate (DETCA), U46619, 
indomethacin, Rb+, fluo-4 AM, bovine serum albumin (BSA) were obtained 
from Sigma-Aldrich, Poole, UK. $QWLERGLHV VSHFLILF WR $03.Į DQG WRWDO
AMPK (New England Biolabs, Hitchin, UK). 
4.2.2. Solutions  
 
Krebs-Henseleit buffer (NaCl 118, KCl 4.8, CaCl2.H2O 1.3, NaHCO3 25.0, 
KH2PO4 1.2, MgSO4.7H2O, glucose 11.1 in (mM). Hanks buffer containing 
(in mM): 5.6 KCl, 138 NaCl, 4.2 NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2, 1.2 
MgCl2, 10 glucose and 10 HEPES [pH 7.4]. Homogenisation solution: 80 
P0 VRGLXP ǃ-glycerophosphate, 20 mM imidazole, 1 mM dithiothreitol 
(DTT), 1 mM sodium fluoride (NaF) [pH 7.6]. Laemmli sample buffer (4% 
(w/v) SDS, 20% (w/v) glycerol, 10% (v/v) 2-mercaptoethanol, 0.004% 
(v/v) bromophenol blue and 0.125 M Tris HCl at pH 6.8). Electrophoresis 
buffer (25 mM Tris, 192 mM glycine and 0.1% (w/v) SDS in distilled H2O at 
pH 8.3). Transfer buffer (25 mM Tris, 192 mM glycine and 20% methanol 
in distilled H20 at pH 8.3). Tris-buffered saline [25 mM Tris, 125 mM NaCl 
to pH 7.6 in distilled H2O].  
4.2.3. Data Analysis  
 
The relaxation responses were expressed as a percentage change from the 
U46619- or KCL induced pre-contraction over time. Values for all figures 
refer to mean ± SEM. Relaxation responses over time were compared by 
using two-way analysis of the variance (ANOVA) followed by a Bonferroni 
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post-hoc test. Differences were considered to be significant when the P 
value was < 0.05. Contractile responses to calcium chloride were 
expressed as a percentage of the 60 mM KCl response. Changes in fluo-4 
fluorescence were analysed by unpaired 6WXGHQW¶VW-test.  
4.2.4. Method 
 
Porcine hearts from pigs of both sexes were obtained from a local abattoir 
and transported back to the laboratory in ice-cold Krebs-Henseleit buffer 
(NaCl 118, KCl 4.8, CaCl2.H2O 1.3, NaHCO3 25.0, KH2PO4 1.2, 
MgSO4.7H2O, glucose 11.1 in (mM) gassed with a mixture of 95% O2 and 
5% CO2). The anterior proximal descending branch of the coronary artery 
was dissected out and cleaned of fat and connective tissues and set up for 
isometric tension recording (see chapter 2). Tissues were pre-contracted 
with cumulative additions of U46619 (a thromboxane A2-mimetic) to about 
50-70% of the second KCl response before addition of a single 
concentration of antimycin A (3 µM to 10 µM), myxothiazol, rotenone, 3-
NP, oligomycin, (all 10 µM) and FCCP (1 µM), and the tone measured for 2 
hours. Control tissues contained vehicle only (0.1% v/v DMSO). In 
separate experiments, the effect of antimycin A after pre-contraction with 
KCl was determined. 
In order to determine the role of endothelial factors on the effects of 
antimycin A, tissues were incubated with the nitric oxide synthase 
inhibitor, L-NAME (300 µM), or the cyclo-oxygenase inhibitor indometacin 
(10 µM) for 20±30 minutes prior to pre-contraction with U46619. The role 
of AMP kinase inhibition on the effects of antimycin A was also determined 
by pre-incubation with GRUVRPRUSKLQH ǋ0 ,Q VRPH H[SHULPHQWV WR
evaluate the role of K+ channels, the segments were pre-incubated with 
the non-selective K+ channel blocker tetraethylammonium (TEA; 10 mM), 
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glibenclamide 3 µM or the Kv channel blocker 4-aminopyridine (1 mM) for 
60 minutes prior to addition of U46619.  
4.2.4.1 Role of reactive oxygen species in antimycin A-induced relaxation  
 
The role of reactive oxygen species (ROS) in the relaxation response to 
antimycin A was investigated by pre-incubation with ebselen, a scavenger 
of hydrogen peroxide (3 µM), and PEG-superoxide dismutase (100 Uml-1) 
which metabolises superoxide free radicals. In a separate set of 
experiments, tissues were incubated with diethylthiocarbamate (DETCA), 
which inhibits superoxide dismutase (10 mM).  
4.2.4.2. Effect of antimycin A on calcium-induced contractions 
 
To assess the effect of antimycin A on calcium influx, a concentration±
response curve for CaCl2 was constructed. Arteries were incubated for 1 h 
in Ca2+-free Krebs-Henseleit buffer with antimycin A 10 µM. Tissues were 
then exposed to 60 mM KCl and then increasing concentrations of CaCl2 (1 
µM to 3 mM) added to induce a contraction. In another set of experiments, 
tissues were incubated with rotenone, myxothiazol, oligomycin (10 µM) or 
FCCP (1 µM) in place of antimycin A.  
4.2.4.3. Effect of antimycin A on calcium influx in freshly isolated smooth 
muscle cells. 
 
Coronary smooth muscle cells were isolated from the proximal coronary 
artery segments by incubating with type II collagenase (2 mg/mL) for 30 
min at 37 ºC and plated on coverslips. The cells were then loaded with 5 
µmol/L fluo-4 AM for 1 hour at room temperature in HEPES-buffered Hanks 
solution (same as chapter 3). Coverslips were then superfused with Hanks 
buffer at 37°C for 5 min for basal recording. The Hanks buffer was then 
replaced with high K+ (50mM) Hanks containing which elicited a sustained 
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increase in the fluorescence ratio. Subsequently, antimycin A 10 µM or 
DMSO (0.1% v/v) as a control were added to the perfusion media.  
4.2.4.4. Atomic absorption spectrophotometric determination of 3Na+/2K+ 
ATPase activity  
 
Rubidium-uptake was measured with atomic absorption spectrophotometry 
(Perkin-Elmer) to study the sodium-potassium pump activity as previously 
described (Ferrer-Martinez et al., 1996). Porcine coronary segments (PCA) 
were cleaned of adherent connective and fatty tissues. The segments were 
cut open longitudinally, ~1.5 cm in length. They were placed into 6-well 
plates pre-filled with 3 ml Krebs-Henseleit solution previously gassed with 
5% CO2 and 95% O2. Test agents 100 nM ouabain, 10 µM antimycin A or 
DMSO were added into the respective wells. Plates were incubated at 37°C 
in a shaker for 1 h. After complete incubation, Krebs solution was replaced 
with K+-IUHH .UHEV¶-Henseleit solution containing 4 mM RbCl with 
respective inhibitors and incubated at 37 °C in a shaker for an additional 
30 minutes. Arteries were then rapidly washed three times with ice-cold 
0.2 M MgSO4 then stored at -20 °C until further assay. Frozen segments 
were fixed with 2 mL fixative (containing 50% ethanol, 49% distilled water 
and 1% acetic acid) and left to evaporate in a fume hood overnight. 
Intracellular Rb+ was then extracted in 2 mL of distilled water and the Rb+ 
content was determined with flame photometry on an atomic absorption 
spectrometer using wavelength of 780 nm. Rb+-uptake levels were 
interpolated from a standard Rb+ curve and individual PCA reading was 
divided by the wet weight of the respective artery segment. 
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4.2.4.5. Measurement of AMP Kinase activation 
 
4.2.4.5.1. Tissue preparation 
 
The phosphorylation state of AMP Kinase was measured using Western 
immunoblotting.  Porcine coronary artery segments were set up in 5 ml 
organ baths connected to a force transducer for isometric tension 
recording. The baths contained Krebs-Henseleit solution and were 
connected to a thermostat to maintain the temperature at 37oC and 
constantly gassed with carbogen (95% O2, 5% CO2). After two consecutive 
KCl (60 mM) challenges, arteries received one of the following treatments: 
U46619 (20 ± 30 nM), in order to achieve 60±85% of the maximal KCl 
contraction. After a steady contractile tone was achieved, antimycin A was 
added to a final concentration of (10 µM). DMSO as a solvent control was 
added to the second channel. Timing of drug treatment was 2 h which is 
consistent with other antimycin A experiments. Control arteries were 
removed at the same time. The segments were frozen rapidly by placing 
the arteries on dry ice. Finally, the arteries were stored at -80ºC. On the 
day of the experiments, the rings were chopped into smaller pieces using 
scissors and homogenised for approximately 30 seconds (FisherBrand 0.1 
ml glass-glass homogeniser) in ice-FROGEXIIHUFRQWDLQLQJP0VRGLXPǃ-
glycerophosphate, 20 mM imidazole, 1 mM dithiothreitol (DTT), 1 mM 
sodium fluoride (NaF) [pH 7.6] with a protease inhibitor cocktail 
(Calbiochem).   
4.2.4.5.2. Bradford Protein Assay 
 
A fraction of each homogenate was used to estimate protein concentration 
using the Bradford protein assay. Firstly, a standard concentration curve of 
bovine serum albumin (BSA) was prepared using the following 
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concentrations: 2 mg ml-1, 1 mg ml-1, 0.5 mg ml-1, 0.25 mg ml-1 and 0.125 
mg ml-1. The diluent used contained homogenisation buffer at 
concentrations listed above. 10 µl of each sample was loaded in pairs onto 
a 96-well plate, along with each concentration of BSA and a pair of blanks 
(diluent only). Each well was topped up with 40 µl BioRad protein assay 
dye reagent concentrate and 150 µl distilled water. Absorbance readings, 
measured at 595 nm, were generated using a microplate reader and used 
to estimate the concentration of protein in each sample. These estimates in 
turn were used to determine the volume of each homogenate sample to be 
used in the next stage of the experiment.   
4.2.4.5.3. Western immunoblotting 
 
The remainder of the homogenised samples were diluted (1:1) in Laemmli 
sample buffer (4% (w/v) SDS, 20% (w/v) glycerol, 10% (v/v) 2-
mercaptoethanol, 0.004% (v/v) bromophenol blue and 0.125 M Tris HCl at 
pH 6.8) and heated at 95ºC for 5 min. Equal amounts of each sample (10 
µg protein) were carefully loaded into wells of pre-cast 4-20% (w/v) 
acrylamide SDS-PAGE gels. Loaded gels were slotted into an electrode tank 
containing electrophoresis buffer (25 mM Tris, 192 mM glycine and 0.1% 
(w/v) SDS in distilled H2O at pH 8.3). A potential difference of 150 V was 
placed across the gel for 40 min, causing protein separation. Protein was 
transferred from gel to nitrocellulose membrane (GE Healthcare Life 
Sciences, Amersham, UK) using a mini Transblot (Bio-Rad Laboratories 
Ltd., Hemel Hempstead, UK) immersed in transfer buffer (25 mM Tris, 192 
mM glycine and 20% methanol in distilled H20 at pH 8.3). A voltage of 100 
V was applied for 60 min.  
To prevent non-specific attachment of antibodies to the nitrocellulose 
PHPEUDQH WKHPHPEUDQHZDV µEORFNHG¶E\ LQFXEDWLQJ IRUPLQ LQ
(w/v) milk solution (Marvel skimmed milk powder dissolved in Tris-
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buffered saline [25 mM Tris, 125 mM NaCl to pH 7.6 in distilled H2O] 
containing 0.1% Tween-20 (TBS Tween). Membranes were incubated 
overnight at 4ºC in 5% BSA (w/v) solution containing a 1 in 1000 dilution 
oI ³SULPDU\´ DQWLERGLHV VSHFLILF WR $03.Į DQG WRWDO $03. Cell Signaling 
Technology, UK).  
The following morning, membrane blots were washed in TBS Tween for 1 
hour and then incubated at room temperature for 60 min in 5% (w/v) milk 
solution containing IR dye taged ³VHFRQGDU\´ DQWLERGLHV  LQ 
dilution) raised in goat against mouse for AMPK and rabbit for 
phosphorylated AMPK (LI-COR Biotechnology Ltd., Cambridge, UK). Blots 
were washed for 1 hour in TBS Tween again, and then washed in distilled 
water. Finally, the blots were then scanned at 700 nm and 800 nm 
wavelengths using an Odyssey Infrared Imaging System (LI-COR 
Biotechnology Ltd., Cambridge, UK). Odyssey software (LI-COR 
Biotechnology Ltd., Cambridge, UK) was used to analyse the optical 
densities and molecular weights of the visualised bands. In order to 
determine if there was a difference in the level of phosphorylation of AMP 
kinase, the density of the bands to phospho-AMP kinase were expressed as 
a ratio of the bands to total AMP kinase. Statistical significance between 
control and antimycin A-treated vessels was determined using a 2-tailed, 
XQSDLUHG6WXGHQW¶VW-test with p<0.05 determining significance. 
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4.3. Results  
4.3.1. Acute effects of antimycin A and myxothiazol on porcine coronary 
artery tone 
 
As shown in figure (4.1 & 4.2), antimycin A (1 ǋM & 10 ǋM) caused 
essentially immediate relaxation of the porcine coronary artery pre-
contracted with U46619 reaching a maximum response at around 100 
minutes. Myxothiazol also produced relaxation of the porcine coronary 
artery, although the response was slower to develop (figure 4.4). DMSO as 
a vehicle control had no effect. Pre-constriction with KCl instead of U46619 
attenuated the relaxation response to both antimycin A and myxothiazol 
(figure 4.3 and 4.4 respectively).   
 
Figure 4.1. Relaxation responses to antimycin A and myxothiazol (both 10 
µM) in segments of porcine coronary artery precontracted submaximally 
with U46619. Data are expressed as a percentage relaxation of the 
U46619-induced contraction and are mean ± SEM from 6 different 
experiments. * indicates P<0.05 and *** indicates P<0.001. 
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Figure 4.2. Relaxation responses to antimycin A (1 µM and 10 µM) in 
segments of porcine coronary artery submaximally precontracted with 
U46619. Data are expressed as a percentage relaxation of the U46619-
induced contraction and are mean ± SEM from 8 different experiments. ** 
indicates P<0.01 and *** indicates P<0.001. 
 
  
Figure 4.3. Effect of antimycin A (10 µM) in segments of porcine coronary 
artery precontracted submaximally with U46619 in comparison with KCl 
precontraction. Data are expressed as a percentage relaxation of the 
U46619 or KCl-induced contraction and are mean ± SEM from 6 different 
experiments. * indicates P<0.05 and ** indicates P<0.01. 
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Figure 4.4. effect of myxothiazol (10 µM) in segments of porcine coronary 
artery precontracted submaximally with U46619 in comparison with KCl 
precontraction. Data are expressed as a percentage relaxation of the 
U46619 or KCl-induced contraction and are mean ± SEM from 5 different 
experiments. * indicates P<0.05.  
 
4.3.2. Effects of complex I inhibitor rotenone, and complex II inhibitor on 
PCA tone 
 
Neither rotenone (10 µM) nor 3-NP (10 µM), had any significant effect and 
the contraction was well maintained over the time course of the 
experiment (figure 4.5).   
 
Figure 4.5. effect of rotenone and 3NP (both 10 µM) in segments of 
porcine coronary artery precontracted submaximally with U46619. Data 
are expressed as a percentage relaxation of the U46619-induced 
contraction and are mean ± SEM from 6 different experiments.  
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4.3.3. Effects of mitochondrial uncoupler FCCP on PCA tone 
 
The mitochondrial uncoupler FCCP at (100 nM), but not at (1 µM), also 
produced a time-dependent relaxation, reaching a maximum at around 120 
minutes (figure 4.6). At the higher concentration of 1 µM, FCCP caused an 
initial, transient contraction, before returning to the same level as the 
control (figure 4.6).  
 
Figure 4.6. effect of FCCP (100 nM and 1 µM) in segments of porcine 
coronary artery precontracted submaximally with U46619. Data are 
expressed as a percentage relaxation of the U46619-induced contraction 
and are mean ± SEM from 6 different experiments. ** represents P<0.01 
and *** indicates P<0.001.  
 
Unlike antimycin A, pre-constriction with KCl instead of U46619 had no 
significant effect on the relaxation response induced by 100 nM FCCP 
(figure 4.7). 
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Figure 4.7. effect of FCCP (100 nM) in segments of porcine coronary 
artery precontracted submaximally with U46619 and KCl. Data are 
expressed as a percentage relaxation of U46619 or KCl-induced contraction 
and are mean ± SEM from 5 different experiments. 
 
4.3.4. Effects of ATP synthase inhibitor oligomycin on PCA tone 
 
The ATP synthase inhibitor oligomycin (10 µM) also produced a slow, time-
dependent relaxation of the coronary artery, which was still relaxing at 120 
minutes (figure 4.8). 
  
 
Figure 4.8. effect of oligomycin (10 µM) in segments of porcine coronary 
artery precontracted submaximally with U46619. Data are expressed as a 
percentage relaxation of the U46619-induced contraction and are mean ± 
SEM from 9 different experiments. * indicates P<0.05 and *** indicates 
P<0.001.  
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4.3.5. Role of NO, Prostacyclin in the relaxation response to antimycin A 
 
A previous study by Rowlands et al. has shown that mitochondrial ROS 
play a role in endothelial NOS activation (Rowlands et al., 2011). 
Moreover, mitochondrial depolarization promotes eNOS activation without 
ROS generation (Katakam et al., 2013). Prostacyclin may be also produced 
by endothelial cells in the presence of mild oxidative stress (Toniolo et al., 
2013). However, pre-treatment of the porcine coronary rings with a nitric 
oxide synthase inhibitor, L-NAME (300 µM), or a cyclooxygenase inhibitor, 
indomethacin (10 µM), had no effect on antimycin A-induced relaxation 
(figure 4.9 & 4.10 respectively).  
  
 
Figure 4.9. Relaxation responses to antimycin A in segments of porcine 
coronary artery precontracted submaximally with U46619 in the presence 
of L-NAME (300 µM). Data are expressed as a percentage relaxation of the 
U46619-induced contraction and are mean ± SEM from 7 different 
experiments.  
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Figure 4.10. Relaxation responses to antimycin A in segments of porcine 
coronary artery precontracted submaximally with U46619 in the presence 
of indomethacin (3 µM). Data are expressed as a percentage relaxation of 
the U46619-induced contraction and are mean ± SEM from 9 different 
experiments.  
 
4.3.6. Role of AMPK in the relaxation response to antimycin A 
 
Inhibition of mitochondrial respiration at complex III with 10 µM antimycin 
A interrupts ATP production and hence elevates ADP concentration. This in 
turn would elevate the concentration of AMP with subsequent AMPK 
activation. A variant mechanism for AMPK activation is by RNS or ROS, 
those latter have been shown to activate AMPK when mitochondrial 
respiration is blocked (Quintero et al., 2006, Mackenzie et al., 2013). Pre- 
incubation with dorsomorphin, an AMP kinase inhibitor, significantly 
reduced antimycin A relaxation (figure 4.11), suggesting that antimycin A-
induced vasodilation is mediated in part by AMP kinase activation. 
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Figure 4.11. Relaxation responses to antimycin A in segments of porcine 
coronary artery precontracted submaximally with U46619 in the presence 
of dorsomorphin (10 µM). Data are expressed as a percentage relaxation 
of the U46619-induced contraction and are mean ± SEM from 9 different 
experiments. * indicates P<0.05. 
 
4.3.7. Role of K+ channels in the relaxation response to antimycin A 
 
The incubation of coronary rings with the KCa channel blocker (TEA, 10 
mM), KATP blocker (glibenclamide, 3 µM) or Kv blocker (4-aminopyridine, 1 
mM) had no effect on the antimycin A-induced coronary relaxation (figure 
4.12, 4.13 & 4.14 respectively).  
 
Figure 4.12. Relaxation responses to antimycin A in segments of porcine 
coronary artery precontracted submaximally with U46619 in the presence 
of TEA (10 mM). Data are expressed as a percentage relaxation of the 
U46619-induced contraction and are mean ± SEM from 5 different 
experiments.  
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Figure 4.13. Relaxation responses to antimycin A (10 µM) in segments of 
porcine coronary artery precontracted submaximally with U46619 in the 
presence of glibenclamide (3 µM). Data are expressed as a percentage 
relaxation of the U46619-induced contraction and are mean ± SEM from 5 
different experiments.  
 
 
Figure 4.14. Relaxation responses to antimycin A (10 µM) in segments of 
porcine coronary artery precontracted submaximally with U46619 in the 
presence of 4-AP (1 mM). Data are expressed as a percentage relaxation 
of the U46619-induced contraction and are mean ± SEM from 5 different 
experiments.  
 
4.3.8. Effect of pre-incubation with FCCP, or rotenone, on the relaxation 
response to antimycin A   
 
Pre-incubation with the mitochondrial uncoupler FCCP (1 ǋM), significantly 
reduced the relaxation to antimycin A. On the other hand rotenone (10 
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ǋM), a complex I inhibitor, caused a partial inhibition of the antimycin A 
relaxation (figure 4.15). The relaxation response to antimycin A was 
reduced after pre-contraction with KCl as mentioned before (figure 4.3). 
Under these conditions, pre-incubation with 10 µM rotenone caused 
complete inhibition of the relaxation to antimycin A (figure 4.16). 
 
Figure 4.15. Relaxation responses to antimycin A (10 µM) in segments of 
porcine coronary artery precontracted submaximally with U46619 in the 
presence of FCCP (1 µM) or rotenone (10 µM). Data are expressed as a 
percentage relaxation of the U46619-induced contraction and are mean ± 
SEM from 10 different experiments. * indicates P<0.05, ** indicates 
p<0.01 and *** indicates P<0.001. 
  
 
Figure 4.16. Relaxation responses to antimycin A in segments of porcine 
coronary artery precontracted submaximally with KCl in the presence of 
rotenone (10uM). Data are expressed as a percentage relaxation of the 
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U46619-induced contraction and are mean ± SEM from 5 different 
experiments. ** indicates P<0.01 and *** indicates P<0.001. 
 
4.3.9. Role of Na+/K+ ATPase pump in the relaxation response to antimycin 
A  
  
A study by Qamirani et al provided evidence that NaN3, a mitochondrial 
complex IV inhibitor, directly dilates porcine coronary arterioles by the 
activation of Na+/K+ ATPase pump (Qamirani et al., 2006). In the presence 
of ouabain, a Na+/K+ ATPase inhibitor, at 100 nM concentration, the 
antimycin A-induced coronary relaxation was significantly attenuated 
(figure 4.17), suggesting that antimycin A affects the Na+/K+ ATPase 
pump. However, the results obtained from rubidium-uptake experiments 
showed that Na+/K+ ATPase pump was not altered by antimycin A (figure 
4.18).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. Relaxation responses to antimycin A (10 µM) in the absence 
or presence of ouabain (100 nM), Data are expressed as a percentage 
relaxation of the U46619-induced contraction and are mean ± SEM from 6 
different experiments. ** indicates P<0.01.  
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Figure 4.18. Measurement of rubidium-uptake (30 min incubation time) in 
porcine coronary arteries to determine the activity of Na+/K+ pump in the 
presence of 100 nM ouabain or 10 µM antimycin A using atomic absorption 
spectrophotometer used in a flame emission mode. Data are expressed as 
rubidium uptake in µmol mgí1 of tissue wet weight and are mean ± S.E.M. 
of 6 experiments. **P < 0.01, one-ZD\ $129$ IROORZHG E\ 'XQQHWW¶V
multiple comparison test compared to the control.  
 
4.3.10. Role of reactive oxygen species in the relaxation response to 
Antimycin A 
 
PEG-superoxide dismutase (100 Uml-1) had no effect on the relaxation 
response to antimycin A (figure 4.19). By contrast, ebselen (3 µM) or 
DETCA (10 mM) inhibited the antimycin A relaxation in the coronary rings 
pre-contracted with KCl (figure 4.20 & 4.21). Pre-contraction with KCl was 
used under these conditions as both ebselen and DETCA reduced the 
U46619-induced tone; the contraction is better maintained with KCl under 
these conditions (Takase et al., 1999).   
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Figure 4.19. Relaxation responses to antimycin A (10 µM) in the absence 
or presence of SOD (100 Uml-1), Data are expressed as a percentage 
relaxation of the U46619-induced contraction and are mean ± SEM from 6 
different experiments.   
 
 
Figure 4.20. Relaxation responses to antimycin A (10 µM) in the absence 
or presence of ebselen (10 µM), Data are expressed as a percentage 
relaxation of the KCl-induced contraction and are mean ± SEM from 6 
different experiments. * indicates P<0.05. 
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Figure 4.21. Relaxation responses to antimycin A (10 µM) in the absence 
or presence of DETCA (10 mM), Data are expressed as a percentage 
relaxation of the U46619-induced contraction and are mean ± SEM from 7 
different experiments. * indicates P<0.05, ** indicates P<0.01. 
 
4.3.11. Effect of antimycin A on Calcium-Induced contractions  
 
In chapter 3, it was demonstrated that simvastatin inhibits calcium-
induced contractions. Therefore, as a comparison, the effect of antimycin A 
on Ca2+ influx was also determined. Re-addition of calcium in the presence 
of 60 mM KCl produced a concentration-dependent contraction in the 
porcine coronary artery. Pre-incubation with antimycin (10 µM) produced a 
concentration-dependent inhibition of the contractile response (figure 
4.22). Similarly, the complex III inhibitor myxothiazol (10 µM) produced 
significant inhibition of the contraction (figure 4.23). On the other hand, 
complex I inhibitor (rotenone, 10 µM) had no effect on the calcium-induced 
contraction (figure 4.22). ATP synthase inhibitor (oligomycin, 10 µM) and 
the respiratory uncoupler (FCCP, 1 µM) also inhibited the calcium-induced 
contraction (figure 4.22 & 4.23).  
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Figure 4.22. Effect complex I inhibitor rotenone (10 µM), complex III 
inhibitors antimycin A (10 µM) and ATPase inhibitor oligomycin (10 µM) on 
calcium-induced contractions in the porcine coronary artery.* indicates 
P<0.05 and *** indicates P<0.001. 
 
 
Figure 4.23. Effect complex III inhibitor myxothiazol (10 µM), and FCCP 
(1 µM) on calcium-induced contractions. Data are expressed as a 
percentage of the contraction to 60 mM KCl in the presence of calcium. 
*** indicates P<0.001. 
 
4.3.12. Effect of antimycin A on calcium influx in freshly isolated smooth 
muscle cells. 
 
Freshly isolated smooth muscle cells produced an increase in intracellular 
calcium in response to 50 mM KCl. In the presence of 10 µM antimycin A, 
this response was significantly reduced (figure 4.24).  
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Figure 4.24. Bar chart of mean data ± SEM from DMSO and from 111 
(antimycin A) cells showing the changes in fluo-4 fluorescence in response 
to 50 mM KCl in the presence of 0.1 % v/v DMSO or 10 µM antimycin A. 
**** indicates p<0.0001 v DMSO, 2-tailed, unpaired t-test.  
 
4.3.13. Effect of antimycin A on AMPK activation in porcine coronary artery 
 
As shown in figure (4.25-A). A representative blot of western 
immunoblotting experiment assessing the effect of antimycin A incubation 
on AMPK activation in isolated PCA rings incubated in tissue baths for 2 h 
in the presence or absence of antimycin. In PCA incubated with antimycin 
A for 2 h, the level of phospho-AMPK to total AMPK was significantly 
increased in comparison with PCA incubated with DMSO as a solvent 
control using 2-WDLOHGXQSDLUHG6WXGHQW¶VW-test (figure 4.25-B).  
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A- 
 
B- 
 
Figure 4.25. A- Representative blot of western immunoblotting 
experiments assessing the effect of antimycin A on AMPK activation in PCA. 
Prior to freezing and homogenisation, PCA rings were incubated in tissue 
baths for 2 h in the absence or presence of antimycin B- Bar chart shows 
the ratio of phospho-AMP kinase to total AMP kinase from antimycin A and 
DMSO treated segments of 5 different tissues. Data are presented as mean 
± SEM, 2-tailed, * indicates p<0.05 XQSDLUHG6WXGHQW¶VW-test.     
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4.4. Discussion  
 
The data presented in chapters 2 & 3 demonstrate that simvastatin 
produces a relaxation of the porcine coronary artery, which is thought to 
be due, a least in part, to inhibition of the mitochondria, probably at 
complex III. The present study demonstrates that antimycin A, a complex 
IIIQi inhibitor, evokes a similar time-dependent relaxation of the isolated 
porcine coronary artery. Myxothiazol, a complex IIIQo inhibitor, also 
produced a relaxation of the porcine coronary artery; however, the 
response was smaller and slower to develop. On the other hand, inhibition 
of complex I with rotenone or complex II with 3-NP had no effect on 
coronary artery tone. These data suggest that mitochondria play a role in 
the regulation of vascular tone through complex III. The relaxation 
responses seen with antimycin A and myxothiazol are not due to general 
inhibition of mitochondrial function as inhibition of mitochondrial complexes 
I and II had no effect on tone. Moreover, uncoupling the mitochondria with 
a high concentration of FCCP (1 µM) did not induce coronary relaxation. 
The current study also provided evidence that the relaxation response to 
antimycin A was inhibited by AMPK inhibition. By contrast the relaxation 
was independent of K+ channel, Na+/K+ ATPase pump, nitric oxide or 
cyclooxygenase activation.   
In most cells, the mitochondrial electron transfer chain is one of the major 
sources of ROS (Turrens, 2003). While complex I can deposit O2
¯ into the  
mitochondrial matrix to be dissipated by the mitochondrial antioxidant 
defence (Chen et al., 2003), complex III (site IIIQo) can release O2
¯ to the 
cytosol where it is converted to hydrogen peroxide by superoxide 
dismutase 1 (Cai, 2005, Hool, 2006, Hawkins et al., 2007). Cytosolic 
hydrogen peroxide is believed to be the primary form of ROS signalling in 
the cell (Liu et al., 2003). Antimycin A is known to increase complex III O2
¯ 
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generation. It prolongs the lifetime of ubisemiquinone at the Qo site with a 
resultant increase in O2
¯ release (Mukhopadhyay et al., 2007, Wolin, 
2009). This may explain why inhibition of complex III, but not complex I or 
II, results in relaxation of the coronary artery. This is supported by the 
evidence that ebselen, a glutathione peroxidase mimic (Liu and Gutterman, 
2009) significantly inhibits antimycin A-induced coronary relaxation. 
Moreover, DETCA, a superoxide dismutase inhibitor, inhibited the 
antimycin A relaxation suggesting that H2O2 formation is important for the 
antimycin A-induced coronary relaxation. 
Uncoupling the mitochondria with FCCP (1 µM) did not produce a relaxation 
in the porcine coronary artery, but inhibited the relaxation to antimycin A. 
Furthermore, incubation with rotenone (10 µM) abolishes antimycin A-
induced relaxation. Both of these compounds might reduce the amount of 
ROS produced by complex III inhibition, and provide evidence that 
mitochondrial ROS may underlie the relaxation effects seen with antimycin 
A (Chen et al., 2003, Liu et al., 2003, Hsieh et al., 2001). 
The U46619-induced contraction is associated with Ca2+ release from the 
sarcoplasmic reticulum and Rho-kinase±mediated Ca2+ sensitization (Dorn 
and Becker, 1993). On the other hand, exposure to high KCl (60 mM) 
activates smooth muscle contraction by changing the K+ equilibrium 
potential and clamping the membrane potential above the resting level 
with subsequent Ca2+ channel activation. Studies have shown that IP3 
induced Ca2+ release becomes inoperative during mitochondrial 
depolarization. Therefore, antimycin A may inhibit U46199- induced Ca2+ 
release by mitochondrial depolarization (Collins et al., 2000, McCarron et 
al., 2012). The data presented also suggest that antimycin A inhibits Ca2+ 
influx as it inhibited the contraction to increasing concentrations of 
calcium, in the presence of KCl. This was confirmed in freshly isolated 
coronary artery smooth muscle cells in which the KCl-induced increase in 
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intracellular calcium was inhibited by antimycin A. Similar effects on Ca2+ 
influx have been seen in vascular and intestinal smooth muscle (Nakagawa 
et al., 1985) and rat tail artery (Sward et al., 2002). Rotenone produced 
complete inhibition of the relaxation to antimycin A after pre-contraction 
with KCl (figure 4.16). The latter suggested that complex I Inhibition with 
rotenone prevents the effect of antimycin A on calcium influx. However, 
rotenone has no effect on the Ca2+ depletion induced by antimycin A, 
therefore the inhibitory effect on the U46199-precontracted vessels is less 
pronounced (figure 4.15). Previously, rotenone has been shown to inhibit 
dilation in human coronary vessels by suppression of O2
¯ and H2O2 
formation (Liu et al., 2003). This ties-in with the data showing that ebselen 
and DETCA inhibit the antimycin A-induced relaxation and supports the 
notion that antimycin A increases ROS formation, leading to coronary 
relaxation. Previous results have shown that H2O2 inhibits Ca
2+ entry and 
the force of contraction of the porcine coronary arteries via SOC inhibition 
(Pande et al., 2012); similarly, superoxide inhibits voltage-dependent Ca2+ 
channels of artery myocytes (Fusi et al., 2001). Some of antimycin A 
effects on calcium influx could be due to activation of plasma membrane 
K+ channels; opening of these channels would lead to hyperpolarization of 
the membrane with closure of the voltage gated calcium channels. 
However, as mentioned above, inhibition of K+ channels with 
glibenclamide, TEA and 4-aminopyridine, had no effect on the antimycin A-
induced relaxation in the porcine coronary artery, indicating that this is 
unlikely to be the mechanism of action.  Collectively, the effects of 
antimycin A suggest a role for mitochondria in regulating L-type Ca2+ 
channel activity (Kubota et al., 2003).  
A study by Janssen et al. has suggested that free radicals can activate the 
Na+-K+ pump, hyperpolarize the cell membrane and relax tracheal smooth 
muscle (Janssen et al., 2000). On the other hand, oxygen radicals can 
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damage Na+-pumps in coronary arteries (Elmoselhi et al., 1994). Our data 
showed that incubation with ouabain, the Na+/K+ ATPase inhibitor, partially 
reduced antimycin A-induced coronary segments relaxation (figure 4.17). 
However, the results of the rubidium-uptake experiments showed that 
Na+/K+ ATPase pump activity was not altered by antimycin A (figure 4.18). 
Therefore, ouabain might act non-specifically to inhibit antimycin A 
coronary relaxation. Previous studies have shown that inhibition of the 
sodium pump results in cell membrane depolarization (Aalkjaer and 
Mulvany, 1985) with a concomitant increase in calcium influx into vascular 
smooth muscle cells (Pulina et al., 2010). The latter may have opposing 
effect to the relaxation induced by antimycin A.  
Mitochondrial ROS have been shown to activate AMP kinase (Quintero et 
al., 2006, Mackenzie et al., 2013). Pre- incubation with dorsomorphin, an 
AMP kinase inhibitor, reduced the antimycin A relaxation, suggesting that 
the antimycin A-induced vasodilation is mediated in part by activation of 
AMP kinase. Activation of AMP kinase inhibits agonist-induced contractions 
of the mouse aorta, which is independent of NO and cyclo-oxygenase 
inhibition. Such relaxation induced by AMPK activation, like antimycin A, 
was reduced in the presence of high K+ (Davis et al., 2012). AMP kinase is 
thought to have a direct action on the smooth muscle via phosphorylation 
and inactivation of smooth muscle myosin light chain kinase and thus 
induce relaxation (Horman et al., 2008). Therefore, it is plausible that 
mitochondrial ROS generation by antimycin A could lead to AMP kinase 
activation with subsequent coronary vascular relaxation. Western blotting 
experiments have shown that acute incubation 2 h of isolated porcine 
coronary arteries with antimycin A 10 ǋM increased AMPK activation as 
compared to control segments.  These findings support the contention that 
AMPK activation in vascular smooth muscle imparts a brake on contraction. 
Previous results have shown that metformin increases mitochondria-
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derived reactive nitrogen species to activate AMPK in vivo (Zou et al., 
2004). It also inhibited phenylephrine-induced contraction in aortic rings 
due to AMPK activation (Sung and Choi, 2012a). Similarly, acetylcholine 
inhibited phenylephrine-mediated contraction in endothelium-denuded rat 
aorta via AMPK-dependent mechanism (Lee and Choi, 2013). On the other 
hand, metabolic challenge could also activate AMPK (Rubin et al., 2005). 
Thus, further studies are recommended for ROS estimation and ATP level 
measurement in order to determine the exact mechanism of antimycin A-
induced AMPK activation. Data from the present study demonstrate that 
AMPK is activated over the time course of antimycin A relaxation; however, 
additional studies are necessary to determine the role of AMPK in coronary 
smooth muscle relaxation.  
Additional findings of the current study is that FCCP (100 nM) and 
oligomycin (10 µM) induced coronary relaxation while FCCP (1 µM) has no 
significant effect on the coronary tone. A previous study has shown that 
FCCP (1 µM) increases Ca2+ by activating Ca2+ influx (Restini et al., 2006). 
However, FCCP is also capable of mobilizing Ca2+ from the intracellular 
Ca2+ pools. The prevention of Ca2+ uptake into the mitochondria, driven by 
the mitochondrial proton gradient, may contribute to the FCCP induced 
Ca2+ increase (Park et al., 2002). Similarly, the present study clearly 
shows that FCCP (1 µM) induced a transient increase in the contraction. 
This initial increase in contraction can be explained by Ca2+ release from 
the intracellular store as well as by activating Ca2+ influx since the 
contractile response is markedly reduced in Ca2+ free Krebs (figure 4.26). 
Increasing calcium influx could explain the mechanism by which FCCP 
inhibited the antimycin A relaxation. An interesting observation of the 
present study is that FCCP at a low concentration, 100 nM, induced 
coronary relaxation (figure 4.6). Previous studies have shown that 
mitochondrial uncoupling with low-dose FCCP improves post-ischaemic 
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functional recovery via a ROS-dependent pathway that is not mediated via 
cellular ATP depletion (Brennan et al., 2006). Therefore at low 
concentrations, FCCP may produce a relaxation through a ROS-dependent 
mechanism. However, at higher concentrations, transient increases in 
calcium leads to vascular contraction (Nicholls, 2005).   
The effect of antimycin A on the coronary artery tone could be a toxic 
effect. However, the fact that the relaxation can be inhibited by further 
inhibition of the mitochondria (i.e. rotenone and FCCP) and by inhibition of 
AMP kinase would rule out a toxic effect. Furthermore, the response of the 
antimycin A-treated segments to U46619 and KCl depolarization was 
comparable to the control segments (figure 4.27). It is also possible that 
inhibition of mitochondrial complexes causes a reduction in ATP (Nakagawa 
et al., 1985). However, again, the fact that the relaxation can be inhibited 
by further inhibition of the mitochondria, would suggest that this is not the 
mechanism.  In conclusion, the data presented in this chapter indicate that 
alteration of mitochondrial function at complex III with antimycin A inhibits 
Ca2+ influx and causes relaxation of porcine coronary artery.  
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A) 
 
B) 
 
 
Figure 4.26. Effect of FCCP (1 µM), mitochondrial uncoupler, on 
basal porcine coronary artery tone. A- in normal Krebs B- in Ca2+ free 
Krebs, the contractile response is markedly reduced in Ca2+ free Krebs.  
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1- 
 
2- 
   
3- 
 
4- 
 
Figure 4.27. Effect of antimycin A (10 µM) incubation on porcine coronary 
artery tone. 1&2- vessels contracted with KCl 60 mM 3&4- vessels 
contracted with U46619.  
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CHAPTER V: Effect of statins on mitochondrial membrane 
potential and KATP Ⱦ-
cells.  
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5.1 Introduction 
 
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, 
collectively referred to as statins, are key drugs to lower plasma 
cholesterol levels in the treatment of hypercholesterolaemia (Pedersen et 
al., 2004, Kostis et al., 2012). Patients with type 2 diabetes may also be 
candidates for statin therapy regardless of cholesterol levels (Betteridge, 
2005, Rocco, 2012). However, in recent years, a number of intriguing and 
still unresolved questions have arisen as to whether the use of statins is 
associated with an increased risk of glucose intolerance and diabetes 
mellitus (Macedo et al., 2014). In fact, evidence from a number of clinical 
and experimental trials have highlighted an association between treatment 
with lipophilic statins and increased risk of glucose intolerance and 
diabetes (Sattar et al., 2010, Bellia et al., 2012, Jukema et al., 2012, 
Wang et al., 2012, Carter et al., 2013, Yoon and Lee, 2013, Bang and 
Okin, 2014).     
A randomized double-blind placebo-controlled study investigating the use 
of rosuvastatin in the primary prevention of cardiovascular diseases 
revealed a link with accelerated diabetes in statin users (Ridker et al., 
2008). A large study on 345,417 subjects over a two-year time period 
demonstrated that fasting plasma glucose (FPG) increased with statin use 
from 102 mg/dL to 141 mg/dL, by contrast FPG increased from 100 mg/dL 
to 129 mg/dL among non-statin users (Sukhija et al., 2009). In a further 
meta-analysis, there was a small (2,082) but significant increase in the 
incidence of diabetes among 57,593 patients on statins during 3.9 years 
(Rajpathak et al., 2009). In fact, in 2012, the Food and Drug 
Administration (FDA) issued a safety communication that statins can 
increase fasting plasma glucose concentrations (2012). In 2003, A 
population based study by Carter et al suggested that there is increased 
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incidence of diabetes, between 10-22%, with the lipophillic compounds 
atorvastatin, rosuvastatin, and simvastatin in comparison with the 
hydrophilic pravastatin (Carter et al., 2013). Similarly, clinical studies in 
patients with type 2 diabetes have demonstrated that simvastatin 
administration raises fasting glucose from 7.66 ± 0.55  mmol/l to 8.32 ± 
0.28 mmol/l after six months DORQJ ZLWK GHWHULRUDWLRQ RI ǃ-cell function 
(Bellia et al., 2012). By contrast, pravastatin, a hydrophilic statin, is 
reported to have no adverse influence on glycaemic control in type II 
diabetes patients (Freeman et al., 2001, Guclu et al., 2004). Therefore, 
despite causing comparable improvements in plasma cholesterol levels, 
different statins have differential risks in development of diabetes (Koh et 
al., 2009, Koh et al., 2011, Koh et al., 2013). The risk of new-onset 
diabetes is associated with intensive-dose (80 mg) daily versus moderate-
dose (20 mg) simvastatin daily (Preiss et al., 2011, Rajpathak, 2012, 
Rocco, 2012). Moreover, this risk was more evident in postmenopausal 
women (Culver et al., 2012, Chen et al., 2013, Ma et al., 2013) and elderly 
patients (Sattar et al., 2010, Ma et al., 2012).   
The diabetogenic effect of simvastatin and rosuvastatin is likely to be 
mediated by a deterioration of insulin secretion (Bellia et al., 2012). An in-
vitro study by Zhou et al (2014) in the ǃ-cells, MIN6, showed that after 48 
h of treatment, simvastatin significantly inhibited glucose-stimulated 
insulin synthesis and secretion (Zhou et al., 2014). Similarly lovastatin 
inhibited MIN6 insulin secretion and content after 24 h incubation 
(Tsuchiya et al., 2010).  
Glucose entry across the ǃ-cell plasma membrane initiates the cascade of 
metabolism±secretion coupling (Figure 5.1). Glucose is phosphorylated by 
glucokinase initiating glycolysis and pyruvate production. Then, 
mitochondrial metabolism generates ATP, increased ATP concentration 
promotes the closure of ATP-sensitive K+ channels (McTaggart et al., 2010) 
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which leads to plasma membrane depolarization. The latter results in Ca2+ 
influx through voltage-gated Ca2+ channels with subsequent triggering of 
insulin exocytosis (Wollheim, 2000, Mears, 2004).  
 
 
 
Figure 5.1. coupling of glucose metabolism to insulin secretion in 
ǃ-cell and the role of KATP channels. Glucose enters the cell via the 
glucose transporter, GLUT. Glycolytic and mitochondrial metabolism of the 
sugar leads to an increase in ATP. This results in KATP channel closure, 
membrane depolarization, opening of voltage-gated Ca2+ channels, Ca2+ 
influx, and exocytosis of insulin granules.  
  
The effects of statins on blood glucose levels in humans suggest that these 
FRPSRXQGV PD\ DOWHU SDQFUHDWLF ǃ-cell function. Simvastatin, but not 
pravastatin, can inhibit calcium signalling-dependent insulin secretion by 
the blockade of L-type Ca2+ FKDQQHOVLQUDWLVOHWǃ-cells (Yada et al., 1999). 
Alternatively, the synthesis of ubiquinone, a central factor involved in the 
mitochondrial production of ATP, has been shown to be suppressed by 
statins with subsequent reduction in insulin secretion (Mabuchi et al., 
2005, Sampson et al., 2011, Larsen et al., 2013). Statins also decreased 
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the expression of glucose transporters (GLUTs) (Nakata et al., 2006), they 
affect the structure and function of GLUTs by reducing plasma cholesterol 
content with subsequent decrease in glucose uptake in adipocytes, skeletal 
myocytes, and hepatic cells (Takaguri et al., 2008, Nowis et al., 2014).  
On the other hand, MIN6 incubation with simvastatin or atorvastatin for 
24-48 h resulted in an unexpected dose-dependent increase in basal 
insulin secretion at low glucose concentration (Ishikawa et al., 2006). 
Similarly, in-vivo randomized, single-blinded, placebo-controlled study 
showed that simvastatin, but not pravastatin, administration for two 
months significantly increased plasma insulin levels (Koh et al., 2009).   
KATP ion channel activity and mitochondrial metabolism are crucial for the 
coupling of glucose recognition to the exocytosis of insulin granules 
(Rustenbeck et al., 1997, Ashcroft et al., 1984, Wollheim, 2000), thus KATP 
channels as well as mitochondria have to be considered as a potential off-
target for statins.     
The modulation of KATP ion channel activity by statins has been observed in 
different tissues. Simvastatin, but not pravastatin has been reported to 
inhibit KATP channel -induced relaxation of the porcine coronary arteries 
(Uhiara et al., 2012). This is consistent with recent data demonstrating 
that simvastatin inhibits KATP channel in porcine coronary artery myocytes 
(Seto et al., 2013). On the other hand, cerivastatin, but not pravastatin, is 
thought to induce relaxation of rat aortic rings through activation of KATP 
channels (Sonmez Uydes-Dogan et al., 2005). Such effects suggest that 
statins have differential effects on KATP channels of different cells.    
On the other hand, other studies have demonstrated that lipophilic statins 
can alter mitochondrial function. In skeletal muscle fibres, simvastatin 
alters the mitochondrial respiratory chain leading to mitochondrial 
membrane potential depolarization (Sirvent et al., 2005b, Sirvent et al., 
2012). Simvastatin has also been shown to cause a concentration-
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dependent mitochondrial membrane potential depolarization in rat 
hepatocytes (Abdoli et al., 2013, Tolosa et al., 2014). The importance of 
mitochondrial metabolism for ǃ-cell function is well established and 
oxidative mitochondrial metabolism is central to glucose stimulated insulin 
secretion (Lowell and Shulman, 2005, Maechler et al., 2010, Wiederkehr 
and Wollheim, 2012). Therefore, another potential way in which statins 
FRXOGDOWHUǃ-cell function is through effects on the mitochondria. 
 
The aim of this present work was to identify the effects of statins on 
PLWRFKRQGULDO PHPEUDQH SRWHQWLDO ƩǓm) and to determine whether the 
statin drugs, simvastatin and pravastatin, functionally interact with KATP ion 
channel activity LQ ǃ-cells, and thereby contribute to the observed side-
effects of these drugs.  
5.2. Materials and Methods 
5.2.1. Solutions: 
 
For the measurement of KATP currents and ƩǓm the extracellular (bath) 
solution contained (in mM): 138 NaCl, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, 1.2 
NaH2PO4, 4.2 NaHCO3 10 HEPES (pH 7.4 with NaOH). For patch clamp, the 
pipette solution contained (in mM): 140 KCl, NaHCO3 4.2, MgCl2 1.1, 
HEPES 10 (pH 7.4 with NaOH). For inside-out experiments, the intracellular 
face of the membrane was bathed in a solution which contained (in mM): 
KCl 140, CaCl2 4.6, EDTA 10, K-HEPES 10 (pH 7.2; free [Mg
2+] <6 nM; 
free [Ca2+] < 30 nM). This solution does not support protein 
phosphorylation since it does not contain Mg2+ or ATP, it also reduces 
rundown of KATP-channels activity in excised patches (Ashcroft and Kakei, 
1989, Smith et al., 1994). Simvastatin was dissolved in either DMSO or 
ETOH. carbonyl-cyanide-p-trifluoro- methoxy-phenylhydrazone (FCCP) was 
dissolved in DMSO, final concentration of the solvents kept less than 
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<0.1%. Pravastatin was dissolved in distilled water. Mitosox (Invitrogen) 
was dissolved in DMSO. All other drugs were obtained from Sigma. 
5.2.2. Preparation of the Ⱦ -cell  
 
ǃ-cells were isolated from mouse islets of Langerhans. The latter were 
acutely dissociated from pancreatic islets isolated from the pancreata of 
30-35g CD1 mice as previously described (Daunt et al., 2006). For 
fluorescence PHDVXUHPHQWV ǃ-cells were plated onto 22 mm glass 
coverslips. For electrophysiology, cells were plated onto 35 mm plastic 
Petri dishes (Nunc). Cells were maintained and grown in RPMI-1640 media 
supplemented with 11 mM glucose, 10 % FCS, 25 mM HEPES and were 
kept at 37°C in humidified air/5% CO2. For all patching experiments, cells 
were preincubated prior to use in a sugar free Hanks solution at 37°C for 
20-30 minutes, unless stated otherwise. Experiments were performed in a 
HEPES-buffered Hanks solution which contained (in mM):138 NaCl, 4.2 
NaHCO3, 1.2 NaH2PO4, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, 10 HEPES (pH 7.4 
with NaOH).  
5.3. Method 
 
5.3.1. Patch clamp recording    
 
Patch pipettes were made from borosilicate glass capillaries (GC150TF-15; 
Harvard, UK). The pipettes were pulled using 2-stage vertical puller 
(Narishige PP83, Japan). The diameter of the pipette tip was assessed 
using the bubble number method. Those with bubble numbers of 7 were 
used for patch clamp. The pipettes were coated with Sylgard (Dow Corning 
Corp) below the pipette tips in order to reduce electrical noise and the 
pipette tips were fire-polished prior to use. Typically, the pipette 
resistances were EHWZHHQDQG0ƻThe pipettes were then filled with 
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high K+ solution using a microsyringe, with care taken to remove bubbles 
from the tip.  
7KHǃ-FHOOVZHUHZDVKHGZLWK+DQN¶VVROXWLRQSULRUWRSDWFKLQJOnly cells 
that appeared to be round and morphologically distinct were patched. 
Recordings were made, cell-attached or inside-out configuration, using an 
Axopatch patch clamp amplifier (Molecular Devices Inc., Sunnyvale, CA, 
USA). Single-channel currents were filtered at 2 kHz prior to digitisation at 
10 kHz using Clampfit 10.3 (Molecular Devices Inc., Sunnyvale, CA, USA). 
Axopatch-1D patch clamp amplifier (Axon instruments). All experiments 
were carried out at a room temperature, 21-23 ºC.  
In the cell-attached mode, single channel currents were recorded at pipette 
potential of 0 mV i.e. at the resting membrane potential. In the excised 
inside-out mode, single- channels recordings were made with pipette 
voltage of +60 mV. 
NPo (open probability) was used as a measure of channel activity. All NPo 
values were calculated from three minutes of single-channel recording. 
Data from each patch membrane served as the control i.e. NPo after seal 
and HANKS perifusion as a basal record, was compared with NPo after 3 
minutes and 10 minutes post drug treatment.  
5.3.2. The use of rhodamine 123 for detection of mitochondria polarization.  
  
Mitochondria are involved in a large variety of cellular functions (Duchen, 
1999). A characteristic feature of mitochondria is the generation of a large 
transmembrane potential mediated by the H+ transport through activity of 
the respiratory chain. Modulation of the mitochondrial potential has been 
implicated in many different pathological situations (Duchen, 2004, Lu et 
al., 2010). Therefore, the determination of the mitochondrial potential is 
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important for the understanding of cellular functions. In the current study, 
ǃ-cells isolated from mice were plated on glass coverslips. Cells were then 
ORDGHGZLWKǋJPO±1 Rh 123 at 37°C for 10 min in Hanks solution (5 mM 
glucose). TKHUHZDVQRDSSDUHQWF\WRWR[LFLW\LQFHOOVWUHDWHGDWǋJPO±1 
(Johnson et al., 1980). Moreover, results of a previous experiment in our 
laboratory by Dr Paul Smith concluded that 10 µM of Rh123 has no effect 
RQǃ-cell oxygen consumption. Rh123 is commonly used to follow changes 
in mitochondrial potential with time following acute cellular insults 
(Palmeira et al., 1996). It is well established that this lipophilic dye is 
predominantly localized to mitochondria (Johnson et al., 1980). The 
attraction of rhodamine 123 molecules by the relatively high negative 
electric potential across the mitochondrial membrane is the basis for the 
selective staining of isolated mitochondria as well as mitochondria in living 
cells (Scaduto and Grotyohann, 1999, Perry et al., 2011, Baracca et al., 
2003). Addition of glucose to the mitochondria leads to the generation of a 
potential with subsequent uptake of Rh123 (figure 5.14). On the other 
hand, agents known to depolarize or de-energize mitochondria results in 
the redistribution of the dye across the inner membrane, relieving quench, 
with associated increase in fluorescence (Johnson et al., 1981). Using this 
property, the effects of simvastatin or pravastatin SHULIXVLRQ RQ ǃ-cell 
mitochondrial potential was measured at 32 °C. Control cells were 
perfused with vehicle only (0.1% DMSO).     
Measurement of mitochondrial membrane potential  
The mitochondrial membrane potential, ǻƺP ZDV PRQLWRUHG ZLWK
Rhodamine-123 (Rh-123) as described previously (Daunt et al 2006). After 
loading with Rh123 (10 µg ml-1 IRUPLQXWHVDWÛ&LQP0JOXFRVH
cells were continuously illuminated at an excitation wavelength of 485±10 
nm at the lowest light intensity that gave a fluorescent signal. The emitted 
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light was long pass filtered at 515 nm and visualised with a Zeiss 
PlanNeofluar 40X/1.3 oil objective (Carl Zeiss Ltd, Welwyn Garden City, 
Herts, UK) heated to 32°C with an Bioptechs objective heater (Intracel 
LTD, Royston, Herts, UK). Images were captured at a frequency of 1Hz 
with a Photonics ISIS CCD camera, DT3155 frame grabber (Data 
translation, UK) and Imaging workbench software (IW5.2 INDEC 
BioSystems, Santa Clara, CA, USA). Images were analysed using equation 
below as shown in the (figure 5.2).  
(A-100)/ (B-100)*100 
Where A value represents the increase in fluorescence induced by 
simvastatin, & B value represents the maximum fluorescence induced by 
FCCP perifusion 
 
 
 
Figure 5.2. Representative fluorescence trace showing method of 
calculating the FL increase induced by statins. mitochondria are 
considered to be fully polarized =100. A value represents the increase in 
fluorescence induced by simvastatin, and B value represents the maximum 
fluorescence induced by FCCP perifusion. 
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5.3.3. Superoxide measurement using MitoSOX:  
 
MitoSOX is a red mitochondrial superoxide indicator with 
excitation/emission of approximately 510/580 nm. It is a highly selective 
dye for detection of superoxide in the mitochondria of live cell (Robinson et 
al., 2006). In the mitochondria, the dye is oxidized by superoxide. Then 
the oxidation product exhibits red fluorescence upon binding to the nucleic 
acids (Robinson et al., 2008). The dye was prepared from 5 mM stock 
solution. MIN6 cells were incubated with 5 µM MitoSOX in HANKS with 5 
mM glucose for 10 minutes at 37°C. The cells were then washed gently 
three times with HANKS followed by incubation with 1 µM simvastatin or 1 
µM antimycin A for two hours duration. Lastly, the cells imaged with DMRB 
Fluorescence microscope LeicaEM.  
5.4. Statistical analysis: 
 
Single channel kinetics and NPo were estimated using the half-amplitude 
threshold technique as implemented in clampfit. Channel kinetics from only 
single events were then exported into a bespoke program that fitted a 
conditional probability density function as described in (Smith et al., 1994) 
to determine the effect of the drug we used the open time of highest 
probability and the closed time which represents closure between events. 
Data were ascertained to be normally GLVWULEXWHG E\ WKH '¶$JRVWLQR-
Pearson omnibus Normality test. In this study statistical analysis was 
accomplished by SWXGHQW¶V unpaired t-test or 1-way ANOVA, statistical 
significance was attributed when P<0.05. The analysis was accomplished 
using Prism 6. Data are given as mean ± S.E.M and n is the number of 
experiments in cell attached, inside out recordings, or mitochondrial 
potential measurement. Each experiment came from a different petri dish.     
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5.5. Results:  
5.5.1. Patch clamp recordings 
5.5.1.1. Effect of glucose on KATP channel activity 
 
The aim of these experiments was to investigate the effects of simvastatin 
on KATP FKDQQHOVRISDQFUHDWLFǃ-cells. The cell-attached configuration was 
chosen fRU VXFK SXUSRVH VR WKDW WKH ǃ-cells retain an intact glucose 
metabolism (Ashcroft et al., 1984). As a point of reference, the NPo of KATP 
channels was calculated in zero glucose conditions followed by the NPo 
examination in 5 mM glucose. Significant inhibition of KATP channel activity 
by glucose addition was observed (figure 5.3). It is FRQFOXGHGWKDWWKHǃ-
cells used for the experiments were intact and responded to the glucose 
with increased ATP generation and subsequent KATP channel inhibition.  
 
Figure 5.3. Effect of glucose 5 mM on KATP channel activity in 
pancreatic ǃ-cells: changes of the NPo after the addition of 5 mM 
glucose. * indicates P<0.05, 6WXGHQW¶V XQSDLUHG t-test of 5 different 
patches. 
 
 
 
188 
 
5.5.1.2. Effect of statins on KATP channel activity  
 
In cell-attached patch clamp experiments, the channel opening probability 
of the cells treated with 10 µM simvastatin was calculated alike.  As shown 
in figure (5.4-A), simvastatin (10 µM) significantly reduced KATP channel 
activity by 71 ± 16% (n=6, p<0.05). Figure (5.4-B) illustrates the 
individual NPo values for the block of KATP channel activity. A maximal 
block was observed after perifusion of 10 µM simvastatin for 10 minutes in 
5 mM glucose conditions.  On the other hand, DMSO (0.1%) had no effect 
on NPo in the presence of 5mM glucose (Figure 5.4-C). 
    
B- 
    
A- 
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C- 
 
Figure 5.4. Effect of simvastatin on KATP channel activity in the 
presence of 5 mM glucose. A- changes of the NPo after the addition of 
10 µM simvastatin (statin) in 5 mM glucose B- changes of the NPo in the 
progress of the experiments, the addition of 5 mM glucose significantly 
decreased NPo, subsequent addition of 10 µM simvastatin caused a time 
dependent block in comparison to equivalent experiment for the vehicle 
control. After 10 min statin had almost abolished channel activity unlike 
the vehicle control. C- changes of the NPo after DMSO perifusion in 5 mM 
glucose. ** indicate P<0.01, 6WXGHQW¶V XQSDLUHG t-test of 6 different 
patches.  
 
5.5.1.3. Effect of simvastatin on KATP channel activity in the absence glucose: 
 
In the absence of glucose, 10 µM simvastatin significantly reduced KATP 
channel activity (Figure 5.5-A). Figure (5.5-B) is a representative KATP 
channel recording trace showing the effect of simvastatin perifusion on the 
KATP channel activity NPo.  
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A- 
 
B- 
 
Figure 5.5. Effect of 10 µM simvastatin on KATP channel activity 
(NPo) in the absence of glucose: A- KATP channel activity after 3 min 
and 10 min of 10 µM simvastatin (statin) perifusion dissolved in DMSO 
compared to the KATP channel basal activity (NPo) prior to addition of 
simvastatin from a cell-DWWDFKHGSDWFKRQLVRODWHGǃ-cells in a glucose-free 
HANKS solution, simvastatin caused block ~67 % block after 3 min 
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perifusion and by ~90 % block after 10 min perifusion. * P< 0.05, ** 
P<0.01, 1 way ANOVA with Dunnett's multiple comparisons of 11 different 
patches.  B- representative KATP channel recording trace showing the effect 
of simvastatin perifusion on the KATP channel activity NPo.   
 
Changes of the NPo ratio after 3 min and 10 min of 10 µM simvastatin 
(dissolved in ethanol) were also calculated (figure 5.6-A). Figure (5.6-B) is 
a representative KATP channel recording trace showing the effect of ethanol 
perifusion on the KATP channel activity NPo. 
A- 
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B- 
 
Figure 5.6. Effect of 10 µM simvastatin (statin) and its vehicle 
control (EtOH) on NPo ratio: A- effect of 10 µM simvastatin (statin) 
after 3 min and 10 min on KATP channel activity NPo normalized to basal 
channel activity in comparison with ethanol (EtOH) as a solvent control 3 
min and 10 min perifusion using cell attached patch from a cell-attached 
SDWFKRQǃ-cells isolated in a glucose-free HANKS. * P< 0.05, ** P<0.01, 1 
way ANOVA with Dunnett's multiple comparisons of 10 different patches. 
B- representative KATP channel recording trace showing the effect of (EtOH) 
perifusion on the KATP channel activity NPo.    
 
5.5.1.4. Effect of the solvent control on KATP channel activity 
 
In order to verify that results made with simvastatin were not due to the 
solvents used, the effects of DMSO and ethanol on KATP channels were 
evaluated separately. Neither of the two solvents affected NPo values 
(figure 5.7-A&B). In chapter II ethanol induced a transient contraction to 
the coronary vessels incubated with 300 µM L-NAME, thus DMSO was used 
as alternative solvent.  
 
193 
 
A- 
 
B- 
 
Figure 5.7. KATP channel activity (NPo) after 3 min and 10 min of A- DMSO 
& B- ethanol (EtOH) perifusion as a vehicle control compared to the KATP 
channel basal activity. 1 way ANOVA with Dunnett's multiple comparisons 
of 10 different patches for each. 
 
5.5.1.5. Effect of the pravastatin on KATP channel activity  
 
As part of the comparison, the effects of the hydrophilic statin, pravastatin, 
on the channel opening probability was also examined. As shown in (figure 
5.8-A) 10 µM pravastatin had no effect on the parameter tested. Figure 
(5.8-B) is a representative KATP channel recording trace showing the effect 
of pravastatin perifusion on the KATP channel activity NPo. 
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A- 
 
B- 
 
Figure 5.8. Effect of pravastatin on KATP channel activity with cell 
attached patch: A- Single channel current recorded from a cell-attached 
SDWFK RQ ǃ-cells after 10 min perifusion of 10 µM pravastatin in HANKS 
solution. Pipette potential was held at 0 mV throughout the experiment. 
6WXGHQW¶V unpaired t test of 7 different patches. B- representative KATP 
channel recording trace showing the effect of pravastatin perifusion on the 
KATP channel activity NPo.    
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5.5.1.6. Effect of simvastatin on KATP channel activity using inside-out 
configuration: 
 
Similar to the results obtained with cell attached patch, using inside-out 
configuration the addition of 10 µM simvastatin caused a significant 
reduction in KATP channel activity. The reduction in the NPo ratio with cell 
attached patch was 71.57% and with inside-out patch it was 73.86% 
(figure 5.9-A). Figure (5.9-B) is a representative KATP channel using inside-
out configuration showing the effect of simvastatin perifusion on the KATP 
channel activity NPo. 
A- 
 
 
 
 
 
 
 
196 
 
B- 
 
Figure 5.9. comparison of the effect of simvastatin (10 µM) on NPO 
in both cell attached and inside-out patch: A- effect of 10 µM 
simvastatin (statin) after 3 min on KATP channel activity NPo normalized to 
basal channel activity using cell attached patch in comparison with inside-
RXWSDWFKRQǃ-cells in a glucose-free HANKS. Pipette potential was held at 
0 mV with the cell attached patch and the Pipette potential was held at -60 
mV with inside-out experiments. * indicates P<0.05, 1 way ANOVA with 
Dunnett's multiple comparisons of 6 different patches. B- representative 
KATP channel using inside-out configuration showing the effect of 
simvastatin perifusion on the KATP channel activity NPo.    
 
5.5.1.7. Effects of simvastatin on KATP channel kinetics:  
 
To determine further the molecular nature of the interaction between 
simvastatin and the KATP channel, an analysis of single channel kinetics was 
performed. In this study simvastatin 10 µM significantly inhibited the single 
channel amplitude by 18.17 % of the basal amplitude after 3 min of 
treatment, additional inhibition of the channel amplitude was observed 
after 10 min of drug treatment 44.8 6% (figure 5.10).  
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Figure 5.10. Effect of 10 µM simvastatin on KATP channel amplitude 
with cell- attached patch: effect of 10 µM simvastatin (statin) after 3 
min and 10 min on KATP channel amplitude, data were normalized to basal 
channel amplitude (Amp ratio) using cell attached patch RQ ǃ-cells in a 
glucose-free HANKS. * indicates P<0.05, **** indicates P<0.0001. One 
way ANOVA by Tukey's multiple comparisons test of 9 different patches. 
 
A smaller but significant effect on the amplitude (14.55 %) was seen after 10 
min of simvastatin perifusion in an inside-out patch configuration (figure 
5.11). On the other hand, 10 µM simvastatin significantly increased the 
KATP channel opening time (figure 5.12). 
 
Figure 5.11. Effect of 10 µM simvastatin on KATP channel amplitude 
with inside-out patch: effect of 10 µM simvastatin (statin) after 10 min 
on KATP channel amplitude, data were normalized to basal channel 
amplitude (Amp ratio) using inside-out patch RQǃ-cells. Pipette potential 
was held at -60 mV throughout the experiment. * indicates P<0.05, 
6WXGHQW¶Vunpaired t-test of 6 different patches.  
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Figure 5.12. Effect of 10 µM simvastatin on KATP channel open time: 
effect of 10 µM simvastatin (statin) after 10 min on KATP channel open time 
(To), data were normalized to basal channel open time (To ratio) using 
cell-attached patch in a glucose-free HANKS. ** indicates P<0.01, 
6WXGHQW¶VXQSDLUHGt-test of 5 different patches.  
 
5.5.1.8. Effect of antimycin A and myxothiazol on KATP channel activity: 
 
In our study simvastatin is proposed to act as a mitochondrial complex III 
inhibitor, thus as part of the comparison, the effects of the standard 
complex III inhibitors, antimycin A DQG P\[RWKLD]RO RQ ǃ-cell NPo were 
examined. Results showed that myxothiazol inhibited the open probability 
of the KATP channel (figure 5.13), while antimycin A had no significant 
effect on the KATP channel activity. 
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Figure 5.13. Figure 4: Effect of 10 µM complex III inhibitor, 
myxothiazol, on KATP channel activity (NPo): KATP channel activity after 
10 min of 10 µM myxothiazol (myxo) perifusion dissolved in DMSO 
compared to the KATP channel basal activity (NPo) from a cell-attached 
SDWFKRQLVRODWHGǃ-cells. * indicates P<0.05, SWXGHQW¶VXQSDLUHGt-test of 9 
different patches.  
 
5.5.2. Effects of simvastatin on mitochondrial potential in B-cell: 
 
In the current study, the distribution and subsequent quenching of the 
fluorescent lipophilic cation Rh123 was used to monitor changes in 
mitochondrial potential (ƩǓm). In the presence of 5 mM glucose, FCCP, a 
proton ionophore, dissipated '\m and increases Rh123 fluorescence. On 
the other hand, FCCP had negligible effect on Rh123 fluorescence in the 
absence of glucose. This suggests that ǃ-cell mitochondrial potential is 
depolarized in the absence of glucose. Furthermore, the mitochondrial 
potential is restored as the glucose concentration is increased (figure 5.14 
DW VHFRQG 7KXV WKH HIIHFW RI VLPYDVWDWLQ RU SUDYDVWDWLQ RQ ǃ-cell 
mitochondrial potential was examined in 5 mM glucose (figure 5.15 & 5.16 
respectively). Simvastatin (10 µM & 3 µM) FDXVHGGHSRODUL]DWLRQRIƩǓm as 
evidenced by a 94% & 76% increase in Rh123 fluorescence respectively 
(figure 5.17 & 5.18). DMSO, as a solvent control, had no effect on 
mitochondrial potential (figure 5.14). By contrast, the water soluble statin 
(pravastatin, 10 µM) had no effect on mitochondrial potential (figure 5.16 
& 5.17).    
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Figure 5.14. Representative effect of DMSO on Rh 123 
fluorescence: 5KIOXRUHVFHQFHWUDFHVIRUSULPDU\ǃ-cells examined 
the effects of DMSO, applied at 200s, as a solvent control on the 
mitochondrial potential. DMSO clearly had no effect on the mitochondrial 
potential. At 1000s, suSHUIXVLRQ RI ǃ- cells with glucose-free HANKS for 
one minute, caused increase in the fluorescence signal due to 
mitochondrial depolarization. After few seconds superfusion of HANKS with 
glucose resulted in reversal of the basal Rh123 signal due to mitochondrial 
repolarization with subsequent RH123 quenching. At the end of the 
recording, at 1150s, FCCP 1 µM is added as positive control to get the 
maximum fluorescence.  
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Figure 5.15. Representative effect of simvastatin on Rh 123 
fluorescence: 7KHWUDFHIRUVLQJOHSDQFUHDWLFǃ-cells isolated from mice, 
examined the effects of 10 µM simvastatin on the mitochondrial potential. 
Simvastatin was applied for the duration of the bars, at 620s, FCCP 1 µM 
was perfused as positive control to get the maximum fluorescence.   
 
Figure 5.16. Representative effect of pravastatin on Rh 123 
fluorescence: 7KHWUDFHIRUVLQJOHSDQFUHDWLFǃ-cells isolated from mice, 
examined the effects of 10 µM pravastatin on the mitochondrial potential. 
Pravastatin was applied at the point indicated on the trace in the presence 
of 5 mM glucose. At 1150s, FCCP 1 µM was perfused as a positive control 
to get the maximum fluorescence.  
 
 
Figure 5.17. effect of simvastatin 10 µM on mitochondrial potential. 
Cumulative fluorescence data from pancreatic ǃ-cells loaded with Rh123 in 
the presence of simvastatin (10 µM), pravastatin (10 µM), or vehicle 
control (0.1% v/v DMSO). Data are expressed as a percentage of the 
response to 1 µM FCCP in the same cells and are mean ± SEM from n=7 
separate experiments. *** indicates p<0.001, one-way ANOVA, followed 
by Tukey's multiple comparisons test.  
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Figure 5.18. effect of simvastatin 3 µM on mitochondrial potential. 
Cumulative fluorescence data from pancreatic ǃ-cells loaded with Rh123 in 
the presence of 3 µM simvastatin or vehicle control (0.1% v/v DMSO). 
Data are expressed as a percentage of the response to 1 µM FCCP and are 
mean ± SEM from n=14 separate experiments 6WXGHQW¶VXQSDLUHG t-test. 
**** indicates p<0.0001. 
 
 
5.5.3. Effects of simvastatin on superoxide generation in MIN6: 
 
Mitochondria are the most important cellular source of ROS in ǃ-cells 
principally through complexes I and III of the respiratory chain (Chen et 
al., 2003, Muller et al., 2004). Results in the previous section have shown 
that simvastatin depolarizes the mitochondria in SDQFUHDWLFǃ-cells. Thus, 
the effects of simvastatin on superoxide generation were examined. MIN6 
cells were XVHG DV D PRGHO IRU SDQFUHDWLF ǃ-cells. Figure (5.19) are 
representative images showing the increase in superoxide production in 
the mitochondria of MIN6 in the presence of 10 µM simvastatin or 1 µM 
antimycin A. Quantitative data expressing changes in mean fluorescent 
intensity of basal MitoSOX fluorescence following 10 µM simvastatin 
exposure in comparison with 1 µM antimycin A is shown in (figure 5.20). 
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Figure 5.19. effect of simvastatin on superoxide production in 
MIN6: Representative images showing the increase in superoxide 
production in the mitochondria of MIN6 using Mitosox. A- basal 
fluorescence in the presence of vehicle (0.1% DMSO), B- in the presence 
of 10 µM simvastatin and C- in the presence of 1 µM antimycin A.  
 
  
Figure 5.20. Effect of simvastatin and antimycin on mitochondrial 
superoxide formation in ǃ-cells (MIN6): Quantitative data expressing 
changes in mean fluorescent intensity of basal MitoSOX fluorescence 
following 10 µM simvastatin (statin) exposure in comparison with 1 µM 
antimycin A measured by DMRB Fluorescence microscope LeicaEM. Data 
presented as average ± standard deviation of 124 cells from 4 different 
repeats. ****P < 0.0001, one-way ANOVA followed by Tukey's multiple 
comparisons test.  
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5.6. Discussion 
 
The statins, simvastatin and pravastatin are currently important drugs for 
the treatment of hyperlipidaemia. The effects of these drugs on the early 
steps of the insulin-VHFUHWRU\ SDWKZD\ LQ WKH SDQFUHDWLF ǃ-cells were 
examined in the present study. The rationale for this investigation was a 
recent meta-analysis of clinical data which highlighted an increased risk of 
type II diabetes mellitus in hyperlipidaemic patients when administered 
certain statins (Baker et al., 2010, Carter et al., 2013, Bang and Okin, 
2014, Macedo et al., 2014)3ULPDU\SDQFUHDWLFǃ-cells isolated from mice 
were used for this investigation. The KATP channel open probability (NPo), 
open time and amplitude were investigated using cell-attached and inside-
out patch configuration. The effects of simvastatin on single channel 
activity were analysed in the absence and the presence of 5 mM glucose.  
KATP channels were blocked by glucose, consistent with the previously 
documented effects of glucose on KATP channel kinetics i.e. decrease NPo 
and amplitude (Ashcroft et al., 1984). This is due to the concomitant 
increase in cell metabolism with subsequent raising of the ATP/ADP ratio 
which inhibits KATP channels. Subsequently, simvastatin or pravastatin were 
perifused at 10 µM concentrations. The experiments revealed that 
simvastatin, but not pravastatin, inhibits channel activity (NPo). Further 
analyses of the channel kinetics showed that simvastatin significantly 
reduced channel amplitude and increased the open time of KATP channels 
(To).    
,QRUGHUWRIXUWKHULQYHVWLJDWHWKHDFWLRQRIVLPYDVWDWLQRQǃ-cell function, 
RXU VWXG\ H[DPLQHG WKH HIIHFWV RI VLPYDVWDWLQ RQ ǃ-cell mitochondrial 
membrane potential as possible target of statins. Simvastatin has been 
previously shown to depolarize mitochondria in skeletal muscle (Sirvent et 
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al., 2005b, Sirvent et al., 2012), liver cells (see appendix) (Abdoli et al., 
2013, Tolosa et al., 2014) and smooth muscle (chapter II). The present 
study clearly shows that 10 µM simvastatin depolarizes the mitochondria 
membranHSRWHQWLDOLQǃ-cells within 10 min of perifusion. Similar results of 
mitochondrial depolarization were obtained with 3 µM simvastatin, however 
longer perifusion period, around 20 min, was usually required in order to 
depolarize the mitochondria at this concentration. The effect of 1 µM 
simvastatin on mitochondrial membrane potential was also tried. At this 
concentration the mitochondria depolarized after about 30 min of 
continuous simvastatin perifusion. However, because of the continuous 
bleaching of Rh123, the results failed to reach a significant effect. Thus, 
our study confirms that simvastatin at 3 µM & 10 µM depolarizes the 
PLWRFKRQGULD RI WKH ǃ-cell, which in turn may lower ATP concentration 
provided by the oxidative phosphorylation. However the exact mechanism 
of mitochondrial depolarization remains to be defined and further studies 
are recommended to shed light on this proposal.   
The studies with excised patches demonstrate that the effect of 
simvastatin on KATP channels is likely to be direct and independent of 
changes in the mitochondria or other intracellular signalling. Accordingly, it 
is clear that simvastatin acts on different targets in ǃ-cells which exert 
opposing effects, the first one is a direct inhibition of KATP channel, and the 
VHFRQGHIIHFWLVǃ-cell mitochondrial depolarization which gives the reason 
behind the increase in KATP channel opening time (figure 5.21). A previous 
study by Smith et al (1999) has shown that tolbutamide uncouples the ǃ-
cell mitochondria and has a blocking effect of KATP channel (Smith et al., 
1999). The Seto et al study (2013) illustrated that simvastatin acutely 
inhibits vascular KATP channel openings in coronary artery myocytes (Seto 
et al., 2013), which was thought to be mediated via AMPK activation (Seto 
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et al., 2013). The study by Zou et al demonstrated that respiratory chain 
inhibition generate mitochondrial O2¯ which then leads to AMPK activation 
(Zou et al., 2004). In fact, the AMPK activator, AICAR, inhibited KATP 
opening in mouse pancreatic islets ǃ-cells (Wang et al., 2005). However, it 
is implausible that KATP channel inhibition by simvastatin in SDQFUHDWLFǃ-
cells is mediated by AMPK phosphorylation since the inhibitory effect of 
simvastatin was observed in excised patches, i.e., in the absence of 
metabolic regulation. On the other hand, pravastatin, a hydrophilic statin 
had no effect on either measurement. The latter evidence suggests that 
VWDWLQ DFWLRQ RQ ǃ-cell function is related to the lipophilicity of these 
compounds (Joshi et al., 1999).      
The reduction in the amplitude suggests a direct block of KATP channels by 
simvastatin. Results suggest also that simvastatin acts by interaction with 
the SUR subunit of the KATP channels like e.g. tolbutamide which would 
decrease NPo. In cell-attached patches the amplitude reduction appears 
larger than inside-out patches. The latter suggests membrane potential 
changes with cell depolarization due to block of KATP channels by 
simvastatin. However, KATP channel opening time appear to be increased 
with simvastatin perifusion, although NPo decreased, this may be due to 
inhibition of mitochondrial metabolism and reduced ATP generation. 
The inhibition of KATP channels by simvastatin is likely to underlie the 
increase in insulin secretion observed by previous in-vitro study after 24 h 
incubation (Ishikawa et al., 2006) and in-vivo study after two months daily 
administration of 20 mg (Koh et al., 2009, Moutzouri et al., 2011). On the 
other hand, the block of KATP FKDQQHOVLVXQOLNHO\WRHOLFLWH[RF\WRVLV LQǃ-
cells in a situation of a decreased ATP supply induced by mitochondrial 
depolarization (Rustenbeck et al., 1997). The latter may explain the 
impaired glycaemic control and insulin secretion after 12 months of 20 mg 
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daily use (Bellia et al., 2012). In the pancreatic ǃ-cell, mitochondrial 
metabolism plays a pivotal role in the generation of signals coupling 
glucose recognition to insulin secretion (Maechler, 2003, Maechler et al., 
2010). Glucose equilibrates across the plasma membrane through specific 
transporters thereby initiating glycolysis, subsequently mitochondrial 
metabolism leads to an elevated intracellular [ATP]/[ADP] ratio which 
promotes the closure of ATP-sensitive K+ channels (Ashcroft et al., 1984, 
Koster et al., 2005, Remedi et al., 2006, McTaggart et al., 2010). Plasma 
membrane depolarisation promotes Ca2+ influx, which raises cytosolic Ca2+ 
and triggers insulin exocytosis (Eliasson et al., 2008). Besides the 
importance for ATP generation, mitochondria promote the generation of 
metabolite coupling factors, such as succinate, amplifying the action of 
Ca2+ signal for sustained insulin secretion (Leibowitz et al., 2005). 
Therefore, interfering with mitochondrial metabolism by blocking the 
respiratory chain abolishes glucose-stimulated insulin secretion 
(MacDonald and Fahien, 1990, Wollheim, 2000, Martin and McGee, 2014, 
Green et al., 2004).      
Inhibition of KATP FKDQQHOVE\ VLPYDVWDWLQ FDXVHVGHSRODUL]DWLRQRI WKHǃ-
cell membrane. In turn, this should trigger the opening of the voltage-
gated Ca2+ channels, eliciting Ca2+ influx, which should stimulate the 
exocytosis of insulin-containing secretory granules (Bokvist et al., 1995, 
Satin, 2000). Moreover, the elevation of cytosolic Ca2+ is also a 
prerequisite for sustained insulin secretion (Mears, 2004, Maechler et al., 
2006). Unfortunately, our study did not examine the effects of simvastatin 
on Ca2+ LQIOX[LQSDQFUHDWLFǃ-cells. However, a previous study by Yada et 
al, showed that lipophilic HMG-CoA reductase inhibitors inhibit glucose-
induced Ca2+ signalling and insulin secretion by blocking Ca2+ currents in 
rat ǃ-cells (Yada et al., 1999). Data have shown that mitochondria 
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maintain Ca2+ oscillations (Straub et al., 2000, Camello-Almaraz et al., 
2002, Camello-Almaraz et al., 2006b). Furthermore, mitochondria could 
act as a buffer of the localized increase in Ca2+ just beneath the plasma 
membrane (Theler et al., 1992, Toescu et al., 1993, Tinel et al., 1999, 
Rizzuto et al., 2012). Due to its localization in the vicinity of Ca2+ release 
or influx channels (Brini, 2003), the mitochondria have the ability to 
rapidly accumulate and then release large quantities of Ca2+ (Park et al., 
2001). A previous study by Li et al, in diabetic mice has demonstrated that 
defective mitochondrial function in pancreatic ǃ-cells is a key cause of 
abnormal insulin secretion by altering Ca
2+ 
influx (Li et al., 2012). 
Moreover, mitochondrial complex III block by antimycin A blocks the 
increase in Ca2+ induced by succinate. On the other hand rotenone, a 
mitochondrial complex I inhibitor, was without effect. Accordingly we may 
suppose that simvastatin by blocking mitochondrial respiratory chain 
downstream of complex II may lead to Ca2+ desensitization (Maechler et 
al., 1998). However, further studies are recommended to determine if this 
is the case. 
Simvastatin and ROS generation: 
Significant increase in superoxide production was observed in MIN6 cells 
after 2 h treatment with 10 µM simvastatin (figure 5.20). Similarly, 
simvastatin (5 µM, 1 h) incubation induced human liver carcinoma cell 
(HepG2) mitochondrial depolarisation with a significant increase in 
mitochondrial superoxide (Tolosa et al., 2014). The exact relationship 
between insulin secretion and reactive oxygen species generation in 
pancreatic ǃ cells is still debated (Sakai et al., 2003, Pi et al., 2007). 
Superoxide O2¯ ions are normally converted by superoxide dismutase to 
H2O2 that is then reduced to water by catalase or glutathione peroxidase. 
ROS may have different actions according to cellular concentrations being 
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either below or above a specific threshold, i.e. signalling or toxic effects. 
Accumulated evidence suggests that small fluctuations in the steady state 
concentration of ROS play an essential role in insulin secretion (Leloup et 
al., 2009). However, exposure to oxidative stress is sufficient to impair 
glucose stimulated insulin secretion in pancreatic islets (Maechler et al., 
1999, Sakai et al., 2003, Green et al., 2004, Li et al., 2009).  In fact, ǃ-
cells are characterized by relatively weak expression of free radical-
quenching enzymes SOD, CAT, and GPx (Grankvist et al., 1981, Lenzen et 
al., 1996). Thus, mitochondrial inner membrane components are at a high 
risk for oxidative injuries, resulting in depolarized mitochondrial membrane 
and impaired ATP production. Lastly, ROS alone cannot promote insulin 
release since glucose induced elevations in ATP are necessary for glucose-
stimulated insulin secretion (Kajikawa et al., 2002).   
 
In summary, although it is clear that statins have beneficial effects on 
cardiovascular disease prevention; our study suggests that long-term use 
of large doses of lipophilic simvastatin may have adverse effects on 
glucose metabolism and insulin secretion by acting on KATP channels and ǃ-
cell mitochondrial potential. Therefore, patient blood glucose levels should 
be monitored to reduce adverse events caused by simvastatin especially in 
elderly patients (Sattar et al., 2010, Ma et al., 2012) and those using 
intensive simvastatin dosing (Preiss et al., 2011, Rajpathak, 2012, Rocco, 
2012). Aging per se is associated with a continuous decrease, 1% per 
year, in basal insulin release beginning early in life (Iozzo et al., 1999, 
Chiu et al., 2000). Thus, high-dose simvastatin may be detrimental in the 
elderly, particularly with chronic treatment. Future research should focus 
not only on determining the incidence of new-onset diabetes with various 
statins, but also on clarifying the potential pharmacologic mechanism for 
such a relationship. 
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Figure 5.21. HIIHFWRIVLPYDVWDWLQRQSDQFUHDWLFǃ-cell: The sites of 
simvastatin action proposed by our study, as indicated by red arrow, are 
mitochondrial depolarization. Furthermore simvastatin blocks KATP 
channels. Our proposal includes also ROS generation as a result of 
mitochondrial inhibition, mitochondrial depolarization may inhibit Ca2+ 
influx (as indicated by ?). However, more studies are recommended to 
examine the effect of simvastatin on Ca2+ influx.  
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6. CHAPTER VI: DISCUSSION & CONCLUSION  
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6.1. GENERAL DISCUSSION  
6.1.1. Short term effect of Simvastatin in comparison with Lovastatin and 
Pravastatin:  
 
The benefits of long-term statin administration, i.e. lowering of serum 
cholesterol and treatment of hypercholesterolemia, are well established as 
the primary mechanism underlying therapeutic benefits in cardiovascular 
diseases (Bestehorn et al., 1997, Pedersen et al., 2004).  In recent years, 
however, clinical and basic science research associated with statins showed 
that statins might also exert early cholesterol independent effects by acting 
on multiple targets (Wassmann et al., 2003, Takagi et al., 2006, Iida et al., 
2007). These cholesterol independent effects were collectively known as 
pleiotropic effects (Bonetti et al., 2003). In fact, little has been addressed 
with regard to the matter of how statins affect the coronary circulation. 
Clinical studies have shown that patients with acute coronary syndrome 
may benefit from early statins use (Laufs et al., 2001, Stenestrand et al., 
2001, Spin and Vagelos, 2003, de Lemos et al., 2004); however, it was not 
investigated whether these positive results were related to the lipid 
lowering effects of statins and/or specifically caused by the relatively early 
pleiotropic effects of statins (Kirmizis and Chatzidimitriou, 2009, 
Antoniades et al., 2011). Thus, the attention is now turning to the more 
immediate therapeutic effects of statins in the management of acute 
vascular conditions, which in turn would favour an immediate beginning of 
statin therapy (Spin and Vagelos, 2003).      
In order to assess the vascular pleiotropic of statins our research was 
designed to study the very short-term effects of statins which appear over 
a range of 1-2 hours after in vitro incubation. The existence of non-lipid 
effects was further investigated by indirect evidence, such as studying 
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statins with different pharmacokinetics profile and/or treating animals, with 
different age and sex, obtained from local abattoir.  
Currently simvastatin, pravastatin and lovastatin are approved for 
treatment of hypercholesterolemia in humans (Armitage, 2007). Despite 
differences in their pharmacokinetic profiles (Joshi et al., 1999), all have 
the characteristic in common of inhibition of enzyme HMG-CoA reductase 
(Sirtori, 1990). Thus, in order to expand our knowledge concerning the 
effects of statins on vascular contractility, we investigated the effects of 
simvastatin and lovastatin, both available in the lactone prodrug form 
(Schachter, 2005b), on the contraction of isolated porcine coronary rings 
by U46619. The action of these inactive, lactone prodrugs was then 
compared with that of pravastatin, available as the hydroxylated active 
form. The ability of the lipophilic simvastatin to interfere with vascular tone 
in vitro at bath concentrations nearly similar to the maximal therapeutic 
concentrations (0·3±ǋPRO/PD\WKXVKDYHSRWHQWLDOFOLQLFDOVLJQLILFDQFH
(Lilja et al., 1998). The hydrophilic pravastatin, with a lipid-lowering effect 
similar to simvastatin, but without an in-vitro effect on coronary tone, 
provides a suitable control for this non-lipid related effect of simvastatin. 
Lovastatin, another example of a lipophilic statin, similarly depressed the 
U46619-induced contraction of the coronary rings. The link between 
lipophilicity and relaxation is supported by the lack of effect of pravastatin 
on the coronary tone (Gryglewski et al., 2001, Mukai et al., 2003, Bergdahl 
et al., 2003) (Lorkowska and Chlopicki, 2005).     
6.1.2. Simvastatin induced relaxation of the coronary vessels precontracted 
with U46619, ET-1 and KCl:    
 
There is significant evidence that TXA2 plays a role in the cardiovascular 
diseases such as sustained hypertension, cerebral vasospasm, unstable 
angina, acute myocardial infarction, heart failure, and various thrombotic 
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disorders (Tada et al., 1981, Houston et al., 1986, Mistry and Nasjletti, 
1988, Sellers and Stallone, 2008). Thus pharmacological modulation of 
TXA2 is of great clinical interest. Our results have clearly shown that 
incubation with simvastatin attenuated U-46619, a TXA2 mimetic, mediated 
vasoconstriction, independent of NO and PGI2 pathway inhibition. Previous 
data have shown that simvastatin possesses a significant component of 
vascular relaxation that is independent of endothelium NO (Alvarez De 
Sotomayor et al., 2000, Mraiche et al., 2005). Similarly, chronic statin 
treatment suppresses Rho-kinase-mediated rat aortic contraction via NO 
independent mechanism (Budzyn et al., 2004). However, others have 
shown that L-NAME incubation inhibits endothelium-dependent aortic 
relaxation induced by simvastatin (de Sotomayor et al., 2005). The reason 
could be related to different artery species (Christie et al., 1989).  
The involvement of ET-1 in the development of hypertension, coronary 
atherosclerosis and endothelial dysfunction has been suggested by 
previous studies (Lerman et al., 1995, Ikeda et al., 1997, Schiffrin, 2001, 
Cediel et al., 2002, Iglarz and Schiffrin, 2003). Moreover, endothelin 
antagonism prevents the development of endothelial dysfunction in 
experimental hypercholesterolemia and hypertensive humans (Hopfner and 
Gopalakrishnan, 1999, Schiffrin, 2001). This study has also demonstrated 
that simvastatin inhibits ET-1 mediated coronary vasoconstriction. Both 
ET-I and TXA2 induced contraction utilises extracellular Ca
2+ entry through 
the L-type Ca2+ channels in addition to Rho dependent Ca2+ sensitisation 
(Egashira et al., 1990, Tosun et al., 1998b, Nobe and Paul, 2001). 
Simvastatin, by inhibiting Ca2+ entry through the L-type Ca2+ channels, 
shown by our results, is likely to be the main mechanism of inhibition of 
the U-46619 and ET-1 contractions by simvastatin (Tesfamariam et al., 
1999, Kang et al., 2014).      
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On the other hand, the depolarization of vascular smooth muscle cells, 
regardless of the mechanism, would result in enhanced Ca2+ permeability 
which is a fundamental response of the vasculature to high blood pressure 
(Van de Voorde et al., 1992). Moreover, enhanced vascular depolarization 
is a stimulus for Ca2+ channel upregulation that may contribute to the 
development of abnormal vascular tone (Harder et al., 1985, Van de 
Voorde et al., 1992, Pesic et al., 2004). Simvastatin according to our study 
inhibits Ca2+ influx in the depolarized vascular smooth muscle cells and 
significantly relaxed the depolarized coronary vessels which in turn may 
explain the clinically meaningful effect of simvastatin on blood pressure 
(Strazzullo et al., 2007). 
Our data also demonstrated that simvastatin can attenuate 
vasoconstriction independently of endothelial function, which is clinically 
relevant given the prevalence of endothelial dysfunction amongst patients 
with vascular diseases (Yasue et al., 2008). Collectively, these lipid-
independent effects of simvastatin, which have been found in vitro using 
animal tissue, could easily explain the substantial cardiovascular benefits 
observed with simvastatin in clinical practice both in normo- and 
hypercholesterolemic individuals (Bonetti et al., 2003, Koh et al., 2008, 
Juncos et al., 2012).    
6.1.3. Clinical significance of mitochondria and KATP channel inhibition 
induced by simvastatin:  
  
The aggregate of our results and of other experimental trials in vascular 
smooth muscle and coronary segments support the notion that simvastatin 
induce coronary relaxation by a mechanism/s other than KATP activation 
furthermore, previous evidence suggests that simvastatin inhibits KATP 
channel activation (Seto et al., 2013). Indeed, KATP channel activation is an 
important mechanism in the hypotension characteristic of vasodilatory 
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shock e.g. in hypoxia, septic shock due to lipopolysaccharide 
administration, hemorrhagic shock, and cardiogenic shock. It is for this 
reason simvastatin may be expected to reduce vasodilatation and 
peripheral vascular resistance reduction in such cases (Landry and Oliver, 
1992, Landry and Oliver, 2001). However, the inhibition of KATP channel 
activation by simvastatin may interfHUH ZLWK ǃ-adrenoceptor agonist 
relaxation (Uhiara et al., 2009). Such issue requires more investigation to 
determine the clinical significance of simvastatin interaction ZLWK ǃ-
adrenoceptor agonist mediated relaxation in-vivo and other KATP channel 
openers.     
KATP channels may also be an effector of myocardial ischemic 
preconditioning, i.e. protection conferred by brief periods of ischaemia 
against infarction produced by a subsequent long ischaemia (Hanley and 
Daut, 2005, Zhao et al., 2006). This idea was reinforced by the findings 
that KATP channel openers like cromakalin, bimakalim, or pinacidil could 
also mimic myocardial protection (Critz et al., 1997). Several studies have 
suggested that simvastatin may exert cardioprotective effects in animal 
models via enhancement of endothelial NO release or KATP channel 
activation (Di Napoli et al., 2001, Zhao et al., 2006, Yang et al., 2007). In 
fact, during ischaemia, mitochondria generate cytotoxic reactive oxygen 
species that contribute to cardiomyocyte damage (Becker et al., 1999). 
Two different studies by Bacher et al, and Lesnefsky et al, have shown that 
inhibition of the mitochondrial electron transport chain with rotenone, 
complex I inhibitor, or myxothiazol, complex III inhibitor, lessens damage 
to mitochondria (Becker et al., 1999, Lesnefsky et al., 2004). Thus 
simvastatin cardioprotective effects may be mediated at least in part 
through mitochondrial inhibition. On the other hand, mitochondrial 
membrane potential has a critical role in Ca2+ accumulation. Thus, 
depolarization reduces the driving force for mitochondrial Ca2+ uptake and 
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thereby prevents mitochondrial Ca2+ overload as a mechanism of cellular 
protection induced by simvastatin (Brennan et al., 2006). Further studies 
are needed to determine the effect of simvastatin on KATP in myocardial 
ischaemic conditions and the role of ischaemic oxidant generation as vital 
treatment strategies for ischaemia and reperfusion.  
Mitochondrial complex I has a vital role in organic nitrate biotransformation 
(Sydow et al., 2004). Findings presented by Garcia-Bou et al. suggest that 
mitochondrial dysfunction results in the appearance of tolerance to nitrates 
(Garcia-Bou et al., 2012).  Thus our results regarding mitochondrial 
inhibition lead us to propose a possible interaction of simvastatin with 
Glyceryl trinitrate (GTN). Such a possibility needs more investigation, 
especially in patients receiving chronic treatment with GTN and in 
comparison with hydrophilic statins. The latter have protective effects 
against nitrate tolerance by counteracting NAD(P)H oxidase superoxide 
production (Otto et al., 2006). Similarly, simvastatin-induced vascular 
relaxation with subsequent blood pressure reduction in patients with 
hypertension may be induced as a downstream effect of mitochondrial 
depolarization. Previous studies have demonstrated that mitochondrial 
depolarisation causes cerebral artery vasodilatation via activation of nitric 
oxide synthase (Katakam et al., 2013, Katakam et al., 2014). This effect 
may account for a part of the beneficial effects of simvastatin in the 
prevention of cardiovascular disease (Jiang and Roman, 1997, Correa et 
al., 2014, Juncos et al., 2012). In comparison to simvastatin, the 
administration of pravastatin did not induce additional blood pressure 
lowering effect in hypertensive patients (Mancia et al., 2010), which is 
supported by the data presented here showing that pravastatin does not 
produce relaxation of the coronary artery. 
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6.1.4. Ⱦ-cells. 
 
It seems likely that the simvastatin effect on KATP channels is not selective 
for cardiovascular tissues. Our results clearly have shown that simvastatin 
inhibits pancreatic ǃ-cell KATP channels directly. ATP-sensitive K+ channels 
play a major role in controlling ǃ-cell membrane potential and thereby 
insulin release (Cook and Hales, 1984, Miki et al., 1999), such effect would 
explain the results of the increase in insulin secretion obtained by some in-
vivo and in-vitro experiments (Ishikawa et al., 2006, Koh et al., 2009).    
On the other hand, the present study clearly provides evidence for 
PLWRFKRQGULDO GHSRODUL]DWLRQ E\ VLPYDVWDWLQ LQ PLFH SDQFUHDWLF ǃ-cells. 
Mitochondrial capacity is central to the key function of the pancreatic ǃ-
cell-regulated insulin secretion (Wollheim, 2000). If these findings 
translate to humans, then this could explain the glucose intolerance 
induced by the lipophilic simvastatin (Szendroedi et al., 2012). In contrast, 
pravastatin had no effect on the mitochondrial potential. Therefore, the 
current results may explain the differential metabolic effects between 
simvastatin and pravastatin in hypercholesterolemic patients, which in turn 
may be clinically relevant in patients prone to metabolic diseases (Koh et 
al., 2009, Koh et al., 2013). Studies have shown that thiazide diuretics and 
ǃ EORFNHUV H[KLELW XQGHVLUDEOH JO\FDHPLF HIIHFWV WKXV simvastatin 
combination with such agents may be associated with an increased risk of 
incident diabetes especially in elderly patients (Betteridge, 2005) and 
those on prolonged intensive dose therapy (Preiss et al., 2011). The use of 
pravastatin or alternate-day dosing may be helpful with fewer side effects 
(Koh et al., 2009, Marcus et al., 2013). However we need to make greater 
efforts to understand the relationship between statin use and diabetes in 
clinical trials and as part of mechanistic exploration. 
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6.1.5. Additional Benefits of Statins in Cardiovascular Disease 
 
Proliferation and migration of vascular smooth muscle cells are pivotal 
events in atherogenesis. In in vitro studies, the lipophilic simvastatin and 
lovastatin, but not the hydrophilic pravastatin, may induce vascular 
smooth muscle cell apoptosis in a dose-dependent manner (Guijarro et al., 
1999, Indolfi et al., 2000, Corpataux et al., 2005a, Corpataux et al., 
2005b). The difference might be attributed to differences in the ability of 
the statins to penetrate the cell. Our study demonstrated that the lipophilic 
simvastatin, but not the hydrophilic pravastatin, induced mitochondrial 
depolarization in vascular smooth muscle cells, which may represent the 
mechanism of simvastatin-induced smooth muscle cell apoptosis. Similar 
data of smooth muscle cell apoptosis with lipophilic statins have been 
provided by previous studies (Corsini et al., 1991, Guijarro et al., 1999, 
Corpataux et al., 2005a). Furthermore simvastatin causes inhibition of 
Ca2+ influx. In fact, in experimental atherosclerosis, there is increase in 
calcium transport and subsequent treatment with Ca2+ channel blockers 
was able to suppress such experimental atherosclerosis (Bangalore et al., 
2007, Martin-Ventura et al., 2008). Thus, simvastatin administration by 
the inhibition of Ca2+ influx could have beneficial additive effects. In view 
of the association of deranged Ca2+ homeostasis and atherosclerosis, there 
may be additional benefits of simvastatin that is not related to the lipid 
lowering effects. However, such effects may eventually lead to functional 
abnormality and/or apoptosis after prolonged exposure (Dirks and Jones, 
2006, Sung and Choi, 2012b, Salabei and Hill, 2013). Vascular smooth 
muscle dysfunction may parallel the statin induced-myotoxicity observed in 
skeletal muscle, which is manifested as muscle weakness and 
rhabdomyolysis (Kang et al., 2014). In this context, potential beneficial 
effects of statin in pathological settings like inhibition of smooth muscle 
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proliferation in atherosclerosis could be detrimental to the normal 
vasculature.   
As shown from our imaging and organ bath experiments, simvastatin 
inhibits Ca2+ influx, thus simvastatin co-administered with other Ca2+ 
channel blockers like nifedipine may result in additive effects on the 
haemodynamic parameters like heart rate, blood pressure and total 
peripheral resistance, as suggested by other studies (Jasinska et al., 2006, 
Clunn et al., 2010).  In fact, the usefulness of the conventional L-type Ca2+ 
channel blockers are sometimes limited by their inability to dilate the 
venous circulation with resultant ankle oedema as a side effect (Thakali et 
al., 2010). Simvastatin may represent a useful combination therapy. 
Further studies are aimed to ascertain whether these findings are 
translatable to the clinical setting. 2Q WKH RWKHU KDQG WKH ǃ-blocker 
propranolol, like simvastatin, causes mitochondrial inhibition (Wagner et 
al., 2008). Thus simvastatin and propranolol combination might increase 
the risk for developing muscle myopathy.   
6.1.6. Simvastatin concentrations used in the study 
 
The effect of simvastatin observed in vitro might be of potential clinical 
importance since the concentrations that induced coronary relaxation in 
our experiments are within the maximum range encountered in plasma of 
treated patients 0.03-1 µM (Lilja et al., 1998). However, for the majority of 
studies investigating the mechanism of relaxation, higher concentrations of 
simvastatin (3-10 ǋM) were used. These concentrations that we have used 
are higher than would be expected in the plasma of patients. Since the 
study aim was to determine the role of mitochondria and KATP channels in 
the acute coronary artery relaxation induced by simvastatin, accordingly 
the exposure to simvastatin must be for short periods of time. For isolated 
tissue bath experiments the exposure time was around 2-hours and for the 
221 
 
imaging experiments the exposure time was usually less than 30- min to 
avoid bleaching of the dye. In comparison, the long term therapeutic in-
vivo use of simvastatin is sometimes maintained over several years. 
Therefore, it can be argued that higher simvastatin concentrations were 
needed to detect cellular responses over this short period. Indeed, the 
higher concentration of simvastatin required to induce mitochondrial 
depolarization of the smooth muscle cells in comparison to pancreatic B-
cell may be related to the unusual rhodamine 123 retention of the smooth 
muscle (Summerhayes et al., 1982).   
Long-term exposure to statins may lead to accumulation within cells, such 
that the intracellular concentration is greater than that measured in the 
plasma. Previous studies have shown that statin-induced skeletal muscle 
cytotoxicity is associated with intracellular accumulation (Kobayashi et al., 
2008), since the lipophilic statins enter the skeletal muscle by passive 
diffusion, while on the other hand the transporters play less significant role 
(Ohtawa et al., 1999). Sidaway et al. have demonstrated that the ratio of 
simvastatin accumulation in gastrocnemius muscle relative to plasma was 
higher than cerivastatin. They also proved that the hydrophilic rosuvastatin 
had the lowest ratio of accumulation (Sidaway et al., 2009). In addition, 
lipophilicity plays a major role in mitochondrial uptake i.e. lipophilic 
molecules had higher uptake compared to hydrophilic molecules (Durazo et 
al., 2011). Lipophilic compounds can easily pass through the mitochondrial 
membrane and as the pH in the mitochondrial matrix is higher than the pH 
in the cytosol, these lipophilic compounds can become charged. As a 
consequence mitochondria can trap lipophilic compounds (Rashid and 
Horobin, 1991). Our hypothesis is that lipophilic statins accumulate within 
the mitochondria. Therefore, the concentration of statin within the 
mitochondria may be higher than that measured in the plasma. The time 
taken for uptake into the mitochondria would explain why the relaxation to 
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lower concentrations of simvastatin (300 nM) was slow and reached 
significance after around 145 minutes after addition. Further studies are 
required to measure accumulation of statins within mitochondria. 
Concomitant administration of simvastatin with agents that inhibit 
cytochrome P-450 isoenzyme CYP3A4, responsible for the metabolism of 
simvastatin, for e.g. macrolide antibiotics like erythromycin, Ca2+ channel 
blockers like verapamil and diltiazem (Kantola et al., 1998), antifungal 
agents like ketoconazole and itraconazole (Neuvonen et al., 1998), and 
even grapefruit juice, taken daily, considerably increase simvastatin 
plasma levels (Lilja et al., 1998, Lilja et al., 2004).  It is noteworthy to 
mention that human smooth muscle cells are more sensitive to statins than 
experimental animals, thus lower concentrations are required in human in 
order to inhibit smooth muscle cell proliferation (Corsini et al., 1993). 
Similarly, we might expect that lower concentrations might be required to 
induce human coronary relaxation.   
Further studies to investigate the outcomes of the current body of work in 
isolated human vessels are needed to estimate the clinical significance of 
the experimental results and whether these findings are translatable to the 
clinical setting.   
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6.2. General Conclusion 
 
In summary, we have demonstrated that simvastatin alters mitochondrial 
membrane potential in vascular smooth muscle cells DQG SDQFUHDWLF ǃ-
cells. The relaxation to simvastatin in the porcine coronary artery is 
dependent, in part, upon mitochondrial activity. Alteration of mitochondrial 
membrane potential by simvastatin may lead to inhibition of calcium influx, 
hence stimulation of relaxation. How the mitochondria might regulate 
influx of extracellular calcium through calcium channels is unknown. ROS 
from the mitochondria into the cytosol can inhibit L-type calcium channels. 
However, as mentioned, antioxidant treatment had no effect on the 
relaxation to simvastatin. Mitochondria are able to regulate intracellular 
calcium homeostasis through accumulation (McCarron et al., 2013). For 
example, the reduction in intracellular calcium after depolarization in 
colonic smooth muscle is thought to be due to, in part, uptake into 
mitochondria (McCarron and Muir, 1999). Uptake of calcium into the 
mitochondria is also thought to prevent calcium-induced inhibition of 
voltage-gated calcium channels (Demaurex et al., 2009). On the other 
hand, the effects on mitochondrial membrane potential in SDQFUHDWLFǃ-cell 
may be detrimental, particularly with chronic treatment due to the 
increased risk of diabetes observed with lipophilic statins. 
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Appendix: 
 
1. Effect of simvastatin on KATP channel activity in human aortic 
smooth muscle cells 
As described earlier ZLWK ǃ-cells, patch clamp experiment performed on 
smooth muscle cells isolated from PCA. The enzyme mixture consists 
containing DTT (6.0 mg ml-1), papain (2.0 mg ml-1) collagense type II (7.5 
mg ml-1) and bovine serum albumin (fatty-acid free; 2.0 mg ml-1) for 45 ± 
60 mins at 37ºC. In fact, it proved difficult to isolate healthy smooth 
muscle cells and only a few cells stuck to the glass bottom. Furthermore, 
attempts to generate seals using suction were frequently unsuccessful, 
presumably due to a loss of cell membrane integrity during enzymatic 
digestion. The decision was finally taken to abandon the isolation 
procedure. As alternative, human aortic smooth muscle cells (Lonza; 
passages 7 to 9) were grown on sterilized glass cover slips were used to 
examine the effect of simvastatin on KATP channels in smooth muscle cells. 
Results of 5 repeats show that simvastatin 10 µM significantly inhibits KATP 
channels (figure 1). However more experiments are recommended to 
examine the effects in inside out patch and to compare the results with 
DMSO as a solvent control.  
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Figure 1. Effect of 10 µM simvastatin on KATP channel activity (NPo) 
in human aortic smooth muscle cells: A- KATP channel activity after 15 
min of 10 µM simvastatin (statin) perifusion dissolved in DMSO compared 
to the KATP channel basal activity (NPo) prior to addition of simvastatin 
from a cell-attached patch on human aortic smooth muscle in a glucose-
free HANKS solution. * P< 0.05, 6WXGHQW¶V unpaired t test of 5 different 
experiments. 
 
2. Macro scripts for Ca2+ image analysis 
//calcium 27Feb2014// 
draw -n ds -d 1 -w 1.5 -l -v 2; 
draw -n de -d 1 -w 1.5 -l -v 3; 
draw -n ks -d 1 -w 1.5 -l -v 4; 
ds.hmove=1; 
de.hmove=1; 
ks.hmove=1; 
layer -d; 
worksheet -d B%[%h,>'A']; 
%n=C%h; 
%A=%h; 
d=0;K=0; 
ncs=wks.ncols; 
nrs=xindex(wks.nrows,wcol(1)); 
xen=nrs-1; 
//type %h %n $(i) $(ncs);// 
//normalize// 
// for(i=ncs;i>1;i--){ 
//   %A=%h!wks.col$(i).label$; 
//   wcol(i)=100*wcol(i)/%a; 
//check cells// 
 for(i=ncs;i>1;i--){ 
  window -t plot calibrate1 %n; 
  layer -w %A i 1 i nrs 200; 
  getyesno (Use record) Y; 
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  layer -d; 
  if (y==0){ 
   d=d+1; 
   del wcol(i); 
  } 
  else{ 
   k=k+1; 
  }; 
 }; 
//now form average// 
ncs=wks.ncols; 
nct=ncs+1; 
tot=ncs-1; 
worksheet -c average; 
col(average)[nrs]=0; 
wcol(nct)=0; 
for(i=2;i<=ncs;i++){ 
wcol(nct)=wcol(nct)+wcol(i); 
}; 
//calculate average and plot// 
wcol(nct)=wcol(nct)/(ncs-2); 
wks.col$(nct).label$=$(ncs-1); 
 
%n=%h; 
window -t plot calibrate2 G%nAverage; 
layer -w %n nct 1 nct nrs 200; 
de=xen-60; 
//get timings// 
getnumber 
(50K start) Ks 
(Drug start) Ds 
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(Drugend) De 
 
(Measurement times); 
layer -d; 
kk=ds-180; 
//find max and normalize//; 
  loop (n,2,ncs){ 
   ym=0; 
   yn=ds-kk+1; 
    loop (m,kk,ds){ 
     ym=ym+%(%n,n,m); 
    }; 
   wcol(n)=100*yn*wcol(n)/ym; 
  }; 
 
 
 ncc=wks.ncols-1; 
 nrs=wks.nrows; 
 d=0; k=0; 
 for(i=ncc;i>1;i--){ 
  worksheet -s i 1 i xen; 
  worksheet -p 200 calcium1; 
  getyesno KEEP Y; 
  layer -d; 
   if (y==0){ 
    del wcol(i); 
    d=d+1; 
   else{ 
    k=k+1; 
 
//now form average// 
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ncs=wks.ncols-1; 
nct=ncs+1; 
col(average)[nrs]=0; 
wcol(nct)=0; 
for(i=2;i<=ncs;i++){ 
wcol(nct)=wcol(nct)+wcol(i); 
}; 
//calculate average and plot// 
wcol(nct)=wcol(nct)/(ncs-2); 
wks.col$(nct).label$=$(ncs-2); 
 
%n=%h; 
worksheet -s 2 1 ncs xen; 
worksheet -p 200 calcium1; 
window -r %h G%n; 
 
//draw limits and reset if necessary// 
draw -n ds -d 1 -w 1.5 -l -v ds; 
draw -n ks -d 1 -w 1.5 -l -v ks; 
draw -n de -d 1 -w 1.5 -l -v de; 
ds.hmove=1; 
ks.hmove=1; 
de.hmove=1; 
//get timings// 
getnumber 
(50K start) Ks 
(Drug start) Ds 
(Drug end) De 
(Measurement times); 
draw -n ds -d 1 -w 1.5 -l -v ds; 
draw -n ks -d 1 -w 1.5 -l -v ks; 
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draw -n de -d 1 -w 1.5 -l -v de; 
//output// 
window -n n results; 
type.notes$=results; 
type.redirection=2; 
type \n; 
type Worksheet %n; 
type Basal 50K drug; 
type $(KS) $(DE); 
type Cell\tarea\tbasal\t50K\tdrug; 
 
loop (n,2,ncs){ 
 Cbasal=0;c50k=0;cdrug=0; 
  loop (m,1,180){ 
  Cbasal=Cbasal+%(%n,n,ks-m); 
  c50k=c50k+%(%n,n,ds-m); 
  cdrug=cdrug+%(%n,n,de-m); 
  Cbasal=Cbasal/180; 
  c50k=c50k/180; 
  cdrug=cdrug/180; 
 type $(n-1)\t%(n,@L)\t$(int(cbasal))\t$(int(c50k))\t$(int(cdrug)); 
